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Thesis Summary 
Periodontitis is a widely spread disease, affecting about 80% of the worldwide population, resulting 
in teeth loss, a heavy impact on patients in terms of function and aesthetic. Type 2 Diabetes Mellitus 
(T2DM) is described to be linked to the exacerbation of periodontitis and delayed healing. This link 
between these two diseases, however, is not fully evaluated and the mechanisms are yet to be fully 
elucidated. Osteopontin (OPN) is described to inhibit mineral crystal formation. Herein, it has been 
hypothesized that increased OPN in diabetic healing bone may be the causative factor of delayed 
healing in periodontitis and subsequent deterioration, leading to teeth loss. This project aims to gain 
a greater understanding of the effect of high glucose (HG) levels on mesenchymal stem cells (MSCs) 
and macrophages, their ability to synthesise OPN and hence, its effects on MSCs to synthesise new 
bone tissue.  Further, the influence of Porphyromonas gingivalis lipopolysaccharides (Pg-LPS) on 
these cells was analyzed, in an attempt to create a model to study the healing in the presence of 
periodontitis and T2DM. Investigating the MSCs isolated from the rat compact bone (CB-MSCs) 
during the growth in culture, revealed two main populations; a heterogenous population appeared 
with predominantly mature characteristics at PD15. This population then demonstrated a change in 
its heterogeneity and became more immature in nature at PD50. These two main populations differed 
in their growth rate and capability of osteodifferentiation. HG environments exerted significant 
decreases in osteogenic differentiation on PD15, but not PD50. Addition of pg-LPS showed inhibitory 
effects on osteodifferentiation on PD15 cells more than PD50. Conversely, in the combined presence 
of HG and pg-LPS, PD50 showed a significant decrease in osteodifferentiation. OPN levels 
demonstrated a gradual decrease in CB-MSCs in both normal and HG conditions. Investigating OPN 
levels secreted by macrophages, however, revealed interesting results. Synergistic effects of both HG 
and pg-LPS exhibited a significant increase in OPN levels in both pro-inflammatory M1 macrophages 
and in repair related M2 macrophages. In conclusion, HG was mainly reported to inhibit osteogenic 
differentiation of the mature cell population, whereas the immature population was found to be 
affected by combined pg-LPS and HG. OPN levels in HG conditions were shown to decrease along 
the osteodifferentiation period. However, macrophages showed increase secretion of OPN by the 
synergistic effects of both pg-LPS and HG in both M1 and M2 and by pg-LPS effects in M2 
macrophages. These outcomes as far as we are aware, are novel and disclose a new mechanism of 
bone resorption in the case of T2DM patients concurrently with periodontal disease.  
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   Chapter 1: General Introduction 
 
    1.1:  Background Introduction       
Diabetes Mellitus (DM) is a clinically and genetically, heterogeneous group of disorders affecting 
the metabolism of carbohydrates, lipids and proteins, in which hyperglycemia is the main feature 
(Graves et al. 2006). There are different forms of diabetes, but the most prevalent one is type 2 
diabetes mellitus (T2DM). It forms 90% of all diabetes cases and involves about 382 million people 
worldwide with this number predicted to rise to 592 million by the year 2035. Moreover, the 
prevalence rates of T2DM appear to be more among males (8.4%) than females (7.1%). This 
relatively high percentage has a dramatic impact on the health system, through high morbidity and 
mortality amongst affected individuals in both western and developing countries (Carnevale et al. 
2014). 
T2DM is usually associated with insulin resistance. This resistance comes from adipose tissue, in 
addition to free fatty acid, which is considered as an active regulating hormone. This releases 
metabolically active molecules that can inhibit the body’s ability to respond to insulin. These 
metabolic disturbances associated with T2DM may lead to high levels of the pro-inflammatory 
cytokines, such as tumor necrosis factor (TNF-α); and the formation of advanced glycation end 
products (AGEs), in addition to oxidative stress. Accumulation of these products is proposed to lead 
to diminished bone formation (Graves et al. 2006).  In this situation, the body responds to produce 
extra insulin, leading to hyperinsulinemic states, to maintain normal blood glucose levels (Dickson 
and Rhodes 2004). 
It has been reported that a long-term hyperglycemic situation can lead to activation of pathways, 
such as polyol pathways, advanced glycation endproducts (AGEs), high levels of protein kinase C 
(PKC) activity; and hexosamine bisynthesis pathways, that may exacerbate the diabetic state. The 
complications can be exemplified by retinopathy, neuropathy, nephropathy, angiopathy, 
atherosclerosis and periodontitis. In the oral cavity, T2DM alters inflammatory responses of the 
periodontium to oral pathogens, raising the susceptible risk for periodontal disease two to five fold, 
compared to non-diabetic patients (Tunes et al. 2010). Examination of human gingival crevicular 
fluid from diabetic patients has demonstrated higher levels of TNF-α, interleukin-1β (IL-1β) and 
prostaglandin E2 (PGE2), in comparison to non-diabetics with a similar level of periodontal disease. 
2 
 
Such high levels have been implicated in delayed healing and diminished bone formation. 
Conversely, this risk may be reduced by better glycemic control (Taylor 2001). 
The mineralised tissues have been reported to be affected by T2DM. The harmful effects are 
proposed to come from, firstly, insulin resistance which results in higher levels of insulin. Initially, 
this may increase bone mineral density, however, in the long-term, bone turnover will be affected 
due to an accumulation of AGEs. Secondly, prolonged hyperglycemia results in AGE production, 
which alters bone quality by affecting osteoblast differentiation (Carnevale et al. 2014). 
Dysregulation of certain genes, which induce osteoblast proliferation and differentiation is another 
factor, which may affect the bone tissue. Consequently, deleterious effects and bone damage appear 
to be associated with T2DM (AI-Aql et al. 2008). 
During bone wound healing, progenitor cells are described to be recruited to the injury site by 
different chemotactic signalling pathways. Several growth factors contribute to the repair process, 
such as transforming growth factor-β (TGF-β1), bone morphogenic proteins (BMPs) and platelet-
derived growth factors (PDGFs). These growth factors stimulate the proliferation and differentiation 
of progenitor cells to form osteoblasts that synthesize the mineralised matrix. It has been reported 
that hyperglycemia, resulting from T2DM, exerts strong effects on specific stages in the bone 
healing process, including inflammation, clot formation, vascularization, mineralisation, bone 
matrix synthesis and remodelling (Valero et al. 2007). As a result, this situation leads to alter bone 
turnover and remodelling. A delay in wound healing is a common condition associated with 
diabetics. 
One of the most important non-collagenous matrix proteins, which has a pivotal role in bone 
mineralisation and healing is osteopontin (OPN). OPN is synthesized by different cells, such as 
osteoblasts, macrophages and fibroblasts. It is one of the earliest secreted proteins in the osteogenic 
process (McKee et al. 2011). OPN binds to mineral crystals to inhibit their growth and consequently, 
inhibits bone formation. Another function of OPN synthesized by macrophages is that of coating 
the surface of small particulate mineralised tissue debris, which is generated through some surgical 
procedures, such as implant placement, acting as an opsonin to facilitate its phagocytosis by 
macrophages (Pedraza et al. 2008; McKee et al. 2011). A study by Andrews et al. (2012), reported 
that blocking OPN expression at the site of injury in a murine model showed a reduction in the 
inflammatory response and subsequent granulation tissue formation. Colombo et al. (2011) showed 
that there is a delay in bone healing around an implant inserted into diabetic rats, that correlates to 
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increases in OPN levels. This may perpetuate the inflammation and delay osteocalcin (OCN) 
synthesis, resulting in delayed bone healing. These studies have demonstrated the importance of 
OPN secretion in the body homeostasis.  
In periodontal disease, bacterial lipopolysaccharides (LPS) play a major role in the disease 
pathogenesis. LPS is bacterial endotoxins in the form of glycolipids. It is present in the outer cell 
membrane of all Gram-negative bacteria, such as Porphyromonas gingivalis, Tannerella forsythia 
and Prevotella intermedia, which are all associated with sub-gingival periodontal lesions (Tanner et 
al. 1979; Slots et al. 1986; Moore and Moore 1994; Nakamura et al. 2004). A broad number of 
studies have proposed that the central periodontopathic agent among these etiological factors is 
Porphyromonas gingivalis (P. gingivalis) (Marcotte and Lavoie 1998; Maiden et al. 2003; Paster et 
al. 2006; Hajishengallis et al. 2012). P.gingivalis comprised 86% of subgingival plaque samples 
from patients affected by chronic periodontitis (Datta et al. 2008). P.gingivalis-LPS (pg-LPS) has 
the ability to activate the host inflammatory responses through cell surface receptors, called Toll-
Like Receptor 2 and 4  (TLR-2 and TLR-4) which in turn, induce a production of proinflammatory 
cytokines, IL-1β, IL-6, IL-8 and TNF-α, disrupting the bone repair process (Jiang et al. 2002; Graves 
et al. 2011; Herath et al. 2011; Kato et al. 2014). On the other hand, hyperglycemia from T2DM has 
been reported to alter the host response to bacterial endotoxins through cytokine dysregulation by 
AGEs, in addition to prolonged TNF-α expression (Graves et al. 2006). Thus, combined effects of 
hyperglycemia and pg-LPS has been described to exacerbate the situation by enhancing more bone 
resorption, especially when T2DM is associated with periodontal disease.    
To date, although there has been scientific research on the effect of the hyperglycemic environment 
on the cells associated with bone formation, as part of bone remodelling, little is known about the 
effects of pg-LPS derived from periodontal pathogens on this process and the role of OPN. This 
project will attempt to elucidate further the importance of OPN matrix protein, which we proposed 
to play a pivotal role in delayed bone healing in a diabetic environment and the role of pg-LPS in 
aggravating this process. 
  
4 
 
    1.2: Periodontal Disease 
                     Periodontitis is a chronic inflammatory disease involving the periodontium. It is characterized by a 
slowly growing progressive destruction of tooth-supporting structures. If left untreated, this disease 
can lead to tooth mobility and subsequently tooth loss (Nanci and Bosshardt 2006). It has been 
reported that periodontal disease is highly prevalent and that severe cases affect 10-12% of adults in 
most populations, while the moderate form of the disease is more common and involves 40-60% of 
adults. Periodontal disease has been described to be associated with cardiovascular disease 
complications, such as myocardial infarction (MI) and ischemic stroke (Mattila et al. 1989; Lu et al. 
2008; Holmlund et al. 2017). The disease is always associated with numerous negative impacts on 
quality of life, in terms of social interactions, confidence and food choices (Fox 1992; Fox et al. 
1994; O’Dowd et al. 2010). Periodontal disease classification is very complex, considering the 
clinical feature, age, the rate of disease progression; and the local and systemic factors that may 
elevate its risk. The main classification of periodontal disease, includes gingivitis when the 
inflammation is confined to it. Gingivitis is known to be reversible following proper oral hygiene. 
The second type is periodontitis, in which the inflammation extends to the deeper part of the 
periodontium, resulting in tissue and alveolar bone destruction. Consequently, periodontitis leads to 
a breakdown of the periodontal ligament and formation of largely irreversible periodontal pockets 
between the tooth and the gingiva. Interestingly, the condition in early stages is asymptomatic and 
many patients are unaware of its presence. Subsequently, the situation would progress to result in 
tooth mobility. The alveolar bone resorption occurs in parallel with the progression of attachment 
loss of the periodontal ligament. Although it is a painless disease, advanced cases of periodontitis 
are characterized by gingival erythema, swelling, bleeding, recession, tooth mobility, drifting, 
suppuration from the pockets and eventually tooth loss (Preshaw et al. 2012). 
 
                      Although the main aim of the host response is to counteract the invading pathogens, it is now 
regarded to be a major part of the problem of progression of periodontal disease. The invading 
pathogens can induce periodontal tissue destruction through proteinase enzymes and endotoxins, or 
indirectly through provoking a strong host response. Leukocyte infiltration can limit the bacterial 
invasion, but at the same time could be harmful to the tissues. The leukocyte recruitment is promoted 
by several factors, such as bacterial products, cytokines, chemokines and cross-talk between innate 
and adaptive immune responses (Page et al. 1997). The resident cells of periodontium, such as 
fibroblasts, cells of junctional epithelium and vascular endothelium, in addition to leukocytes; can 
assist in response to the exposure to bacterial products, such as LPS, by secreting cytokines IL-1β, 
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IL-6, TNF-α and PGE-2. When continually expressed, these are proposed to participate in tissue 
destruction (Hung et al. 2013; Jiang et al. 2013). In this context, the balance in cytokine secretion 
can determine whether the tissues maintain homeostasis, or lead to an increase in the severity of the 
inflammation and tissue destruction (Gemmell et al. 2002). 
 
                     One of the complexities of periodontal disease, is that the disease is associated with a wide range of 
pathogenic bacteria, such as Prevotella intermedia, Tannerella forsythia and P. gingivalis. These 
specific periodontopathic agents have a prime role in the progression of the tissue destruction (Wang 
et al. 2013). The critical components of host cells, which respond to the bacterial products is the 
Toll-Like Receptor family (TLRs). These receptors, when activated by binding to various bacterial 
components can induce an innate immune response, resulting in more cytokines and chemokines 
production, which can change the balance towards further tissue destruction (Mahanonda and 
Pichyangkul 2007).  
                      
    1.2.1: Bone Repair in Periodontal Disease 
                     Bone repair is a process involving complex biological events, that includes a multitude of 
intracellular and extracellular molecular signalling pathways, which are coordinated by different 
cell types to restore the function to normal conditions. This process, however, can be delayed due to 
different diseases, such as diabetes, osteoporosis and the age of the individual, which can affect 
signalling events, revascularization and mineral matrix formation (Armas and Recker 2012). In the 
case of craniofacial tissue, rapid bone healing is the main goal. This is achieved by primary bone 
healing through intramembranous ossification, where the repair process can be facilitated by 
revascularization and bone synthesis without micromotion. Excessive micromotion results in 
secondary bone healing, which consists of a double process, chondrogenesis in regions near the 
fracture site of periosteum, while an intramembranous ossification at the other site. The bone repair 
process is divided into several stages; haematoma formation, a reparative phase which leads to the 
formation of woven bone and finally the remodelling phase whereby woven bone is replaced by 
lamella bone. Haematoma phase occurs early during tissue damage and may last from 1-3 days. 
There will be an activation of complement cascade and promotion of platelets accumulation 
(Kikuchi 2005). The platelets aggregate in a stable fibrin clot, which is provided from plasma 
fibrinogen and thrombin to form a provisional matrix. This platelet matrix provides an important 
source of various signalling factors, such as TGFβ1 and β2, PDGF, serotonin and histamines, which 
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trigger chemotactic signalling for neutrophils, monocytes and lymphocytes; and subsequently 
progenitor cells (Kuzyk and Schemitsch 2011). These inflammatory cells are responsible for 
secreting the inflammatory mediators, including the proinflammatory cytokines, such as IL-1, IL-6, 
IL-8, TNF-α and macrophage colony stimulating factors (M-CSF). Despite these inflammatory 
factors having a chemotactic function to recruit inflammatory cells and amplify further 
inflammatory events, they are also described to be necessary for extra cellular matrix (ECM) 
synthesis and bone repair (Gerstenfeld et al. 2001). Angiogenesis generation was reported to start 
by means of vascular endothelial growth factor (VEGF), together with basic fibroblast growth factor 
(bFGF) and PDGF. These factors stimulate budding of new vessels (AI-Aql et al. 2008). The second 
phase of the healing process is the reparative stage, which lasts from 3-50 days, during which 
granulation tissue and osteoid are formed. The MSCs are recruited to the wound site from the bone 
marrow and periosteum, by the prominent role of the provisional fibrin matrix, which includes 
various signalling milieu, such as PDGF and TGF-β1, β2 and β3. Another source of MSCs is the 
pericytes, cells associated with the endothelial cells of veins and capillaries, which assist in the 
angiogenesis process. In terms of intramembranous ossification, there are important effects of TGF-
β and BMP-2 in inducing osteogenic differentiation of MSCs, via upregulation of Runx2 and Osterix 
transcription factors. Wnt family of ligand is another pathway that induces osteoinduction, resulting 
in activation of the canonical β-catenin pathway, as well as osteogenic genes (Clément-Lacroix et 
al. 2005; Yang et al. 2011). This provisional granulation matrix is subsequently replaced by an 
unmineralised collagenous matrix, called osteoid; and at the same time, angiogenesis formation 
takes place to form the Haversian canal system. During osteoblast differentiation, several 
noncollagenous proteins have been observed to be produced, which have the capability to inhibit 
crystal growth, such as OPN (McKee et al. 2011); and decorin and biglycan in their dermatan 
sulphate-conjugated forms (Waddington et al. 2003). OPN attachment to the MSCs or osteoblasts 
can be performed by its RGD binding sequence (McKee et al. 2011). On completion of osteoid 
formation, the remodelling process is conducted by removal of these inhibitor proteins and 
osteoblasts start to synthesize noncollagenous proteins, which facilitate the deposition of 
hydroxyapatite crystals along the collagen fibril framework to form bone. In this mineralisation 
stage, the chondroitin sulphate-conjugated forms of decorin and biglycan, are expressed together 
with OCN and osteonectin. Herein, some of the osteoblasts become entrapped inside the mineralised 
matrix and form osteocytes. Alternatively, other osteoblasts undergo apoptosis to arrest further bone 
synthesis. Importantly, the growth factors become embedded within the bone matrix and to be 
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released in case of matrix is resorbed, as a sequence of the remodelling process. Osteoblasts also 
secrete osteoprotegerin (OPG), which acts to prevent binding of RANKL to the osteoclast cell 
surface receptor, RANK; to control osteoclastic activities. MSCs of bone marrow and pericytes 
origin subsequently differentiate into osteoblasts to replace the lost bone in sequences similar to the 
reparative stage. The remodelling process, however, is much slower than the reparative stage, lasting 
from approximately 6 months up to 4 years to replace the woven bone (Kwong and Harris 2008).  
                      
                     The late remodelling of woven bone occurs around 2 months later, which requires the activation of 
osteoclasts for bone removal (Kwong and Harris 2008). This process is non-inflammatory in general 
and it is strongly controlled by MSCs and osteoclasts, which produce RANKL and M-CSF 
cytokines, facilitating monocyte cells recruitment, differentiation and activation of osteoclasts that 
capable of bone matrix degradation (Edwards and Mundy 2011).  
 
                     In the periodontium, this process is more complicated, depending on the tissue and cells that 
contribute to this healing process. It is required a new attachment of principle fibres to the root 
surface cementum occurs, which has been previously affected by periodontal pathogens. In order to 
obtain healing in periodontium, there should be organized events taking place, the progenitor 
periodontal ligament cells should migrate to the root surface, to form a new attachment apparatus. 
Likewise, osteoprogenitor cells must also migrate, mature and conjunct with periodontal ligaments 
to achieve tissue regeneration. In this context, there is a requirement to healthy cells and precise 
coordination, in terms of spatial and temporal events, to ensure the availability of the appropriate 
cells of periodontal regeneration. Clinically, this is difficult to achieve and hence total regeneration 
is often minimal. In addition, the profile of periodontal disease demonstrates a cyclic nature, 
commencing as a period of aggressive alveolar bone destruction, followed by a period of remission 
and then wound repair. This repair period was proposed to be insufficient to replace the lost bone 
especially, when another cycle of bone destruction begins, due to loss of the balance between bone 
formation and bone resorption (Zeichner-David 2006; Chen and Jin 2010). 
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    1.3: Growth Signalling Factors  
                    
    1.3.1: Transforming Growth Factor-β (TGF-β) 
                     TGF-β is part of a large family growth factors encompassing several isoforms, ranging from TGF-
β1 to TGF-β5, BMPs, growth differentiation factors (GDFs), inhibins, activins and anti-Mullerian 
hormones (Dimitriou et al. 2005). This large family contributes to various systemic regulation and 
cell functions; namely proliferation, differentiation and ECM synthesis. Different TGF-β isoforms 
coordinate with specific heterodimer receptor complex, that are comprised of two distinct proteins 
termed as TGF-β receptor I (TGF-β1R) and TGF-β receptor II (TGF-β2R). These two receptors 
belong to the serine/threonine kinase receptors, which activate a broad complex range of 
intracellular signaling pathways (Janssens et al. 2005). While Type III receptor was reported not to 
be directly associated with TGF-β signalling and may have a pronounced binding effects of TGF-β 
to receptor III (Pfeilschifter et al. 1998). In bone healing, TGF-β has been described to have a 
positive effect by inducing in vitro cell growth via IGF-I activation, causing a significant increase 
in osteogenic differentiation of primary human osteoblasts (Viereck et al. 2002). It has a role in 
controlling MSCs proliferation by means of other factors, such as extracellular environment, its 
concentration at the healing site and ligand-receptor that interacts with other growth factors. Thus, 
the role of TGF-β in bone healing is more modulatory rather than stimulatory (Pfeilschifter et al. 
1998). Furthermore, TGF-β was proposed to play an important role in bone remodelling by 
contributing to reduce bone resorption through inducing apoptosis of osteoclasts and suppressing 
their activity (Ehnert et al. 2010). 
 
                     In the early inflammatory stage (days 1-3), TGF-β1 has been described to be increased, whereas 
TGF-β1, β2 and β3 have been reported to increase in the reparative stage (days 3-50) and remodelling 
stage (2-9 months) (Cho et al. 2006; Würgler-Hauri et al. 2007). It has been found that higher levels 
of TGF-β1 in the early stage of healing tissues could be associated with excessive scar formation 
(Tsubone et al. 2006). In diabetic healing bone, TGF-β1 was found to be delayed expression until 
week 9, when high level was observed (Colombo et al. 2011). It has been also found to stimulate 
migration of monocytes in the hyperglycemic microenvironment, by induction of p38 pathways and 
ALK5 kinase via phosphoinositide 3-kinase (PI3K) (Olieslagers et al. 2011). These pieces of 
evidence may refer to the potential capacity of TGF-β1 to induce altered bone healing in 
hyperglycemic environments. 
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   1.3.2: Bone Morphogenic Proteins (BMPs) 
                     Bone morphogenic proteins are the most important growth factors of the TGF-β superfamily. BMPs 
play a critical role in regulating differentiation and apoptosis of various cell types, such as 
osteoblasts, chondroblasts, neural and epithelial cells. Their regulatory effects differ according to 
the phenotype of targeted cells, the stage of cell differentiation, as well as interactions with various 
circulatory factors (Sakou 1998). MSCs, osteoprogenitor cells, osteoblasts, in addition to 
chondrocytes within the ECM, are all reported to contribute to the production of BMPs. There are 
four members of the BMP family, based on their amino acid sequences. The first group consists of 
BMP-2 and BMP-4. Another group encompasses BMP-5, BMP-6 and BMP-7. The third group 
includes BMP-12, BMP-13 and BMP-14, whereas the last group includes BMP-3 (osteogenin) and 
BMP-3b (GDF-6) (Tsiridis et al. 2007). Each BMP has a unique function and a distinct expression 
pattern during fracture healing, although they are structurally and functionally related to each other. 
It has been observed that knockout mice for BMP-5, BMP-7 and BMP-11, showed localized bone 
abnormalities (Luo et al. 1995). Chen et al. (2004) suggested after a series of analysis of the 
osteogenic activities to numbers of BMPs, that there is a hierarchical model of BMPs. BMP-2, BMP-
6 and BMP-9 are the most potent BMPs in terms of inducing differentiation of mesenchymal 
progenitor cells into osteoblasts. Furthermore, BMPs may stimulate the production and secretion of 
other bone growth factors, for example, insulin growth factor (IGF) and vascular endothelial growth 
factor (VEGF) (Tsiridis et al. 2007). 
 
    1.3.3: Wnts 
                      Wnts (Wingless) are a group of more than 19 secreted proteins that bound to receptors, known as 
membrane-spanning frizzled (FZD). These are implicated in various cellular activities, namely the 
recruitment of progenitor cells and their differentiation into osteoblasts; and apoptosis. Wnt 
signalling occurs by the canonical and non-canonical pathways. The canonical pathway includes 
different Wnt proteins, FZD as well as low-density receptors LRP5 and LRP6 (Arvidson et al. 2011). 
Strong evidence proposes that the canonical pathway had a critical role in bone synthesis and is 
involved in the expression of osteoblast specific markers (Westendorf et al. 2004; Jackson et al. 
2005). It has been reported that Wnt binding to FZD and LRP5/6 complexes inhibits glycogen 
synthase kinase 3 (GSK3) activity, resulting in the blocked phosphorylation of β-catenin by 
preventing its ubiquitin-degradation, which can cause β-catenin translocation to the nucleus  and 
interact with T-cell factor/lymphoid enhancer factor, leading to activation of transcription factors of 
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target genes (Fujita and Janz 2007).  β-catenin protein levels are known to be elevated in osteoblast 
precursors, while inactivation of β-catenin, leads to chondrocyte differentiation of MSCs (Day et al. 
2005). Levasseur et al. (2005), reported that loss of function mutations in LRP5 results in 
osteoporosis-pseudoglioma syndrome. On the contrary, functional mutations in LRP5 cause 
increased bone density, associated with upregulation of bone marker formation, such as OCN 
(Boyden et al. 2002). It has also been observed that there is a high bone mass, as well as an increase 
in Runx-2 and OCN expression, in the case of an over-expression of Wnts in transgenic mouse 
models. This suggests that Wnts signalling might contribute to osteoblast differentiation (Gaur et al. 
2005). However, the exact role of Wnt signalling in osteoblastogenesis is still not conclusive (Luo 
2004). 
                              
    1.3.4: Platelet Derived Growth Factor (PDGF) 
                     PDGFs are a family of growth factors that act as strong chemotactic signals, which stimulate 
inflammatory cells, mesenchymal and osteoprogenitor cells, to migrate to injury sites (Tsiridis et al. 
2007). PDGFs consist of three isoforms; first, homodimers consist of polypeptide chains PDGF-A 
(PDGF-AA), second, PDGF-B (PDGF-BB) and third, a heterodimer (PDGF-AB) (Heldin and 
Westermark 1999). The primary PDGF signals commence through PDGF receptor α (PDGFRα), 
while the predominant PDGF signals are via PDGF receptor β (PDGFRβ). Signals are mainly 
through the MAPK pathway (Donovan et al. 2013). It has been found that deletion of PDGFRβ 
resulted in MSC differentiation into osteoblasts and upregulation of Runx2 and OCN (Tokunaga et 
al. 2008). Inhibition of PDGF-BB receptor in human MSCs, however, demonstrated a decrease in 
cell proliferation but has no influence on osteo-differentiation (Kumar et al. 2010). 
                        
   1.3.5: Fibroblast Growth Factor (FGF) 
                     FGF family members contain twenty-three monomeric polypeptides. The action of FGFs is through 
binding to tyrosine kinase receptors (FGFR1-FGFR4) (Tsiridis et al. 2007). FGFs are produced by 
monocytes, macrophages, MSCs, chondrocytes and osteoblasts. Simultaneously, FGFs promote the 
growth and differentiation of different cells, such as fibroblasts, osteoblasts, chondrocytes and 
myocytes. It has been reported that FGFs play a pivotal role in angiogenesis, in addition to MSC 
mitogenesis at the early phases of bone healing. The role of fibroblast growth factor 1 or α (FGF-1 
or FGF-α), is mainly in regulation of chondrocyte proliferation and possibly maturation, while in 
general, osteoblasts express FGF-2 or FGF-β, which is more potent than FGF-1 (Lieberman et al. 
2002). In a study using a canine tibial osteotomy model, it has been reported that FGF-2 was 
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accompanied with an early increase in callus formation (Nakamura et al. 1998). Conversely, FGF-2 
knockdown in mice showed a decrease in bone mass, compared to normal mice. Additionally, there 
is a lower expression of Runx-2 and decreased bone nodule formation in cultured bone marrow 
stromal cells (Naganawa et al. 2008). Over-expression of FGF-2 leads to an increase in apoptosis in 
a transgenic mouse model (Mansukhani et al. 2000). FGF-2 addition to bone marrow progenitor 
cells appears to improve their proliferation and differentiation potential (Delorme et al. 2009). FGF-
2 also stimulates epithelial to mesenchymal transition, which is of importance during development 
and tissue healing (Shirakihara et al. 2011). FGF-18 is expressed in mesenchymal cells and assists 
in the differentiation of osteoblasts, in addition to inducing osteogenic differentiation of MSCs. This 
process is achieved by activation of MAPK and P13K signalling, after activation of FGFR-1 and 
FGFR-2 (Naganawa et al. 2008).  
 
   1.3.6: Insulin-Like Growth Factors (IGFs)  
IGF family members mainly consist of two forms, IGF-I (somatomedin-C) and IGF-II (skeletal 
growth factor). The sources of IGFs are the bone matrix, osteoblasts, endothelial cells and 
chondrocytes. Growth hormone regulates the serum concentration of IGF-I, which in turn promotes 
the formation of the bone matrix, such as type I collagen and non-collagenous matrix proteins. This 
is achieved by enhancing fully-differentiated osteoblasts. The second type is IGF-II, which is less 
potent than IGF-I and it acts at a later phase of endochondral bone formation, in addition to 
stimulation of type I collagen synthesis, matrix production and cellular proliferation (Tsiridis et al. 
2007). IGFs have been observed to have a synergistic function with other growth factors, such as 
BMP-2. There is an increase in the expression of IGF-I and II in rat calvaria cell cultures when 
treated with BMP-2 (Canalis and Gabbitas 1994). Another study has reported that TGF-β1 increases 
IGF-I and II expression in human osteoblast cultures (Okazaki et al. 1995). Taniguchi et al. (2006) 
postulated that IGF-1R possibly had the same homological structure of insulin receptors, which may 
give the possibility that IGF-1 would have the affinity to bind to the insulin receptor. In experimental 
studies, there is an elevation in osteoblastic activity, cell proliferation and higher expression of 
alkaline phosphatase (ALP), due to insulin application. Based on this outcome, administration of 
insulin could possibly bind to IGF receptor, activating cell proliferation and stimulating certain 
growth factor receptors (Gandhi et al. 2005). This assumption, however, is expected to be different 
in T2DM, because of insulin resistance, based on this physiological disorder, which may never 
respond to IGF stimulation.  
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It is worth stating that despite this information, there is lack of full understanding of the synergy of 
signalling pathways.    
      
    1.4: Stem Cells and Their Role in Bone Repair 
Stem cells are unspecialized cells, which can differentiate into other types of cells during 
development and bone repair. They are also capable of self-renewal by means of signalling 
pathways, which are believed to be controlled by certain growth factors, existing within the stem 
cell niche. Almost all connective tissues have a stem cell population, that is believed to have an 
important role in tissue injury and repair (Lin et al. 2008). According to their ability to differentiate 
into other types of cells, there is some evidence that they may play a pivotal role in the future cell 
therapy (Denham et al. 2005). In respect to stem cells differentiation capacity, the cells can be 
identified according to their differentiation potency. There are currently five identified phenotypes, 
stem cells which are Toti-, Pluri-, Multi-, Oligo- and Uni-potent following a reverse hierarchy. 
Going down through this hierarchy pattern, the cells show lower capacity for differentiation. 
Totipotent cells can differentiate into all types of cells of a body organism including membranes, 
placenta and extra-embryonic tissues. Zygotes and their immediate descendants in the morula of 
developing embryo are considered as a true Totipotent cell (Seydoux and Braun 2006). Pluripotent 
cells can differentiate into different phenotypes from various germ layers. Multipotent cells can only 
differentiate into a specific type of cells, similar to their tissues, such as MSCs. Oligopotent cells 
can differentiate into a few descendent phenotypes namely, lymphoid and myeloid cells, in addition 
to mammalian ocular surface cells (Hombach-Klonisch et al. 2008; Majo et al. 2008). Unipotent 
cells can only differentiate into a mature cell closely related phenotype within a single tissue; a 
typical example for them is the committed osteoprogenitor cells. Additionally, there is another 
classification of stem cells into 3 main classes; germ-line stem cells (GSCs), embryonic stem cells 
(ESCs) and adult (somatic) stem cells (SSCs). Germ-line and embryonic stem cells are described as 
pluri-potent cells; these exist and contribute to growth events in the earlier stage of embryonic 
development. They are derived from the inner cell mass of the 5-6 day old human blastocyst (Bongso 
and Lee 2005). Adult/somatic stem cells (SSCs) are described as multi-potent cells which are present 
in different body tissues, such as bone, the blood stream, cornea and retina, skeletal muscle, liver, 
skin, gastrointestinal tract, pancreas, spinal cord and brain. SSCs generate intermediate cell types 
called progenitor cells, that have a commitment to their tissues and contributing to body homeostasis 
(Verstappen et al. 2009). These cells have the capability for differentiation into specific tissues, 
depending on the site and specific signals from their niche (Gafni et al. 2004; Lin et al. 2008). There 
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are several types of adult stem cells and their classification is mostly according to their location in 
a body organ. 
    1.4.1: Mesenchymal Stem Cells (MSCs)                                                                                        
MSCs were first described by Friedenstein et al. (1968) in bone marrow, defining them as osteogenic 
stem cells. Nevertheless, Caplan (1991) was the first person who called MSCs by this name. Their 
morphology is mononuclear with a fibroblastic shape (Mareschi et al. 2001). MSCs have the 
capability to differentiate into different types of cells in vitro, such as osteoblasts (Rickard et al. 
1996), adipocytes (Bennett et al. 1991), chondrocytes (Ashton et al. 1980) and myoblasts (Wakitani 
et al. 1995). Furthermore, other studies have shown their ability to differentiate into bone and 
cartilage in vivo during implants via ceramic carriers (Friedenstein et al. 1987; Goshima et al. 1991). 
Because of the wide diversity of these cells in differentiation into osteoblasts, chondrocytes and 
adipocytes, in addition to ease of handling, this makes MSCs a "gold standard" for tissue engineering 
and regenerative medicine. Differentiation of MSCs is controlled by different signals and growth 
factors, such as TGF-β, BMP and TNF-α (Kratchmarova et al. 2005).                                                    
    1.4.2: Hierarchy Model of MSCs                                                                                                                                                                                  
The pattern of stem cell division consists of two types, symmetrical and asymmetrical cell division. 
Symmetrical cell division produces two identical cells. However, asymmetrical division produces a 
cell identical to the mother and another cell more able to proliferate and differentiate. In terms of 
stem cells, division is achieved by asymmetrical division of mother cell, to give rise to a daughter 
cell, which assists to retain self-renewal ability, that is identical to the mother cell. This mother stem 
cell has a long-lifespan and it is proposed to maintain its ‘slow’ division mechanism to minimize the 
possibility of DNA replication mutations (Reya et al. 2001; Riquelme et al. 2008). The second cell 
derived is a rapidly proliferative daughter cell, which is proposed to form a transit amplifying (TA) 
cell after frequent proliferations. TA cells were described to form large colonies, exhibiting the 
highest proliferative capacity, as well as highest multipotency (Figure 1.1). As cell division 
continues, TA cells exhibited a decreased proliferative potential and smaller colonies. During this 
period, TA cells commence transformation into lineage-restricted MSCs. These lineages 
demonstrated tri-, bi- and uni-potentiality (Chan et al. 2004; Phinney 2012). Thus, the population of 
MSCs is a heterogeneous mixture and differs in their stage of lineage commitment and ranges of 
differentiation. These lineages have different potency to differentiate into bone, cartilage and 
adipose tissue (Sarugaser et al. 2009), or could be bi-potent for only two of these lineages. The uni-
potent cells, however, are committed to only one cell phenotype (Lee et al. 2010). It has been 
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reported that tri-potent MSCs had a high ability to proliferate and in colony forming efficiency. 
However, in bi-potent and uni-potent cell lineages, this ability has been reported to be decreased 
(Russell et al. 2010). For many years, MSCs and CFU-fibroblasts have been considered as identical 
cells, however, more recently, Shipounova et al. (2013), proved that there are marked differences 
between them and they reported that increased levels of FGFR2, VEGF and BMP4 in MSCs, may 
indicate the more immature nature of these cells. This hierarchy model elucidates the described 
cellular phenotype regarding MSC populations derived from compact bone and bone marrow.  
        
 Figure 1.1: Hierarchy model of stem cells division (Adapted from Chan et al. 2004). 
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   1.4.3: Mesenchymal Stem Cell Characterization                                               
Recently, MSCs have generated considerable interest through their therapeutic potential in 
biomedical disciplines, tissue engineering and regenerative medicine. However, the literature has 
reported a wide range of different methodologies utilised for their isolation and expansion; and 
varied approaches for their characterization. These different approaches have created some issues 
and hampered progress in the field, in terms of comparisons amongst studies. In addition, the 
heterogeneity in morphology and function provides evidence regarding the difficulty in identifying 
an ideal phenotypic fingerprint of MSCs (Bianco 2014). The International Society for Cellular 
Therapy (ISCT) states the minimal criteria to define MSCs (Dominici et al. 2006). These criteria 
consist of three requirements which are, first, that the cells should adhere to plastic in standard 
culture conditions; secondly, their expression of specific surface antigens and lastly, the cells should 
be able to differentiate into somatic cells. The property of plastic adherence is well-described, when 
MSCs are maintained in tissue culture in the presence of standard culture conditions (Colter et al. 
2000). The second criterion is ≥ 95% of MSCs must express the specific surface antigens, ecto 
5'ectonucleotidase (CD73), Thy1 (CD90) and endoglin (CD105). Simultaneously, MSCs should 
lack expression of hematopoietic antigens CD45; pan-leukocyte marker, CD34; primitive 
hematopoietic progenitors and endothelial cells; CD14 and CD11, which are related to monocytes 
and macrophages; CD79α and CD19β cell markers and HLA-DR, which do not express on MSCs, 
unless stimulated by interferon-γ (IFN-γ). The third and the final criterion for MSCs is that they 
must be capable of differentiating into osteoblasts, chondroblasts and adipocytes, by using standard 
protocols and tissues culture conditions (Dominici et al. 2006). 
 It has been found that these criteria, however, do not meet the characterization requirements for all 
MSCs, because of several critical shortcomings. Firstly, ISCT criteria lack a unique marker that can 
be universally shared among all species. Secondly, it emphasized on the positive expression of 
CD105, CD90, CD73, however, none of these markers are expressed by all human and animal 
species (Boxall and Jones 2012). Thirdly, the criteria refer to the ability to differentiate into three 
independent cell phenotypes; osteoblasts, chondrocytes and adipocytes, while it lacked the multiple 
differentiation pathway, including the immature MSCs, which have been described to have the 
ability to differentiate into the majority of cells in the body (Abdalla and Kassem 2008; Samsonraj 
et al. 2015). The plastic adherence, nonetheless, is reported to be shared by the majority of stem cell 
populations, thus it is not such a unique MSC marker itself. Moreover, these classical markers are 
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observed to be upregulated or downregulated with increasing culture expansion (Jones et al. 2010; 
Halfon et al. 2011; Harrington et al. 2014). In addition to the markers that been described by ISCT, 
there are other surface markers that have also been identified such as, STRO-1, HLA-A, HLA-B, 
HLA-C, HLA-DR, HLA-1, Oct4, Oct 4A, Nanog, Sox-2, telomerase (TERT); and others (Mafi et 
al. 2011). STRO-1 is molecule attributed to be highly specific for MSCs (Simmons and Torok-Storb 
1991). It has been observed that STRO-1 expression is down-regulated during extended culture. The 
effect of STRO-1 on MSCs remains widely unknown. One study has shown that expanding STRO 
-1+ MSCs has a better homing capacity in comparison to STRO-1- MSCs, suggesting it has a strong 
role in migration and attachment of MSCs to the ECM (Bensidhoum et al. 2004). Gronthos et al. 
(2003) added CD106 (VCAM-1) as another MSCs marker. Similar to STRO -1, CD106 expression 
has been reported to decline with prolonged culture (Jones et al. 2010; Jung et al. 2011). FGFR1 
(CD331) is another marker, which is important in organizing epithelial-mesenchymal transition 
(EMT) and mesoderm morphogenesis, which assists in cell migration and patterning, which can be 
achieved by controlling Snail1 expression (Eghbali-Fatourechi et al. 2005). It has been reported that 
absence of FGFR1 and Snail1 during development, leads to craniofacial abnormalities, namely cleft 
palate (Goncharova et al. 2012). In conclusion, it is difficult to conclude that all MSCs resident in 
various tissues and organs have the same markers. More research is needed to obtain a wide range 
of knowledge about cell phenotype and gene expression profile of MSCs in vitro and in their original 
niche in vivo study, with continued search for novel markers, which can be shared among all MSCs 
phenotypes and would undoubtedly assist in developing an improved methodology for 
characterization (Boxall and Jones 2012). 
    1.4.4: Senescence of MSCs                                                                                                                        
Senescence is a limited ability of the cells to proliferate. It was firstly described by Hayflick and his 
colleagues, when they reported that human diploid fibroblasts had a limited proliferative ability in 
culture (Hayflick and Moorhead 1961). In vivo, however, this process consequently ends by cell 
death and may negatively impact bone healing and repair process (Campisi and d’Adda di Fagagna 
2007). It was reported that the mitotically-competent cells may respond to various stresses and 
undergo cellular senescence or so-called “end replication problem”, which subsequently, leads to 
cell-cycle arrest. Examples of these stresses involve dysfunctional telomeres, disorders that affects 
the chromatin organization, DNA damage, in addition to strong mitogenic signals (Turinetto et al. 
2016). At the end of each chromosome, there is a repetitive region of DNA called the telomere, 
which comprises of tandem chromatin TTAGGG. During cell division and proliferation activities, 
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the process is usually accompanied by telomere shortening. Telomerase is an enzyme, which 
preserves telomeres from shortening, encoding by the telomerase reverse transcriptase, TERT, with 
a template of telomerase RNA component (TERC) (Blasco 2005). Despite this telomere preserving 
activity, it has been reported that after each cell division, the telomere becomes shorter and loses 50-
200 base pairs of telomeric DNA, because of incomplete chromosomal replication by DNA 
polymerases (Wagner et al. 2008).  It has been reported that these enzymes are associated with 
immortal (cancer cells) and embryonic cells in high levels and are at lower levels in human adult 
stem cells (Zimmermann et al. 2003). On the other hand, telomerase was described to be expressed 
at high levels in mouse stem cells (Hiyama and Hiyama 2007). Senescent cells face irreversible 
growth arrest. However, they continue to be metabolically active and develop a flat, large 
morphology and disclose some characteristic changes in their gene expression. Senescent cells have 
been described to typically exhibit a senescence-associated β-galactosidase (SA-β-gal) activity, 
reveal a persistent DNA damage nuclear foci (PDDF) that contain DNA damage response proteins, 
such as γH2AX and 53BP1(Rodier et al. 2011). In addition to the features above, there is an 
accumulation of heterochromatin structure called senescence-associated heterochromatin foci. 
Furthermore, the senescent cells secrete a number of cytokines, growth factors and proteases, that 
have potent autocrine and paracrine activities (Acosta et al. 2008; Coppé et al. 2010; Turinetto et al. 
2016). At a molecular level, it has been found that senescence is induced by the retinoblastoma 
protein (Rb) or p53 pathways, which in turn activates the cyclin-dependent kinase inhibitor, p16 and 
p21, pathways. Importantly, these pathways can act on each other to induce senescence after 
blocking the cell cycle to sustain growth arrest (Bargonetti and Manfredi 2002; Chau and Wang 
2003; Turinetto et al. 2016). 
    1.4.5: Osteogenic Differentiation Pathway of MSCs 
Osteogenic differentiation into osteoblasts is a complex process, required for the formation of bone 
tissue. Various signalling molecules and transcription factors have been described to be involved in 
this sophisticated process, for example runt-related transcription factor-2 (Runx2), Tafazzin (Taz), 
Osterix, and Distal-Less Homebox5 (Dlx5). Runx2 is considered as a master gene to achieve 
osteogenic differentiation. It is also known as core-binding factor subunit α (Cbfa1). In cases where 
Runx2 has been knocked out, it has been reported that this leads to loss in the ability to differentiate 
to osteoblasts (Otto et al. 1997). Runx2 has been found to regulate the expression of OCN, bone 
sialoprotein (BSP), OPN, collagen type I and some other signalling molecules (Ducy et al. 1997; 
Javed 2001). Despite the pivotal role of Runx2, its transcriptive action has been reported to be 
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inhibited by TNF-α (Abbas et al. 2003). Taz is another transcription factor that activates Runx2 
expression through FGF2, to enhance osteoblast differentiation (Cui et al. 2003; Byun et al. 2014). 
Taz is proposed to provide a prime role in inhibiting adipogenesis by repressing peroxisomal 
proliferator-activated receptor gamma (PPAR-ϒ) gene expression. Therefore, Taz has been 
suggested to control the fate of multipotent MSCs and determine the switching between osteogenesis 
and adipogenesis (Hong et al. 2005). Osterix transcription factor is proposed to act downstream to 
Runx2, expressed in all developing bone and thus holds an important role in bone biomineralisation. 
Nakashima et al. (2002) have revealed that knockout of Runx2 in mice showed no Osterix 
expression. Osterix activation enhances pre-osteoblasts to mature into osteoblasts. This is observed 
by upregulating the expression of mature osteoblast markers OCN, BSP and type I collagen (Komori 
2006; Choi et al. 2011). Dlx5 is another important bone-inducing transcription factor, assisting in 
osteoblasts differentiation. Its major role is to induce BMP-2 downstream to transcription factor 
Runx2 leading to induce Osterix expression (Lee et al. 2003). Increased expression of Dlx5 is 
proposed to be associated with upregulation of OCN expression and gives an indication of 
mineralised matrix formation in culture (Tadic et al. 2002). 
    1.5: Non-Collagenous Extracellular Matrix Proteins 
                     There are a number of non-collagenous extracellular matrix proteins (NCPs) in bone, which have 
vital roles in the regulation and direction of the construction and maintenance of the ECM. These 
proteins may only comprise about 2% of total bone weight, however, they play critical roles in 
development and embryogenesis, in addition to regulating the formation of collagen fibrils, 
signalling pathways and mineralisation control. These proteins are divided into several classes. In 
this review, the focus will be placed on OPN, due to its diverse functions in bone injury and healing. 
 
     1.5.1: Osteopontin (OPN) 
                      OPN is also called secreted phosphoprotein. It was first identified in 1985 as sialoprotein 
(component of mineralised tissues, such as bone, calcified cartilage, dentin and cementum), derived 
from the bovine bone matrix (Franzén and Heinegård 1985). The name, OPN, is composed of 
'osteon' that means bone in Greek and 'pons' the Latin word for bridge, which refers to OPN function 
as a linking factor (Reinholt et al. 1990). OPN is considered as a member of the Small Integrin-
Binding Ligand N-linked Glycoprotein (SIBLING), of mineralised tissue-associated proteins 
(Fisher and Fedarko 2003). It is secreted by osteoblasts in the early phases of osteogenesis. It acts 
as an inhibitor for mineral formation and crystal growth. It is found in regions of reduced 
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mineralisation, such as bone cement lines, in addition to the periodontal ligament and root 
cementum. (Junaid et al. 2007) have suggested that OPN is also found in the cytoplasm and the 
nucleus of cells, which is called intracellular OPN and has a different function from that of secreted 
OPN. It is found in various cells, namely pre-osteoblasts, osteoblasts, chondrocytes, fibroblasts, 
macrophages, smooth and skeletal muscle cells and endothelial cells. OPN functions have been 
reported to be highly regulated because of post-translational modifications (Kazanecki et al. 2007; 
Boskey et al. 2013). Transglutaminase 2 enzyme can introduce a conformational change in cross-
linking with OPN (Kaartinen et al. 2002; Nishimichi et al. 2009). Other enzymes, for example, 
thrombin, plasmin and matrix metalloproteases-3, -7 and -9, can induce functional motifs for cell 
attachment and migration (Agnihotri et al. 2001; Christensen et al. 2010; Lindsey 2015), and acts as 
a potent regulator of bone mineralisation (Boskey 1995; Pampena et al. 2004). OPN has also been 
reported to play an important role in chronic inflammatory diseases, such as Crohn's disease and 
multiple sclerosis, in addition to cardiovascular diseases and several types of cancer (Kahles et al. 
2014). In contrast, OPN upregulates mineralisation at sites of pathological calcification, namely 
vascular calcification, renal crystals formation and gallstones (Imano et al. 2010; Hirose et al. 2012; 
Berezin and Kremzer 2013). Moreover, OPN has proposed to play a critical role in the development 
of adipose tissue and insulin resistance in diabetes in mice (Nomiyama et al. 2007).  
 
     1.5.1.1: OPN Role in Bone Biomineralisation and Remodelling 
                      Recently, it is well-recognized that the critical physiological function of OPN is the control of the 
biomineralisation process. After an injury or surgical procedure, OPN acts as a secreted chemokine-
like protein. It acts as a chemoattractant and an inflammatory amplification signal for neutrophil and 
macrophage recruitment to the site of trauma or injury (Cooper et al. 2005). OPN has also been  
reported as one of the earlier secreted proteins at the site of biomineralisation by pre-
osteoblasts/osteoblasts or macrophages; and it is reported to be accumulated at the margins of the 
resorbed bone surfaces forming what is called “OPN-rich cement line” (Pedraza et al. 2008; McKee 
et al. 2011). OPN has been described to act through adhesion and also via cell signalling, to recruit 
the maturing osteoblasts to the bone surface area, regulating early steps of bone mineralisation and 
assisting in the bonding of new bone to current bone forming an OPN cement line (Pedraza et al. 
2008; McKee et al. 2011). OPN has been described to have a high proportion of acidic amino acids 
and many phosphorylation sites distributed along the full-length of the protein. These kinds of 
properties allow for protein peptides to bind tightly to apatite crystals, acting as an opsonin to inhibit 
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their formation and assist in the bone remodelling process (Hunter et al. 1996; Addison et al. 2007; 
Hunter 2013). Bone remodelling is the physiological activity by which old bone is removed by 
means of osteoclasts, followed by bone formation by osteoblasts. The role of OPN in bone 
homeostasis not only involves inhibiting new mineral formation, but also by promoting osteoclast 
differentiation and enhancing its activities (Standal et al. 2004). Interestingly, knockdown of OPN 
was found to impair bone remodelling (Asou et al. 2001). 
 
    1.5.1.2: The Role of OPN in Obesity and Type 2 Diabetes Mellitus  
                     Obesity is considered as a chief risk factor for insulin resistance development, which subsequently 
leads to T2DM and its complications. In obesity, there is a chronic low-grade inflammation which 
has been described as a substantial part of the expansion of adipose tissue. This inflamed adipose 
tissue has the ability to enhance the secretion of cytokines, which specifically recruit macrophages 
(Ahlqvist et al. 2013). These cytokines including resistin, visfatin, apelin, omentin, chemerin, IL-
6,  monocyte chemoattractant protein-1 (MCP-1) and TNF-α have a role of linking obesity to the 
development of insulin resistance (Gualillo et al. 2007). It has been observed that in mouse models, 
there is an elevated OPN expression in macrophages recruited to adipose tissue, following 
administration of a high-fat diet. In contrast, there is a significant reduction in adipose tissue 
expression of IL-6, TNF-α, MCP-1 and inducible nitric oxide synthase (iNOS) in the mice that lack 
the OPN gene. Interestingly, OPN reduction not only leads to decrease in adipose tissue 
inflammation, but also improves total body glucose tolerance as well as reduced insulin resistance 
in mice (Nomiyama et al. 2007). To date, the mechanism by which OPN is upregulated in inflamed 
adipose tissue remains unclear, despite OPN expression being enhanced by various cytokines and 
growth factors (Kahles et al. 2014). Some studies have indicated that after the analysis of adipose 
tissue cellular components, macrophages within adipose tissue are the main source of OPN in both 
human and murine genetic, in addition to diet-induced, obesity (Nomiyama et al. 2007; Kiefer et al. 
2008). Of note, obesity and T2DM are strongly associated with hepatic disorders known as a non-
alcoholic fatty liver disease (NAFLD). This is proposed to range from simple hepatic steatosis to 
non-alcoholic steatosis, in addition to steatofibrosis, eventually leading to liver cirrhosis and 
hepatocellular carcinoma, when OPN is upregulated. It has been noticed that OPN expression is also 
upregulated in the liver during obesity and hepatic OPN levels correlate with hepatic triglyceride 
content levels (Bertola et al. 2009). 
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    1.5.1.3: The Role of Osteopontin in the Periodontium  
                     OPN is known to regulate the mineralisation in both in vitro and in vivo study models, in both normal 
and pathological situations (Hunter et al. 1996; Boskey et al. 2002; Wesson et al. 2003; Erik Holm 
et al. 2014). It has been reported that OPN is one of the constituents of the ECM of both dental 
cementum and alveolar bone, within the periodontium (Bronckers et al. 1994; Mckee et al. 1996; 
Bosshardt et al. 1998; Foster 2012). Foster et al. (2018), have reported an important role of OPN in 
mineral regulation in the periodontium. They have suggested that OPN may influence the property 
of tissue density of the periodontal ligament, alveolar bone and cellular cementum. However, it does 
not affect the apposition of acellular cementum. Lack of OPN was reported to promote increasing 
bone volume and mineral tissue in mandibular bone in mice (Foster et al. 2018). Similarly, the 
formation of dentin and cellular cementum were also observed to be rapidly increased in absence of 
OPN, suggesting that OPN may regulate the pace of dentinogenesis and control the matrix 
mineralisation of the alveolar bone (Erik Holm et al. 2014; Foster et al. 2018). 
 
                     There are contradictory findings between reports about the phosphorylated status of OPN (Neame 
and Butler 1996; Salih et al. 1996; Sodek et al. 2000; Qin et al. 2004). Dephosphorylation of OPN 
was described to render it less effective in biomineral regulation (Addison et al. 2007; Narisawa et 
al. 2013). The periodontium was proposed to be extremely rich in tissue-non-specific alkaline 
phosphatase isozyme (TNAP); an enzyme that hydrolyzes inorganic pyrophosphate (PPi) and potent 
inhibitor of the mineralisation process, expressed by skeletal and dental cells (Millán and Whyte 
2016), where there is high activity of TNAP/ALP (Groeneveld et al. 1995; Bos and Beertsen 1999; 
Mckee et al. 2013). Therefore, Foster et al. (2018) have suggested that OPN in this area is relatively 
in a dephosphorylated state. This raises the possibility that the function of OPN may be more about 
cell attachment and signalling activities (Christensen et al. 2012). This piece of knowledge is 
valuable to be further studied in case of increased OPN levels in diabetes and whether its function 
here is for biomineral regulation or more for chemoattractant and signalling activities. 
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    1.6: Macrophages 
                     Macrophages have the prime role in response to pathogens by both innate and adaptive immunity. 
They control tissue homeostasis by secreting certain inflammatory mediators and regulate different 
steps of wound healing through secretion of cytokines and chemokines. Researchers have recently 
categorized macrophages into two main groups, residents and circulating macrophages. The resident 
macrophages are described to be derived from hematopoiesis of yolk sac of the embryo and reside 
in all tissue of mammals in uterus (Schulz et al. 2012; Sieweke and Allen 2013). Resident 
macrophages have been proposed to be heterogeneous and have the capacity of self-renewal. They 
can differentiate into macrophages in their ‘home’ tissue and take different nomenclatures according 
to the host tissue, such as osteoclasts in the bone, Kupffer cell in the liver and microglia in the brain. 
These unique classes of macrophage populations have been described to have various transcription 
profiles (Gautier et al. 2012). 
 
                     The circulating macrophages have been reported to derive from monocytes which originate from 
hematopoietic stem cells (HSCs) in bone marrow and consequently may differentiate into 
macrophages (Akashi et al. 2000; Fogg et al. 2005; Liu et al. 2009; Hettinger et al. 2013). These 
macrophages can display two different phenotypes, the development of which is dependent upon 
the nature of stimulating factors, such as granulocyte-macrophage colony stimulating factor (GM-
CSF) or macrophage colony stimulating factor (M-CSF). The former stimulating factor would 
trigger the cells to form macrophages specific for pro-inflammatory conditions and phagocytosis 
activities, in case of pathogenic stimulus and are called M1 macrophages, whereas the latter would 
drive the cells to display anti-inflammatory action by certain cytokines to repress the inflammation, 
remove the dead tissue  and commence the repair process and are called M2 macrophages (Tushinski 
et al. 1982; Bartocci et al. 1987; Hamilton 2008; Yang et al. 2017). The function of the circulating 
and resident macrophage phenotypes is the same in all tissues. Nevertheless, circulating 
macrophages, which are described to stay for short periods (1-2 days) in the circulation, support the 
function of resident macrophage phenotypes according to the severity of the pathogen. In cases 
where they have not been recruited to face pathogens, they undergo apoptosis (Italiani and Boraschi 
2014; Yang et al. 2017). M1 macrophages have been reported to produce chemokines in response 
to the presence of high levels of the pro-inflammatory cytokines of the inflamed area, such as TNF-
α, and IFN-γ, IL-1β and IL-6, to help perform their phagocytotic activity (Sima and Glogauer 2013). 
On the other hand, M2 macrophages can be primed by IL-4 and IL-13; and exhibit anti-inflammatory 
markers, for example arginase 1 (Arg-1), IL-10, CD163 and CD206 (Sima and Glogauer 2013). This 
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classification, however, cannot reflect the in vivo environment, in which various cytokines can be 
secreted by other cells and may interact differently compared to in vitro state (Wynn et al. 2013). 
                                                                                                                                                                                                                 
   1.7: Diabetes Mellitus (DM) 
                     DM is a heterogeneous metabolic disease, associated with hyperglycemia due to insulin resistance. 
It constitutes a modern epidemic issue, affecting 382 million people according to the International 
Public Diabetic Federation in 2014. This number is expected to rise to 592 million by 2035. 
Interestingly, 90% of this number is T2DM. Thus, this review focuses on T2DM, due to its heavy 
societal burden. In 2012, the global mortality rate associated with T2DM was 4.8 million. 
Furthermore, the high level of the expenditure for its treatment was estimated at $471 billion. The 
normal blood glucose level is indicated as 5.5mM, for fasting plasma glucose. The increase in blood 
glucose above this level means that diabetes occurs (reviewed by Carnevale et al. 2014). For 
information, T1DM is an auto-immune disease, resulting from the destruction of β-cells of the 
pancreas, owing to a cellular mediated immune reaction. This leads to a total loss of insulin secretion 
(Graves et al. 2007). There are genetic and environmental factors involved in the disease 
progression. It has been reported that there is a rising trend of T1DM in children (Aathira and Jain 
2014). Notably, the present study in going to investigate the pathological disorder of T2DM on bone 
repair. 
 
    1.7.1: Type 2 Diabetes Mellitus (T2DM) 
                     T2DM is also formally known as ‘non-insulin-dependent diabetes’. The main pathology is the 
resistance to insulin, combined with a failure to provide enough additional insulin to compensate for 
this insulin resistance. T2DM is commonly accompanied by obesity, which enhances insulin 
resistance (Kahn and Flier 2000). Increase in adipose tissue can release metabolically active 
molecules, which are reported to inhibit cellular ability to respond to insulin, resulting in insulin 
resistance (Greenberg and Obin 2006). In two-third of obese individuals, insulin resistance can be 
overcome by increasing insulin production, identified by an increase in β-cell number. However, in 
one-third of those obese individuals, there has been found a marked decrease in β-cell numbers, due 
to apoptosis. This condition renders β-cells incapable of compensating for this insulin resistance and 
then, T2DM develops (Dickson and Rhodes 2004). 
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    1.7.2: Signalling Pathways Involved in Hyperglycemic Complications 
                     Hyperglycemia is reported to cause several perturbations associated with some metabolic pathways, 
which are considered to have significant roles in the etiology of diabetic complications. These 
pathways include; polyol pathways, AGEs, high levels of PKC activity and hexosamine biosynthesis 
pathways. Disturbances in each of these signalling pathways may affect the important cellular 
molecular activities, resulting in pathological changes (Vlassara 1997; Koya and King 1998; 
Asnaghi et al. 2003). 
 
                     The polyol pathway has been found to be activated by hyperglycemia, which leads to enhancing 
formation of sorbitol and fructose by activation of aldose reductase and sorbitol dehydrogenase 
(Gabbay 1973; Greeneand and Stevens 1996). This pathway was reported to contribute to diabetic 
microvascular complications and sorbitol accumulation inside cells, which could cause cellular 
damage. In addition, D’Souza et al. (2009), have suggested that Runx2 activation during diabetic 
bone healing is regulated by the polyol pathway.  
 
                     AGEs are non-enzymatic fragments of glucose molecules which bind to proteins. The number of 
glucose molecules that bind proteins is governed by the exposure time and the glucose 
concentrations. Thus, AGEs form and accumulate due to age, as well as in hyperglycemic conditions 
as in diabetes. They appear to have various deleterious effects on wound healing by different 
mechanisms, such as enhancing and prolonging inflammation, inducing cells apoptosis and affecting 
production, repairing and remodelling of the ECM (Owen et al. 1998; Vlassara and Palace 2002). It 
has been found that the blocking of AGEs improved the rate of wound healing in a diabetic mouse 
model. Likewise, down-regulation of pro-inflammatory cytokines, TNF-α, IL-6 and matrix 
metalloproteinase activity, subsequently improves matrix formation (Lalla et al. 2000). The effect 
of AGEs was also proposed to alter the bone metabolism, through the decreased expression of genes 
that enhance osteoblast differentiation, diminish growth factor production and lead to a reduction in 
ECM (Bouillon 1991; Lu et al. 2003). Despite AGE detrimental effects, a basal level of them has 
been reported to be required to maintain cell proliferation and osteogenic differentiation (Autréaux 
and Toledano 2007; Byon et al. 2008; Atashi et al. 2015). 
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                      PKC expression is reported to be increased by hyperglycemia. PKC is activated by a lipid second 
messenger diacylglycerol protein (Kingand and Brownlee 1996; Koyaand and King 1998; 
Hiramatsu et al. 2002). It is also enhanced by the increasing nicotinamide adenine dinucleotide 
/nicotinamide adenine dinucleotide reduced (NAD+/ NADH) ratio (Kingand and Brownlee 1996; 
Good et al. 1998). Increased PKC expression has been suggested to stimulate reactive oxygen 
species (ROS) production, which in turn found to activate NADPH oxidase in endothelial cells, 
resulting in the progression of atherosclerosis in diabetic patients (Inoguchi et al. 2000). 
 
                     Hyperglycemia can also activate and trigger hexosamine biosynthesis pathways (HBP). This leads 
to producing excessive flux of free fatty acids (FFA) and uridine 5-diphospho N-acetylglucosamine 
(UDP-GlcNAc) into the circulation and developing of insulin resistance (Hebert et al. 1996; Buse 
2006). The activation of HBP and glutamine fructose-6-phosphate aminotransferase (GFAT), in 
addition to O-GlcNAclation revealed different pathological perturbations, which are proposed to 
directly participate in micro- and macro-vasculature complications, for example insulin resistance 
(Buse 2006), increased NF-κB-dependent promoter activation (James et al. 2002), in addition to 
developing of hyperlipidemia and obesity (Veerababu et al. 2000) (Figure 1.2). 
 
                                                                                                                                                                                                                                                                                                                        
Figure 1.2: Signalling pathways proposed in diabetic complications (Adapted from Graves and 
Kayal 2011). 
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    1.7.3: Cell and Tissue Damage Induced by Hyperglycemia  
Hyperglycemia is known to be mostly accompanied by high ROS production and this induces 
oxidative stress in various tissue, which negatively affects cellular functions. Where ROS production 
exceeds levels of the endogenous antioxidants, this will result in a state of oxidative stress. In the 
absence of regulation of endogenous antioxidant within the body system, this will exert harmful 
effects on cells and their tissues (Rolo and Palmeira 2006; Fenga et al. 2013). Soardo et al. (2011) 
have revealed that FFA may act as a pivotal role in activating the oxidative stress in human 
hepatocyte cell culture. It has been also reported that a massive level of ROS may result in 
depolymerization of proteins, lipid and even DNA (Waddington et al. 2000; Moseley et al. 2004). 
Glucose metabolism in the normal physiological state is performed through the tricarboxylic acid 
cycle (TCA cycle). This will activate electron pump channels to move the electrons across the 
mitochondrial membrane and produce the energy. High glucose concentrations in the environment, 
however, leads to increase in the voltage across the membrane and produces superoxide (O2
.-) by 
means of NADPH oxidases (Brownlee 2005). O2
.- is considered as important ROS products and has 
a central role in the vasculature. Thereafter, O2
.- undergoes a dismutation by superoxide dismutase 
enzyme (SOD) and form more stable ROS, namely hydrogen peroxide (H2O2), (Figure 1.3). H2O2 
is then turned into H2O and oxygen by the catalase enzyme (Taniyama and Griendling 2003). 
Notably, catalase has been reported as reduced and sometimes absent in diabetic tissues (Góth 2008; 
Waddington et al. 2011). The imbalance of these antioxidant molecules leads to accelerating cellular 
damage (Waddington et al. 2000). Nitric oxide has been also observed to be lower in diabetic patient, 
which affected the endothelial progenitor cells in term of number and functionality, causing an 
impairment of vascularization in a diabetic healing bone (Hamed et al. 2010).        
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Figure 1.3: Diagram elucidates how hyperglycemia enhanced O2
.-  production occurs via the 
mitochondrial electron transport chain (Adapted from Brownlee 2005). 
 
     1.7.4: Diabetic Impact on Bone and Tissue Healing  
                     Wound healing is a sophisticated process encompassing inflammation, granulation tissue formation 
and tissue repair and remodelling. Hyperglycemic environments due to diabetes have been found to 
have deleterious effects, resulting in impairment of wound and bone healing, such as a reduction in 
bone matrix formation (Suzuki et al. 2005; Kwon et al. 2008; Wang et al. 2010b). A broad number 
of studies have been conducted in vitro and in vivo, in order investigate the mechanisms by which 
hyperglycemia impairs bone healing. Evans et al. (2002), stated that this impairment may be due to 
possible alterations to some steps in the healing process. For example, the influx of progenitor cells, 
such as bone marrow and endothelial progenitor cells (EPCs) has been demonstrated to be delayed, 
which consequently results in decreased osteogenesis and angiogenesis (Fiorina et al. 2010). 
Moreover, hyperglycemia has been reported to reduce the proliferation and differentiation capacity 
of these cells (Albiero et al. 2011). In diabetic mice, EPCs were reported to possess decreased 
mobility in the circulation, due to impaired activation of endothelial nitric oxide synthase (eNOS) 
(Gallagher et al. 2007). The decrease in cell migration, in the pro-inflammatory cells, to the site of 
injury or fracture, may be another mechanism of impairment of diabetic wound healing. In case of 
inflammation, activation of macrophages, fibroblasts, endothelial cells and platelets results in 
triggering the release of essential cytokines and growth factors for maintaining the healing process 
28 
 
(Brem and Tomic-Canic 2007). In a diabetic environment, it has been proposed that the chemotactic 
ability to recruit the inflammatory cells to the wound healing site is lower than that in the 
normoglycemic environment. Fewer cytokines and growth factors also lead to reduced angiogenesis 
and bone repair (Medina et al. 2005). This alteration in the inflammatory profile and decrease in 
cellular immune response has been associated with higher levels of infectious complications in cases 
of uncontrolled diabetic rats (Blondet and Beilman 2007). The role of growth factors, such as TGF-
β, IGF, VEGF and others, in bone matrix formation has also been found to be altered in diabetes. 
Dysregulation of these factors results in impairments of neovascularization and consequently, a 
reduction of oxygen and nutrient supply (Maruyama et al. 2007). AGEs stimulate TNF-α expression 
and matrix metalloproteinase enzymes, leading to reduced collagen deposition within the matrix. 
When associated with chronic inflammation, this tends to decrease ECM capacity to support growth 
factor activities, which delays the healing process (Al-Zube et al. 2009). Hyperglycemia has been 
found to induce 71 genes in diabetic animal models, that promote apoptosis and enhance caspase 
activity (caspase-3, caspase-8 and caspase-9), which have been reported to reduce the fibroblast 
density and affect collagen synthesis, resulting in lower matrix formation (Al-Mashat et al. 2006). 
Moreover, diabetes has been reported to drive progenitor cells into adipogenesis rather than 
osteogenesis, by means of PPARγ, which exacerbate the condition and delay bone healing (Botolin 
et al. 2005; Botolin and Mccabe 2007; Wang et al. 2010a). Such harmful effects on bone formation 
are also confirmed by the reduction of OCN concentration, which is an important biomarker for 
osteogenesis. In diabetic individuals, it has been reported that osteocytes have secreted a substance 
into circulation called sclerostin, which is an antagonist of  osteoinductive Wnt/β-catenin (canonical) 
pathway, essential for osteogenesis (Gaudio et al. 2012;  Carnevale et al. 2014).  
 
    1.7.5: Type 2 Diabetes Mellitus and Inflammation  
                     Elevations in the levels of inflammatory systemic markers is a common feature of diabetes. It has 
been reported that the serum levels of TNF-α, IL-1 and IL-6 are increased (Senn et al. 2002; Borst 
2004). This condition has serious implications which lead to micro- and macro-vascular 
complications. One major complication is the cardiovascular disease that contributes to the death of 
80% of individuals with T2DM (Chiquette and Chilton 2002). 
 
                     Diabetes has also been described to affect oral health, involving an altered inflammatory response 
to bacterial plaque. It has been reported that gingival crevicular fluid from diabetic individuals with 
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periodontal disease contained higher IL-1β and PGE2 levels, compared with nondiabetic individuals 
with the same periodontal disease levels (Salvi et al. 1997). Naguib et al. (2004) investigated the 
inflammatory response of T2DM mouse to P.gingivalis, when inoculated into the connective tissues. 
The inflammatory response of both control and diabetes was similar after 1 day. At day 3, however, 
the inflammatory cells infiltrate was reduced in control, while it remained high in diabetic mice. 
Importantly, the bacterial killing mechanism was similar in both control and diabetic groups. 
However, the persistent inflammation exemplified by the prolonged high level of TNF-α can 
exacerbate the situation. Interestingly, knocking out TNF-α with etanercept, a recombinant TNF-α 
receptor, was reported to relieve the inflammation  (Naguib et al. 2004). Thus, prolonged TNF-α 
presence and the dysregulation of cytokine signalling may be considered as important mechanisms 
by which diabetes might alter the host response to a pathogenic challenge (Naguib et al. 2004; 
Graves et al. 2007). 
 
    1.7.6: Diabetes and Cell Apoptosis 
                     Apoptosis is a programed cell death that can be induced by several signaling pathways. By this 
mechanism, the body can remove unwanted cells during the developmental process, in addition to 
infected cells or those susceptible to be tumorigenic. Despite the low percentage of apoptotic cells 
at any given time, the cumulative effects of a one-day period in diabetic patient are considered to be 
quite high (Graves et al. 2006). It has been observed that apoptosis acts a pivotal role in several 
diabetic complications, namely nephropathy and myocardial apoptosis (Cai et al. 2002). Diabetes is 
usually associated with the formation of ROS, pro-apoptotic factors, AGEs and TNF-α. These 
factors have a different potency in apoptosis induction. Intriguingly, AGEs induce nuclear factor-
kB activation, which acts as anti-apoptotic in most cell types (Cai et al. 2002). In other words, AGEs 
and the pro-apoptotic molecules, stimulate both anti- and pro-apoptotic factors; and the overall 
balance between them produce the net result (Alikhani et al. 2005). Therefore, increasing their levels 
in diabetic individuals tends to increase in apoptotic activities. 
 
    1.7.7: Diabetes Impact on Periodontal Disease  
                     Diabetes has been undoubtedly confirmed as a prime risk factor for periodontal disease (Khader et 
al. 2006; Salvi et al. 2008; Chavarry et al. 2009). Diabetes increases the susceptibility of individuals 
to periodontal disease by twofold to fivefold. In addition, there is a well-established relationship 
between the hyperglycemic degree and the severity of periodontal disease (Preshaw 2009). The 
association between these two conditions, however, is not completely understood. The situation 
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between the two diseases involves various aspects, such as the immune function, cytokine biology 
and neutrophil activity. It is postulated by the United State National Health Examination Survey that 
adults with 9% Glycated haemoglobin A1c (HbA1c) level or more for diabetes, had significantly 
higher prevalence of severe conditions of periodontal disease, compared with those without diabetes 
(Tsai et al. 2002; Preshaw 2009).  
 
                     There are several mechanisms proposed to elucidate how diabetes affects periodontitis, however, 
recently, more studies have focused on the established host response in periodontitis (Kornman et 
al. 1997; Preshaw 2009). The immune response to subgingival microflora reported being increased 
in diabetic individuals (Senn et al. 2002; Borst 2004). These include an increase in systemic markers, 
such as TNF-α and IL-6, prostaglandins and matrix metalloproteinases. The increase and 
dysregulated production of these immune mediators, altering and exaggerating the host response to 
bacteria, result in attachment loss, pocket formation and alveolar bone destruction (Preshaw 2009). 
 
                     Impaired neutrophil function is another mechanism that may explain the diabetic impact on 
periodontal disease. Chemotaxis, adherence and neutrophil function have reported being impaired, 
in addition to delayed apoptosis activity in diabetic individuals (Darby et al. 1997; Rai et al. 2005; 
Graves et al. 2007). Neutrophils are the key defensive factors against periodontal plaque bacteria. 
However, delayed apoptosis may result in neutrophil retention in the periodontal tissues, which in 
turn, could elevate tissue destruction due to excessive release of destructive enzymes by neutrophils, 
such as matrix metalloproteinases and ROS (Preshaw 2009). 
 
AGEs have been proposed as a further mechanism that link diabetes to periodontal disease. In 
hyperglycemic conditions, glycosylation of proteins, as well as matrix molecules, take place leading 
to AGE formation. The formation of these products is irreversible, which in turn, increased cross-
linking to collagen molecules, contributing to various diabetic complications, decreasing blood 
vessels elasticity and contributing to periodontal tissue destruction. AGEs can trigger monocytes 
through surface receptor of AGEs, called RAGEs, resulting in the release of numbers of pro-
inflammatory mediators, such as TNF-α, IL-1β and IL-6, which increase tissue damage (Lalla et al. 
2001). Interestingly, Lalla et al. (2000) have demonstrated that blocking AGEs down-regulates 
matrix metalloproteinase activity, which may assist in the matrix formation. Taken collectively, this 
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evidence leads to conclude that diabetes appeared to increase the risk and exaggerate periodontal 
disease in comparison to non-diabetic individuals.   
 
     1.7.8: Periodontal Disease Impact on Diabetes 
                      Recently, the fact that diabetes is considered as a risk factor to periodontal disease has now changed 
and recently, the focus on a new hypothesis ‘two-way’ relationship between the two diseases, where 
periodontitis could demonstrate negative effects on glycemic control (Preshaw et al. 2012). It has 
been found that severe periodontitis was accompanied by an increased risk of hyperglycemia in 
individuals with HbA1c > 9 % at a minimum of 2-years follow-up. This finding suggests that severe 
periodontal disease may be considered as a risk factor to enhance diabetes (Taylor et al. 1996; Costa 
et al. 2017). Another longitudinal study assessed the impact of periodontitis on the HbA1c levels of 
2,973 non-diabetic subjects (Demmer et al. 2010). The participants who had advanced periodontal 
disease at baseline, exhibited an approximately fivefold increase in HbA1c during the 5 years of 
fellow-up, compared to those with no periodontal disease. This result predicts that periodontitis leads 
to progress HbA1c levels among non-diabetic individuals. The study is continuing to identify if 
these subclinical changes in HbA1c levels might progress into increasing the risk of diabetic 
incidence at 10 years. Meta-analyses of different studies indicated that there were reductions by 
around 0.4% of HbA1c in diabetic individuals, after effective treatment of periodontitis (Preshaw et 
al. 2012). Although this is considered as a relatively small change, it still demonstrates the impact 
of periodontitis on diabetes, however, more studies are needed to support this concept. 
                         
    1.7.9: Macrophages Role in Obesity and Type 2 Diabetes Mellitus 
                     Obesity was reported to induce a chronic state of low-grade inflammation (Kammoun et al. 2014). 
This inflammation was described not to be resolved as in acute inflammation, but results in certain 
implications, such as atherosclerosis and T2DM (Osborn and Olefsky 2012; Noto et al. 2013). The 
primary effectors of this inflammation are the immune cells through innate and adaptive immune 
systems. In adipose tissue, macrophages infiltrate and comprise the major effector type of immune 
cells (Okabe and Medzhitov 2014). M1 macrophage phenotype numbers were described to correlate 
with enhancing insulin resistance in obese rodents (Fujisaka et al. 2009). Patsouris et al. (2008), 
demonstrated that ablation of the M1 phenotype from the obese mouse by targeting diphtheria-sense 
CD11c+ cells, resulted in improved glucose tolerance. On the other hand, it has been suggested that 
M2 macrophages had positive effects by strongly promoting pancreatic β-cell proliferation (Xiao et 
al. 2014). 
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                     Macrophages were found to dynamically switch from one phenotype to the other, in response to 
their environmental conditions. In diabetes, M2 has been reported to transform to M1, resulting in 
loss of M1/M2 balance. Increase in M1 in the tissue is associated with more cytokines production, 
concurrently with a decrease in M2 cytokines. This will result in adipose tissue dysfunction and 
insulin resistance through impaired glucose tolerance. Of interest, PPARγ transcriptive factor has 
been proposed to play a major role in switching M2 to M1 cells  (Shi et al. 2006; Davis et al. 2008; 
Kraakman et al. 2014). 
 
    1.8: Macrophages Role in Periodontal Disease  
                     The chronic periodontal disease is known to affect the periodontium, due to dysregulated 
interactions between the subgingival bacterial biofilms and their host immune system (Pihlstrom et 
al. 2005). Macrophages are described to play an important role in fighting periodontal pathogens, 
resulting in periodontal inflammation (Poole et al. 2013). As a response to periodontopathic bacteria, 
the epithelial cells of gingiva, resident macrophages and other dendritic cells secrete cytokines and 
chemokines, such as IFN-γ, IL-1β, IL-6 and IL-8, that result in vasodilation to recruit neutrophils, 
which are considered as the first line of defence (Sima and Glogauer 2013). In addition, further 
circulating macrophages migrate to the area of infection and become active M1 macrophages. In 
this situation, the clinical symptoms of periodontitis have appeared (Yang et al. 2017). The increase 
in M1 cells and imbalance between M1 and M2 macrophages are likely to exacerbate inflammatory 
conditions. Interestingly, the immune system can control the infection in some individuals, which 
remains confined to gingiva during gingivitis. However, in other cases, when macrophages are 
activated to be more M1 rather than M2, inflammation is exacerbated, extending down to involve 
periodontal ligament tissue and the alveolar bone, resulting in periodontal tissue destruction (Yu et 
al. 2016). 
 
    1.9: Aims and Objectives 
The aim of this Thesis is to elucidate the effects of a hyperglycemic environment on                                                                               
MSCs derived from compact bone (CB-MSCs), during expansion in culture; and in terms of 
osteogenic and adipogenic differentiation. This may demonstrate the detrimental effects of 
hyperglycemia on repair processes. OPN is profoundly investigated to determine its effects on bone  
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mineralisation and subsequently on the healing process, as it is proposed to be increased in 
hyperglycemic conditions. In addition, the role of LPS derived from P. gingivalis (Pg-LPS) in 
exacerbation of the inflammatory conditions associated with periodontal disease, was also 
investigated under normal and high glucose conditions. This will underpin the development of a 
solid knowledge, assisting in the successful management of periodontally-involved, patients with 
T2DM. The aims of this Thesis were achieved through the following objectives: 
Chapter 2: Characterization of CB-MSCs at PD15, PD50, PD100 and PD200, in respect to the 
expression of a range of MSC markers, proliferative capacity, cell morphology and ageing. In 
addition, investigation of the hyperglycemic influence on these cells during long expansion in 
culture and the heterogenous profile of CB-MSC populations will be investigated. 
Chapter 3: Investigation of the ability of CB-MSC populations to differentiate into osteogenic and 
adipogenic lineages. The influence of hyperglycemia on these populations, as well as the 
differentiation process was also assessed. The influence of hyperglycemia on OPN expression by 
these cells in vitro, was analyzed, in order to further understanding it’s in vivo effects, which is 
proposed to hamper mineral formation and osteogenesis.  
Chapter 4: Investigation of the effects of Pg-LPS on the osteogenesis of PD15 and PD50 populations 
of CB-MSCs (committed and immature), under normal and hyperglycemic conditions. The effects 
of Pg-LPS on OPN levels were also analysed in an attempt to understand the extensive bone 
destruction in periodontally-involved patients with T2DM. 
Chapter 5: Investigation of the influence of hyperglycemia and Pg-LPS on M1/M2 macrophages 
and the role of M1/M2 macrophages on the expression and secretion of OPN upon exposure to the 
aforementioned factors alone and both together. That was in an attempt to imitate periodontitis and 
explore OPN detrimental effects on the healing in case of periodontitis complicated by T2DM.   
Chapter 6 Summary of the main outcomes obtained from this Thesis. 
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Chapter 2: Characterization of Compact Bone Derived from Mesenchymal Stem Cells of Rat     
Femur 
    2.1: Introduction 
Mesenchymal stem cells (MSCs) are considered to play pivotal roles in bone regeneration and repair, 
due to their ability to differentiate into osteogenic tissue, complemented by their self-renewal 
capacity (Caplan 1991; da Silva et al. 2006). The primary sources of MSCs during bone repair come 
from different sites, namely the bone marrow, periosteum and the endosteal surface of bones (Knight 
and Hankenson 2013). It has been reported through in vitro studies, that the osteoprogenitor cells 
involved in the healing of cortical (direct) fractures come from a perivascular source, with few from 
the endosteal niche (Pittenger et al. 1999; Bari et al. 2001; Noth et al. 2002; Bari et al. 2006). By 
contrast, it has been proposed during in vivo studies during secondary (indirect) fracture healing, 
that both intramembranous and endochondral ossification are required, involving the endosteal niche 
to provide MSCs for osteodifferentiation and bone repair (Zhang et al. 2005; Bielby et al. 2007). 
However, in all of these study cases, tracking of MSCs in terms of their migration and differentiation 
in order to participate in tissue formation, has been impeded by the lack of a consensus and a clear 
definition of the MSC phenotype (Bielby et al. 2007). 
MSCs are proposed to consist of two types of cell niches. First, the perivascular niche, comprised 
around sinusoidal endothelial cells (Kiel et al. 2005; Sugiyama et al. 2006). This cell niche also 
contains the active hematopoietic stem cells (HSCs) involved in renewing the hematopoietic system 
(Wilson et al. 2008; Levesque and Winkler 2011). The perivascular/subendosteal niche is also 
described to have uncommitted MSCs (Balduino et al. 2012). Second is the endosteal niche, which 
is organized around pre-osteoblasts and osteoblasts from lining cells of endosteal bone surfaces 
(Kohler et al. 2009; Xie et al. 2009). This cell niche has, thus, been described to have more 
committed osteoblasts, which have been found to have greater involvement in bone repair (Balduino 
et al. 2012). Macrophages have also been described to be found adjacent to MSCs and osteoblasts 
necessary for supporting the functional integrity of these cell niches. Within this well-arranged 
endosteal cell niche, macrophages have been proposed to have a prime role in supporting 
hematopoietic cell activities  (Chow et al. 2010; Winkler et al. 2010).  
 
 Isolation of MSCs from various tissues by different methods and approaches, has                                                      
demonstrated inconsistencies in study outcomes (Muraglia et al. 2000; Peister et al. 2004). 
Subsequently, the characterization of cells has been difficult, due to the heterogeneous nature of 
MSCs and a lack of standardized criteria to define various MSCs isolated from different tissue 
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(Dominici et al. 2006). This led the International Society for Cellular Therapy (ISCT) to propose 
minimal criteria for MSCs identification. These criteria are firstly, MSCs should have plastic 
adherence by standard culture conditions. Secondly, the cells should express endoglin (CD105), 5’-
ectonucleotidase (CD73) and Thy-1 (CD90) and at the same time, should lack expression of 
hematopoietic stem cell markers CD45, CD34 and CD14. Thirdly, these cells should be capable of 
differentiating into osteoblasts, adipocytes, and chondrocytes in vitro (Dominici et al. 2006).  
 
These criteria, however, do not match the characterization requirements for all MSCs owing to 
several critical shortcomings. First, ISCT criteria lack a unique marker that can be universally shared 
between all organisms. The criteria emphasize on the positive expression of CD105, CD90, CD73, 
despite none of these markers being expressed by all human and animal species (Boxall and Jones 
2012). Thirdly, the criteria refer to the ability of MSCs to differentiate into three independent 
lineages; osteoblasts, chondrocytes and adipocytes, whereas it did not refer to the multiple 
differentiation capacity, including the immature MSCs, which have been described to have the 
ability to differentiate into the majority of cells in the body (Abdalla and Kassem 2008; Samsonraj 
et al. 2015). It has been found that he plastic adherence can be shared by the majority of stem cell 
populations; thus, it is not such a unique MSC marker itself. Furthermore, these classical markers 
are seen to be upregulated or downregulated with increasing passage in culture (Jones et al. 2010; 
Halfon et al. 2011; Harrington et al. 2014). Eventually, it is very necessary to identify unique MSC 
markers, can presumably be found among both animals and human.   
One of the prime characteristic features of MSCs is the hierarchy model that describes MSC 
heterogeneity. In this model, transit amplifying cells (TA) are proposed to be derived from mother 
stem cells after frequent proliferation and exhibit the greatest potential to form large colonies, 
demonstrating a higher proliferative capacity and highest multipotentiality. As cell division 
continues, TA cells demonstrate a decreased proliferative potential with smaller colonies and 
transform into lineage-restricted MSCs, exhibiting tri-, bi- and uni-potentiality (Chan et al. 2004; 
Phinney 2012). This hierarchy model might explain the described phenotypic and cellular 
differences, regarding MSC populations derived from bone marrow and compact bone.  
Hyperglycaemia exhibits a great negative impact on bone healing and repair. High glucose affects 
all steps of bone healing. It has been found to interfere with cell migration and proliferation (Kim et 
al. 2013; Salabei et al. 2016). In addition, a high number of studies have shown that high glucose 
affects bone matrix formation by reducing the stem cells ability to differentiate into matrix 
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production cells (osteoblasts); and through apoptotic effects on these cells by oxidative stress and 
AGEs (Kwon et al. 2008; Fiorina et al. 2017). Consequently, high glucose directly impairs MSCs 
contribution to the healing process (Albiero et al. 2011). In addition to all of the above, ageing effects 
are important consequences, which subsequently lead to cell death. As cells divide, they undergo 
telomere shortening in each single division until the cells reach the Hayflick limit, when cells reach 
a limited point in their replication. Subsequently, the cells suffer from senescence but remain viable, 
although they are no longer able to proliferate (Hayflick and Moorhead 1961; Serakinci et al. 2008; 
Wagner et al. 2008). It has been found that MSCs in high glucose microenvironment demonstrate 
shorter telomere lengths with a decline in telomerase activity, due to the effects of oxidative stress, 
leading to premature cell senescence and ageing (Salpea and Humphries 2010).  
This Chapter aims to provide a detailed characterisation of MSCs derived from the endosteal niche 
of the compact bone and how extensive culture expansion influences the heterogeneous phenotype 
of the MSC population within. MSCs are characterized with respect to the expression and retention 
of a range of MSC markers, including immature MSC markers; proliferative capacity, cell 
morphology and ageing characteristics. In addition, this Chapter has investigated how high glucose 
influences these cells during culture expansion with respect to ageing and the heterogeneous profile 
of the MSC population. 
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    2.2: Materials and Methods 
 
    2.2.1: Isolation and Culture of Mesenchymal Cells from Compact Bone (CB-MSCs) 
The cells used in this study were previously isolated by Dr. Norhayati Yusop, a PhD student at the 
Mineralised Tissue Group (MTG), School of Dentistry, Cardiff University. Cells were isolated from 
the femur and humerus of 28-day-old male Wistar rats by flushing the bone marrow using a 21-G 
needle and syringe filled with isolation medium (IM) [Minimal Essential Medium, (α-MEM), 
(Gibco, ThermoFisher Scientific, UK), 1% antibiotics-antimycotics (Sigma-Aldrich, UK)] to 
remove the bone marrow stromal cells. Bone diaphysis was cut into fragments (1-3mm3) and the 
fragments were digested with 3mg/mL collagenase II (Sigma-Aldrich), in isolation media for 2h at 
37oC with agitation. After 2h, the digestion media with the released cells was removed and the bone 
chips were washed three times with 5mL of basal media [IM and 20% Fetus Bovine Serum (FBS) 
(ThermoFisher Scientific)]. The digested bone chips were incubated with basal media at 37oC in a 
5% CO2 incubator. At day 3, the bone chips and the non-adherent cells were removed; and the 
remaining adherent cells were cultured to allow for expansion. At day 12, adherent cells were 
harvested using Accutase (Sigma-Aldrich) for 10-15min. This passage was considered as passage 
0. Cells were then re-suspended in 1mL of basal media and 10µL of the re-suspended cells was 
mixed with 10µL of 0.4% trypan blue vitality stain; and cells were then counted using Neubauer 
hemocytometer with a light microscope (Nikon Eclipse TS100, Japan). Cells were reseeded and 
culture expanded in basal media. Culture media were changed every two or three days. Once the 
cells reached 80% confluence, further passages were performed and cell population doublings were 
determined. After each passage, a defined number of the cells were frozen in cryovials using 
Bambanker (Bambanker, serum-free freezing medium cryoprotectant, Alpha Labs, UK). 
    2.2.2: Determination of Cell Population Doubling Levels 
Cell population doubling analysis was conducted to monitor cell expansion during the long-term 
culture period. This was determined by counting the total number of cells obtained, following 
accutase treatment and by calculating the total number of re-seeded cells; to establish the population 
doubling levels by the following formula: 
    PD =          log10 (total cell counts obtained) - log10 (total cell counts re-seeded) 
                         log10 (2) 
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    2.2.3: Mycoplasma Testing of Cell Cultures 
Mycoplasma testing was conducted using a VenorGeM Mycoplasma Detection Kit for conventional 
Polymerase Chain Reaction (PCR) (Cambio, UK), using 100μL of the supernatant sample taken 
from approximately 90% confluence cell cultures. Mycoplasma testing was routinely conducted 
every month for each culture. If found positive, cell cultures were treated with 10μg/mL BM-cyclin 
1 and 5μg/mL BM-Cyclin 2 (Roche, UK), for 2 weeks with a repeated dose for 1 week until negative 
results were obtained. 
  
    2.2.4: Cryopreservation and Defrosting of Cells 
Cryopreservation of cultured cells was performed by re-suspending the cells in Bambanker solution 
(Alpha Labs) at a concentration of 1x106/mL. The vials were transferred into Mr. Frosty containers 
with isopropanol; and kept overnight at -80°C before being transferred into liquid nitrogen for long-
term storage. Defrosting of cells was performed by quickly thawing the vial and washing the cells 
with working media, by applying the universal tube into the centrifuge at 400 g for 5 min. 
 
    2.2.5: Characterisation of CB-MSCs 
All subsequent analyses were performed on CB-MSCs at PD15, PD50, PD100 and PD200 in normal 
glucose (5.5mM) and high glucose (25mM) conditions. 
 
    2.2.5.1: Gene Expression for CB-MSCs Markers 
 
2.2.5.1.1: RNA Extraction and cDNA Reverse Transcription  
Cells were seeded at 4,000 cells/cm2 in three wells of 6 well-plates and cultured to 90% confluence. 
Total RNA was extracted using the RNeasy® Mini Kit (Qiagen, UK), as follows. The medium was 
aspirated from the well and cells were washed 3 times with phosphate buffered saline (PBS), before 
adding 600µL of lysis buffer [1mL of RLT buffer with 10μL of β-mercaptoethanol (Sigma Aldrich)], 
to the well for 1min. Cells were harvested and centrifuged with a QIAshredder tube for 2min at 
10,000g (QIAShredder Kit), to homogenize the samples. The cell lysates were mixed with an equal 
volume of 70% (V/V) absolute ethanol (Sigma Aldrich), transferred to RNA Mini Kit columns and 
centrifuged for 15s at 8,000g. The flow-through was discarded from the columns and the remaining 
cell lysate solutions were washed with 350μL of RW1 buffer for 15s at 8,000g. The flow-through 
was discarded, 10μL of RNase-free DNase was mixed with 70μL of RDD Buffer (Qiagen, UK), and 
added to the column membranes for 15min. The columns were washed with 350μL of RW1 Buffer 
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and centrifuged for 2min. Two further column washes were conducted with 500μL of RPE Buffer, 
centrifuged for 15s and 2min, for the first and the second washes, respectively. The flow-through 
was discarded after each wash. The columns were transferred to sterile RNase-free, 1.5mL micro-
centrifuge tubes (Eppendorf, UK), 30μL of RNase-free water was added to the columns and 
centrifuged for 2min. Obtained total RNA was quantified using NanoVue™ (GE Healthcare, UK) 
spectrophotometry. RNA purity was determined by A260/A280 absorbance, with values around 2 
indicating good purity. RNA was directly stored at -80°C for use in reverse transcription reactions. 
cDNA was synthesized using 1μg of the total RNA sample by converting them to the equivalent 
volume, adding 1μL random primer (Promega, UK); and made the volume up to 15μL with nuclease-
free water. This mix was applied to PCR machine (G-Storm™ GSI Thermal Cycler Software 45 
V3.3.0.0), (Genetic Research Instrumentation Ltd., Braintree, UK); and set at 70oC for 5 min. 
Meanwhile, the reaction master mix was prepared, containing 5μL 5X Moloney Murine Leukemia 
Virus Reverse Transcriptase (MMLV) reaction buffer, 1.25μL deoxynucleotide triphosphates 
(dNTPs), 0.6μL RNasin and 1μL MMLV enzyme, added to RNA-free water to 10μL. 15μL of 
random primer/RNA and nuclease-free water was added to the reaction mix to produce a final 
volume of 25μL cDNA. The final 25μL volume was applied to the PCR machine and set at 37°C 
for 1h. The negative control (RT negative) for each cDNA sample was tested, by adding 1μL of 
nuclease-free water to the RT master mix, followed by the same procedure above.  
 
2.2.5.1.2: Polymerase Chain Reaction (PCR)  
PCR was conducted using reagents obtained from Promega, UK. For each reaction, 1µL of cDNA 
sample was used with 5μL 5x buffer, 0.5μL (10mM) deoxyribonucleotide triphosphate (dNTP), 
1.25μL forward and reverse primers, as shown in Table 2.1, 1μL (25mM) magnesium chloride, 
0.25μL Taq polymerase; and 14.75μL RNA-free water, to a total volume of 25μL. Primer sequences 
were obtained from various related studies that fulfill the standards of the National Centre for 
Biotechnology Information (NCBI) Primer-BLAST software. Reactions were performed in a 
Thermal Cycler (G-Storm™ GSI), under the following conditions, one initial denaturation at 95oC 
for 4min and thirty-five cycles of annealing and extension at 95oC for 1min, primer-specific 
annealing temperature 55oC for 1min; 72oC for 1min, and a final cycle extension at 72oC for 10 min. 
For the specificity of the reaction, negative controls, RT-negative (1µL of RT negative added to the 
PCR master mix) and PCR-negative (1µL of nuclease-free water added to the PCR master mix), 
were used. β-actin was used as an endogenous reference gene. PCR products were stored at -20°C. 
40 
 
 
2.2.5.1.3: Agarose Gel Electrophoresis for PCR Products 
A 2% agarose gel was prepared by adding 1.4g of agarose powder (AGTC Bioproducts, USA) to 
70mL of 0.5x tris/borate/ ethylenediamine tetra-acetic acid EDTA (TBE) buffer (89mM trizma base, 
89mM boric acid and 2mM EDTA (Sigma-Aldrich). The solution was heated using a microwave, 
until the agarose had dissolved. The solution was cooled slightly, prior to mixing with 7μL of 
Safeview DNA stain (NBS Biological Ltd., UK). The mixture was poured into a casting tray, 
assembled with a well comb and left to set at room temperature. The gel was transferred to an 
electrophoresis tank filled with 0.5x TBE. 5μL of 100bp DNA ladder (Promega, UK) was added to 
the first well and 10μL of PCR samples/controls for analysis were added to subsequent wells. The 
samples were separated at 90V for approximately 50min. The band visualisation was performed 
using a GelDoc™ Scanner and DocTM EZ Imaging System with Image LabTM Version 5 (Bio-Rad 
Laboratories Ltd., UK). 
 
Table 2.1: Primer sequences and product sizes of selected MSCs markers for RT-PCR analysis. 
 
   Gene Primer Sequence Forward (F)& Reverse(R) Product 
Length 
(b p) 
Annealing 
TemperatueoC 
Source 
  CD105 F: CGGTCTCCAGCTGCGGTGGTGGGCTCC 
R: CACTGCCACCACGGGCTCCCGCTTGCT 
896 62 (Harrington et 
al. 2014) 
  CD 90 F
F: CCTGACCCGAGAGAAGAA  
R: TGAAGTTGGCTAGAGTAAGGA 
125 55 (Harrington et 
al. 2014) 
   CD 73 F: TCCCGCGGCTGCTACGGCACCCAAGTG 
R: ACCTTGGTGAAGAGCCGGGCCACGCCG 
204 62 (Scherer et al. 
2012) 
   CD 45 F: AGCAATACCAGTTCCTCTATGA 
R: TCCGTCCACTTCGTTATGA 
113 55 (L. Wang et al. 
2010) 
  CD106 F: TCCACACTGACGCTGAGCCCTGTGGGTG  
R: CTCCGGCATCCTGCAGCTGTGCCTTGCG 
898 55 (Harrington et 
al. 2014) 
CD146 F: GCAGCGCCACGGGTGTGCCAGGAGAGG 900 62 (Harrington et 
al. 2014) 
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R: CCCCACTGTGGTGCTTCTGGGCGGGCT 
   Snail F: GCGAGCTGCAGGACGCGTGTGTGGAGT 
R: CGGCAAAGGCACGGTTGCAGTGGGAGC 
597 62 (Harrington et 
al. 2014) 
Slug F: CACTCCCCTCTGCCCAGCGGCCTTTCT 
R: GGCATGGGGGTCTGAAAGCTTGGGCTG 
171 62 Lee CP PhD 
thesis (Cardiff 
University) 
Oct4 F: GCCCACCTTCCCCATGGCTGGACACCT 
R: GCAGGGCCTCGAAGCGGCAGATGGTTG 
563 62 Lee CP PhD 
thesis (Cardiff 
University) 
  Nanog F: GGGGATTCCTCGCCGATGCCTGCCGTT 
R: GGGATACTCCACCGGCGCTGAGCCCTT 
477 62 (Harrington et 
al. 2014) 
  TERT F: GCTCCGGTTACACAGCAGCCCCTGGCA 
R: GGTCCAGAGCACGCACACGCAGCACGA 
752 62 Lee CP PhD 
thesis (Cardiff 
University) 
TR Terc  F: CTCCGCCCGCTGTTTTTCTCGCTGACT 
R: GCCACCGAACTCAGGGACCAGTTCCGT 
300 62 Lee CP PhD 
thesis (Cardiff 
University) 
  β-actin F: TGAAGATCAAGATCATTGCTCCTCC 
R: CTAGAAGCATTTGCGGTGGACGATG 
155 55 (Gatto et al. 
2008) 
 
    2.2.6: Cell Morphology     
24-well plates were used and a 13mm glass coverslip (Coverslip, round 13mm, VWR, UK) was 
immersed in 70% alcohol for aseptic purposes, then rinsed in PBS and inserted into each well. Cells 
were cultured at seeding densities of 4,000/cm2 and incubated for 24h at 37oC in 5% CO2 incubator. 
On the second day, the medium was aspirated and the cells were washed 3 times with α-MEM and 
fixed with 4% paraformaldehyde (Santa Cruz, USA) for 30min. The 4% paraformaldehyde was then 
aspirated and the cells were washed 3 times with tris buffered saline (TBS). Cells were 
permeabilized with filtered 1% Triton X-100 (Sigma-Aldrich) for 30min at room temperature and 
washed again three times with TBS, before blocking the non-specific binding sites with 1% Normal 
Horse Serum (Vector Laboratories, UK), in TBS for 1h at room temperature. Normal Horse Serum 
was removed and the freshly prepared phalloidin stain (phalloidin fluorescein isothiocyanate 
labeled, Sigma-Aldrich) (diluted 1:50 in TBS), was applied to the cells for 40min at room 
temperature. Cells were washed 3 times with TBS and left for 5min to dry. The cover slips in each 
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well were gently removed and mounted on the slide using 10µL of DAPI (Vectashield Hard Set, 
Vector Laboratories, UK). Images were taken by an AX70 Olympus Provis microscope with UV 
light, at 20X and 40X magnifications.  
    2.2.7: Colony Forming Efficiency (CFE) 
Cells were reseeded in 6-well plates at 100 cells/well and cultured in the basal media, at 37oC in 5% 
CO2 incubator, for up to 5 days. The cells were viewed by light microscopy (Nikon Eclipse TS100, 
Japan ) every 24h and the number of colonies (colony defined by Jones and Watt 1993, representing 
greater than 32 cells) were identified and recorded, using a marker pen on the underside of the culture 
well. 
    2.2.8: qPCR for Cell Cycle Marker (p53, p21 waf1 and p16 INK4a) Expression 
Expression of cell cycle markers (p53, p21waf1 and p16INK4a) was investigated using quantitative real-
time polymerase chain reaction (q-PCR). RNA was extracted and cDNA was prepared, as described 
previously (Sections 2.2.5.1.1). 1µg of the obtained cDNA was diluted 1:10 with nuclease-free water 
(Promega). For each q-PCR reaction, 2μL of 3μM primers (forward and reverse sequences, detailed 
in Table 2.2), were mixed with 10μL of 2x Precision FAST q-PCR Master Mix (Primer Design, 
UK); and 1μL of nuclease-free water. 5μL of diluted cDNA was applied in triplicate into white 96-
well q-PCR plates (Primer Design), followed by 15μL of pre-prepared Master Mix. Plates were 
covered with adhesive optical seals (Primer Design); and centrifuged at 500g for 5min. q-PCR 
analysis was conducted in a QuantStudio™ 6 Flex Real-Time PCR System machine (ThermoFisher 
Scientific, USA), using QuantStudio™ Real-Time PCR Software (v1.0). Reaction conditions were 
as follows: one initial denaturation at 95°C for 20s, forty cycles of denaturation for 1s and annealing 
for 20s. After cycling was completed, melt curve analysis was performed as follows: 95°C 
denaturation for 15s, 60°C dissociation for 1min and 95°C denaturation for 15s. GAPDH was used 
as an internal reference control for data normalisation. The quantitative analysis of the gene 
expression was calculated using the ΔCt method, through expression the gene as a percentage of the 
GAPDH. Error bars represent standard error of the mean (SEM). 
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Table 2.2: Primer sequences, product sizes and the annealing temperature of the selected MSCs cell 
cycle markers for q-PCR analysis. 
Gene Primer sequence Forward (F),  
Reverse (R) 
Product 
Length 
(b p) 
Annealing 
Temperature oC 
Source 
p16INK4a F: TGCAGATAGACTAGCCAGGGC 
R: CTCGCAGTTCGAATCTGCAC 
184 55 Author 
(Ahmed Al-
Qarakhli) 
p53 F: ACAGCGTGGTGGTACCGTAT 
R: GGAGCTGTTGCACATGTACT 
83 55 P.Battersby 
(Cardiff 
University) 
p21waf1 F: TCTTGCACTCTGGTGTCTCA 
R: GGGCTTTCTCTTGCAGAAG 
147 55 Author 
(Ahmed Al-
Qarakhli) 
 
   2.2.9: Measurement of Cell Telomere Length 
 
   2.2.9.1: DNA Extraction for Telomere Restriction Fragment (TRF) Assay 
DNA was extracted using QIAmp kits (Qiagen). Cells were seeded at 4,000/cm2 in 6-well plates and 
cultured until 90% confluent. Cells were detached from the plate using accutase and centrifuged at 
1,800rpm for 5min. The supernatant was discarded and the pellets re-suspended in 200µL PBS, 
mixed with 20µL proteinase K and 200µL of AL lysis buffer, both provided within the Kit. Samples 
were incubated at 56oC for 10min and mixed by pulse-vortex for 15s. 200µL of 100% ethanol was 
added to each sample and mixed by pulse-vortex for 15s. Samples were transferred to QIAamp mini 
spin columns, setting in a 2-mL collection tube and centrifuged at 6,000g for 1min. The flow-
through was discarded and the columns placed in a new 2mL collective tubes. 500µL Buffer AW1 
was added to each column and centrifuged at 6,000g for 1min. The collection tubes were discarded 
and the columns placed in a new 2mL collective tubes. 500µL of buffer AW2 was added to each 
column and centrifuged at a full speed 20,000g for 3min. The columns were placed in a new 1.5mL 
micro-centrifuge tube, 200µL of buffer AE provided with the Kit was applied to the column, left for 
1min at a room temperature and centrifuged at 6,000g for 1min. The obtained DNA concentration 
was quantified by spectrophotometry (NanoVue) and stored at -20oC.         
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    2.2.9.2: Measurement of Cell Telomere Length by (TRF) Assay 
The telomere lengths of each DNA sample were determined using Telo-TAGGG Telomere length 
Assay Kit (Roche, UK), according to manufacturer’s instructions. Each sample of DNA (1µg) was 
digested with Hinf1/Rsa (1µL) and 10X digestion buffer (2µL), to a final volume of 20µL with 
nuclease-free water. The samples were incubated at 37oC for 2h. The reactions were terminated by 
5µL gel electrophoresis loading buffer. Gel electrophoresis was conducted using 0.8% highly pure, 
nucleic acid grade agarose-agarose MP (Geneflow, UK) in 1X Tris-acetate-EDTA (0.04M Tris-
acetate, 0.001M EDTA, 1X TAE). Digested DNA samples were loaded as following; 1µg of DNA 
digest equal to 20µL were loaded onto wells, in addition to 10µL of diluted DIG molecular weight 
marker (4µL DIG molecular weight markers, 12µL   of nuclease free-water and 4µL loading buffer), 
in the wells on both side of the gel to ensure accurate length measurement and set at 20V overnight, 
until the bromophenol blue separated to about 10cm from the starting wells. The gels were 
transferred to a tank and submerged in a 0.25 M hydrochloric acid solution for 10min at room 
temperature. Gels were rinsed twice with distilled water before being submerged in 2X denaturation 
solution (0.5M sodium hydroxide, 1.5M sodium chloride) for 15min at room temperature and again, 
rinsed twice with distilled water. The gels were then submerged in 2X neutralization solution (0.5M 
Tris-HCl, 3M sodium chloride, pH 7.5), for 15min at room temperature. Washing steps were all 
performed with gentle agitation. 
Southern blotting was conducted using a blotting unit (BIOS, UK). The tank within the blotting unit 
was filled with 2X standard sodium citrate buffer (SSC) (3M sodium chloride, 0.3M sodium citrate, 
pH 7.0). Four pieces of 3mm Whatman paper (Sigma-Aldrich) were placed on the platform of the 
blotting unit. The gel was applied over these papers. A positively charged nylon membrane (Roche, 
UK), was customized and applied on the gel surface to transfer the DNA signal. Four pieces of 
Whatman paper soaked in 20X SSC were placed over the nylon membrane, to enable the 2X SSC 
buffer in the tank to move through the nylon membrane to assist in the transfer of DNA. Finally, 
10cm of dry paper towels was applied on the apparatus to assist in capillary movement; and topped 
with 2kg weight. The whole apparatus was covered with Saran Wrap, to prevent any evaporation 
and left overnight at room temperature to allow for proper transfer. On the morning of the second 
day, the 2kg weight was removed, the nylon membrane was taken, fixed twice for 10s, using UV-
crosslinker (Stratalinker, USA) to make sure good DNA signal stickiness to the membrane. 
Hybridization steps were achieved in a hybridization oven (VWR, UK). The membrane was placed 
side up (DNA signal side) in the hybridization bottle and rotated gently on a rotisserie with 25mL 
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of DIG Easy Hyb (reconstitute the granules (bottle-9-kit from the Kit) with 64mL of autoclaved 
distilled water, incubated for 1h at 42oC. This solution was replaced with 10mL pre-warmed 
hybridization solution mixed with 2µL of telomere probe and incubated at 42oC for 3h. The 
membrane was washed with 25mL of 2X Stringent Wash Buffer I (2X SSC, 0.1% sodium dodecyl 
sulfate) for 5min at room temperature. Another wash was performed with 25mL of 2X Stringent 
Wash Buffer II (0.2 X SSC, 0.1% sodium dodecyl sulphate) for 20min at 50oC and then a wash with 
25ml of washing buffer for 5min at room temperature. After that, the membrane was incubated for 
30min in 25ml of [1X blocking solution (dilution 10X (bottle 13 from the Kit), 1:10 with malic acid 
buffer)] and washed with 25mL washing buffer for 30min at room temperature. The membrane then 
incubated with 25mL [anti-DIG-AP working solution (Dilute bottle 14) 1:10,000 with blocking 
solution), and 1X detection buffer (Dilute 10X (bottle 15), 1:10 with autoclaved distilled water] for 
15min, followed by a final wash for 5min with autoclaved distilled water at room temperature. 
The membrane was removed from the hybridization bottle and incubated for 5min in substrate 
solution at room temperature and wrapped with Saran Wrap. The membrane was laid in a cassette 
(Hypercassette, UK), exposed to a high-performance Chemiluminescence Film (GE Healthcare) for 
1, 2 and 5min, respectively. The film was developed using CURIX 60 Auto-Developer (AGFA, 
Belgium).            
    2.2.9.3: Densitometry Analysis 
To calculate the telomere length, the chemiluminescence film containing the telomeric-specific 
smear of the Southern blot was scanned at 300 resolution. The image was opened in ImageJ software, 
rotated to align vertically to enable the analysis through converting the telomere-specific signal into 
mean TRF. To measure the optical density, 33 rectangular even size boxes were overlaid on each 
specific smear sample (Figure 2.1). The software then converted this optical density into numbers 
on an excel spread sheet. The background density was calculated using the average density of three 
boxes that did not contain a telomere-specific signal and subtracted from each box of the lane that 
contained the sample. The mean density (ODi) of each box containing DNA and the corresponding 
length (Li) according to the molecular weight ladders (measured in kbp) localized at the midpoint 
of the box were calculated and applied to the formula ∑ (ODi) / ∑ (ODi) /Li). Finally, the mean 
TRF was obtained (Kimura et al. 2010). 
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Figure 2.1: Southern blot image showing the boxes overlaid on the telomeric specific smear layer 
to calculate the mean of the telomere length, using ImageJ software.  
    2.2.10: Senescent Associated β-galactosidase (SA β-gal) Assay  
A Senescence Cell Histochemical Kit (Sigma-Aldrich) was utilised to detect senescent associated 
β-galactosidase activity in senescent cells. In accordance with the manufacturer’s instructions, cells 
were seeded in 6-well plates at 4,000/cm2 and cultured in the basal medium at 370C, 5% CO2, for 
24h. The culture medium was aspirated and the cells washed 3 times with PBS, diluted 1:10 in 
ultrapure water. Fixation buffer was diluted 1:10 in ultrapure water (18.2MΩ H2O) and added to the 
cells (1.5 mL/well) for 7min at room temperature. Fixation solution was removed from each well 
and cells were rinsed 3 times with PBS (1mL/well). 1mL of pre-prepared staining mixture was added 
to each well and incubated at 37oC at 5% CO2 overnight. The staining mixture was removed and the 
wells were filled with 2mL PBS and sealed with parafilm to prevent dryness. 5 Images were taken 
by a light microscope (Nikon Eclipse TS100) for each well and then positive blue-stained cells were 
counted. Finally, the percentage of cells expressing β-galactosidase activity was calculated. Three 
repeats experiments were conducted. 
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    2.2.11: Statistical Analyses  
Statistical analyses were performed using One-Way ANOVA with a post-hoc Tukey test to 
determine the statistical differences between sample groups, using the software GraphPad InStat 3 
(v3.06). Statistical significance of differences was defined as significant (*, p<0.05), very significant 
(**, p<0.01) or highly significant (***, p<0.001). 
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    2.3: Results 
 
    2.3.1: CB-MSC Population Doublings (PDs) 
CB-MSCs were cultured and PDs calculated for each passage (Figure 2.2). Cells reached 300PDs at 
about day 350 in both the normal physiological medium (5.5mM glucose, N) and the high glucose 
medium (25mM glucose, G). The cells in both media demonstrated a lag phase until about PD10 
before the growth continued and PDs rose with time to PD300 at about day 350, without any signs 
of slowing growth rates.  
                 
Figure 2.2: Population doublings for CB-MSCs represented by normal (5.5mM blue line) and high 
glucose media (25mM red line). Cells growing initially showed a lag phase for both groups. Seeding 
density was 10,000 cells/cm2. Cell passage was always performed, when cultures reached 80% 
confluence. 
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    2.3.2: Characterization of CB-MSCs 
RT-PCR analysis of gene expression for CB-MSCs to identify the minimally defined gene 
expression markers for MSCs, CD105, CD90 and CD73. These markers   were positively expressed 
in all sample groups (Figure 2.3). β-actin was used as a reference gene marker and consistently 
expressed throughout culture for all PDs in normal and glucose media. Hematopoietic marker 
expression CD45 was negative, whereas CD34 exhibited very low expression. CD146 was 
expressed in all samples, but exhibited low expression at PD200, in high glucose. There was no 
expression of CD106 or the pluripotent stem cell markers, Nanog and Oct4. Embryonic markers, 
Slug and Snail, had an even expression in all groups. In the case of the telomere maintenance 
markers, Tert and TR, Tert was expressed at PD15 N and PD100 N, whereas only trace levels PD50 
N. In glucose exposed cells, Tert expressed at a high level at PD15 and showed a gradual decrease 
in expression at PD50 and PD100. Tert had no expression in PD200 for both normal and high glucose 
conditions. TR was expressed in both normal and high glucose conditions at PD15, PD50 and 
PD100, while showing faint expression in PD200 N, with no signal in PD200 G (Figure 2.3). 
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Figure 2.3: Expression of CB-MSC gene markers using RT-PCR, showed the mRNA expression 
profile of the classical MSC markers, CD105, CD90 and CD73. No expression of hematopoietic 
endothelial marker CD45 with very low expression CD34. There was also detectable expression of 
CD146, Slug, Snail and no expression of CD106 and Oct4, with trace expression of Nanog. Tert and 
TR were expressed in all populations except at PD200. TR showed faint expression at PD200 normal 
and glucose conditions. 
 
    2.3.3: Cell Morphology and Surface Area 
Cells exhibited heterogenous morphology at PD15, with spindle, fibroblast-like and stellate shapes. 
PD50, PD100 and PD200 had more stellate-shape cells, with a typical feature of MSCs (Figure 
2.4A). Cells were treated with FITC-phalloidin stain and digital images were taken using a 
fluorescence microscope (Figure 2.4B). PD15 N and G demonstrated significantly higher cell 
surface areas among all PDs (*** = p<0.001), with various shapes and sizes; both spindle and 
stellate. Some cells had stressed actin fibers, which appeared brighter under fluorescence (Figure 
2.4A). PD50 cells exhibited more stellate shapes, and the cell surface area became significantly 
smaller than at PD15 (*** = p<0.001). PD50 G was significantly (*** = p<0.001) larger than PD50 
N (Figure 2.4 C). PD100 cells were smaller and again maintained the same stellate shape, with the 
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cell surface area being the smallest of all PDs assessed (*** = p<0.001), PD100 G was smaller 
compared to PD100 N (*** = p<0.001) (Figure 2.4C). PD200 had stellate-shape with cells 
significantly larger than these under high glucose conditions (* = p<0.05) (Figure 2.4C).  
             
 
Figure 2.4: CB-MSCs morphology and measured the cell surface areas. A. Cells grown in normal (5.5mM) 
and glucose (25mM) conditions, showed heterogeneous morphologies. Cells at PD15 showed predominantly 
fibroblast-like shapes. Whereas cells at PD50, PD100 and PD200 exhibited more stellate morphologies.  X10 
magnification, scale bar 100µm. 
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B. CB-MSCs were treated with FITC-phalloidin staining to examine the cell shape and measure the cell 
surface area. Digital images were taken at X40 magnification and the scale bar was 100µm.                     
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C. The bar chart demonstrated CB-MSCs mean of cell surface area. PD15 was the largest surface 
area. Cells became smaller with continuing expansion in culture. PD100 N and PD200 N cells were 
significantly larger than G groups. Error bar represents standard error of mean, * = p<0.05, *** = 
p<0.001.  
 
    2.3.4: Colony Forming Efficiency (CFE) 
Colonies started to appear at day 3 in all groups, as at day 1 and day 2, the number of the cells were 
still less than 32 cells to be considered as a colony. PD15 showed very low colonies and significantly 
fewer numbers, compared to PD50, PD100 and PD200 (*** = p<0.001). PD50 and PD100 
demonstrated increase in CFEs, however, there were no significant differences between them. 
PD200 G exhibited significant decrease in CFE formation at day 5, compared to PD100 G at day 5 
(** = p<0.01). In contrast, PD200 N was significantly increased (* = p<0.05), compared to PD100 
N at day 4 and day 5. PD15 demonstrated no significant differences between normal and high 
glucose conditions. PD50 and PD100 showed a significant increase in CFE in glucose, compared to 
normal conditions at day 3, day 4 and day 5 (* = p<0.05). PD200 exhibited significant decrease in 
CFEs under high glucose conditions at day 4 (* = p<0.05) and day 5 (*** = p<0.001) compared to 
normal conditions (Figure 2.5). 
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 A)                        
    
B) 
                                                                                                                                 
                                                   
Figure 2.5: A. CFE capacity of CB-MSCs varied at different PDs. More committed cells (PD15) 
showed a lower number of CFEs, whereas more immature cells (PD50) exhibited gradual increases 
in CFEs. PD100 demonstrated the same trend as PD50. High glucose conditions at PD50 and PD100 
significantly increased CFEs. Subsequently, PD200 showed a significant decrease in CFEs under 
high glucose. Error bar represents standard error of mean, * = p<0.05, *** = p<0.001. B. Image 
demonstrated one cell that proliferated to form a single CFE under normal glucose conditions 
(magnification 5X). 
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    2.3.5: Cell Cycle Marker (p53, p21 waf1 and p16 INK4a) Expression  
Cell cycle marker (p16INK4a, p53, and p21waf1) expression by CB-MSCs, was investigated, using 
qPCR (Figure 2.6). p16INKA4a gene expression, in general, was low in all groups. PD15 N and G 
demonstrated the highest expression of p16INK4a, while differing significantly (p<0.05) compared to 
PD50 G and PD100 N. p21waf1 exhibited very low expression in all groups. p53 demonstrated a 
steady increase in gene expression from PD15 onwards until PD200. There were significant 
differences (p<0.05) in mRNA gene expression between PD15, PD50 and PD100 N. PD100 G 
exhibited significantly higher p53 expression, compared to PD100 N (p<0.05). PD200 N and G 
demonstrated significant gene expression, in comparison to PD50 N and G (p<0.05); and PD15 N 
and G (p<0.01) (Figure 2.6). 
   
                
Figure 2.6: Detection of the cell cycle marker gene expression using qPCR. p16 INK4a gene 
demonstrated the highest expression level at PD15 N and G, whereas the lowest expression was in 
PD50 G and PD100 N (p<0.05). p21waf1 gene exhibited very low expression levels. p53 gene showed 
a gradual increase in gene expression from PD15 to PD200. (* = p<0.05, ** = p<0.01). 
 
    2.3.6: Terminal Restriction Fragment Assay (TRF) 
The average telomere length of PD15 N was demonstrated as significantly shorter compared to 
PD50 and PD200 N (p<0.01) (Figure 2.7). PD15 had almost the same telomere length in N (20.4 
kbp) and G (18.1 kbp) samples. PD50 and PD200 exhibited a significant increase in telomere length 
in N (p<0.01), which had average values 28.4-29.7 kbp respectively. In addition, these groups 
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showed significant decreases in telomere length in G compared to N (p<0.001). PD100 demonstrated 
the shortest telomere length in both N (14.4 kbp) and G (11.9 kbp) groups (p<0.001) (Figure 2.7). 
 
                                       
Figure 2.7: A. Southern blot to measure the average telomere length of the CB-MSCs exhibited the 
DNA telomere-specific smear of sample groups both N and G samples. Molecular weight marker 
contains the standard size ranging from 21.2kbp to 0.8 kbp. High glucose samples demonstrated 
significantly shorter telomere lengths expressed by the dark smear extended with their lanes 
(Southern blot were repeated three times). 
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B. Bar chart demonstrates the terminal restriction fragment for sample groups of CB-MSCs telomere 
length. There were significant decreases in telomere lengths of G samples. PD100 was the 
significantly shortest telomere lengths for both N and G groups. Error bar represents Standard error 
of mean, (* = p<0.05, ** = p<0.01, *** = p<0.001). 
 
    2.3.7: Senescence Associated β-galactosidase Staining 
Cells were treated with SA β-gal staining to visualize senescent cells. The overall number of 
senescent cells were low in all experimental groups. Although, the highest percentage of senescent 
cells were seen in the PD50 N and G. PD15 G demonstrated a higher number of senescent cells, 
compared to PD15 N, with significant differences (* = p<0.05). PD100 and PD200 exhibited the 
lowest number of senescent cells and were significant different to PD50 G (** = p<0.01) (Figure 
2.8). 
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Figure 2.8: A. SA β-galactosidase staining of CB-MSCs to identify senescent cells. Images showed 
senescent cells were larger compared to normal cells with blue colour, pointed by black arrows. 
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B. The bar chart demonstrated general low percentages of senescent cells overall. PD15 and PD50 
demonstrated the highest percentage of senescent cells among all sample groups. PD50 in both N 
and G were higher than PD15, however, percentages of senescent cells decreased in PD100 and 
PD200. Error bar represents Standard error of mean. n=3. (* = p<0.05, ** = p<0.01). 
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    2.4: Discussion 
This Chapter showed a pronounced change in the heterogenous profile of CB-MSC phenotypes 
during extensive culture expansion. Hyperglycemia also exhibited distinctive effects on this change, 
linked to fasten regenerative rates, which then declined at late PDs and steadily decreased telomere 
length. These results would suggest that certain CB-MSC subpopulations have lost during culture 
expansion. High glucose demonstrates more detrimental effects by decreasing telomere lengths, 
which accelerated these changes. 
 At the beginning of in vitro culture expansion, MSCs demonstrated a slow-growing lag phase until 
around PD10. This trend has also been reported by (Harrington et al. 2014; Lee et al. 2015). This 
lag phase period may reflect low numbers of highly proliferative MSCs, concomitant with 
predominant committed cells; and/or the MSCs trying to adapt to the new culture environment, 
which is obviously different from the original in vivo niche environment. The cells then continued 
to proliferate gradually in a faster manner in both types of media. 
During the cell expansion period, characterization procedures at PD15, PD50, PD100 and PD200, 
proposed to prove the criteria of ISCT and may underpin that these cells are pure MSC populations. 
However, this was not enough to further understanding of the heterogenous profile of these CB-
MSCs. Extended characterization investigated a set of other markers to gain a wider knowledge. 
CD146+ (Melanoma Cell Adhesion Molecule, MCAM) was expressed in all samples and is 
considered as an indicator of the ability of MSCs to differentiate into osteoblasts, chondrocytes and 
adipocytes. In addition, Russell et al. (2010), considered CD146 as a marker of multipotency. This 
leads to predict that CB-MSCs might be able to differentiate into another type of cell, however, this 
needs further studies to be proven. CD146 has also described to assist in cell proliferation (Sacchetti 
et al. 2007; Baker et al. 2014), that may be linked to the continuing CB-MSCs proliferation in vitro 
culture. CD106 (Vascular Cell Adhesion Molecule-1, VCAM-1) is reported as a positive on some 
of MSC surfaces (Liu et al. 2012); and has distinct roles in cell attachment, migration and cell signal 
transduction (Meirelles et al. 2006). Within CB-MSCs, CD106 was absent at all PDs. This result is 
in agreement with Mafi et al. (2011), who demonstrated its absence on a number of MSC surfaces 
and was observed to decline with prolonged cell culture. Embryonic pluripotent marker (Nanog and 
Oct4) expression is thought to be a key factor in maintaining pluripotency and self-renewal. Nanog 
had a very trace expression, while Oct4 had no expression. This lack of expression for Nanog and 
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Oct4 is similar to the outcomes of the rodent dental pulp (Kerkis et al. 2006). Furthermore, this 
would suggest that these CB-MSCs are more mature and multipotent, than being pluripotent cells.  
To further extend characterization, Snail and Slug neural crest markers were investigated and found 
to be expressed at all PDs. These markers are implicated in epithelial-mesenchymal transition 
(EMT) (Aybar et al. 2003, Kokudo et al. 2008). They are described to promote commitment to a 
mesenchymal lineage and activation of a mesenchymal promotor (Solanas et al. 2008; Batlle et al. 
2013). Expression of Snail and Slug within CB-MSCs would suggest a level of immaturity of some 
subpopulations and possibly having multipotent capacity rather than being tri-potent MSCs. Such a 
novel finding needs further investigation. Telomerase (TERT) and the RNA binding component 
(TR) were the last investigated markers, which demonstrated a decrease in their expression with 
long-term culture. These findings, however, did not perfectly relate to the mean telomere length 
results (TRF) which, for example, demonstrated an increase in mean telomere length at PD200. This 
may be linked to the heterogenous nature of CB-MSCs, which might have an immature 
subpopulation, possibly assists in increased mean telomere length. Furthermore, adult MSCs are 
unlike embryonic stem cells (ESCs), which exhibited a high level of telomerase activity (Hiyama 
and Hiyama 2007;  Saretzki et al. 2010). 
PD15 exhibited a heterogeneous cell morphology with varied shape phenotypes, such as large 
spindle, stellate and flat-shaped cells. In terms of CFE, this PD demonstrated cells with low ability 
rates. It is described that each clonal colony would proliferate at a rate controlled by its mother cell. 
So, when there is a low ability for colony forming, this may reflect that the mother cell has either 
reached a committed stage or approaching a terminal proliferative stage. This cell profile and colony 
forming ability trend, however, was found to be changed at PD50. Furthermore, at PD15 the average 
telomere length was shorter and cell morphology showed brighter actin stress fibers in some large 
cells treated by phalloidin staining, which would suggest that some of the subpopulation cells have 
a signs of a senescence (Asumda and Chase 2011). Taken all together, these characteristic features 
proposed that PD15 consisted of a heterogenous population and subpopulations of more committed 
cells and another possible population of immature cells. Herein, the p16INK4a cell cycle marker, 
which is proposed to be involved in cell growth arrest may support the notion that its presence may 
represent a subpopulation of mature osteoblasts differentiated from MC3T3 cells (Zhang et al. 
2010). This marker was seen to be elevated at PD15. Cell cycle markers, p21waf1 and p53, are known 
to act in a dependent and independent way to arrest the progression of the cell cycle at G1/S phase 
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to regulate cell proliferation and also acting as tumour suppressors (Macleod et al. 1995). Herein, 
p21waf1 expression was very low in all PDs, which is reported to be upregulated when cells enter G0 
(quiescent phase) (Spencer et al. 2013). This suggests the expression of p21waf1 and p53 would come 
from the active proliferative subpopulation within CB-MSCs. 
This heterogenous nature of the PD15 population might ‘suffer’ from senescence and was noticed 
to have changed at PD50, when the spindle-like cells disappeared leaving MSCs with smaller cell 
surface areas, demonstrated by predominant stellate-like cells. This would link to the large cells seen 
at PD15, as a committed large cell lineage is proposed to be lost during the expansive culture, leaving 
a subpopulation of immature cells. This speculation may be inferred, due to a marked longer mean 
of telomere length, highly proliferative capacity within this population; and the significantly 
declined mean cell surface areas, compared to PD15, may be attributed to the loss of the large spindle 
cells. SA β-gal stain, however, demonstrated low percentages number of senescent cells. This stain 
is known to be active only in senescent cells not in quiescent, pre-senescent or differentiated cells 
(Dimri et al. 1995), due to increasing lysosomal mass through long cellular replication (Lee et al. 
2006). This may explain the low number of SA β-gal stained cells. Looking to a low expression 
level of cell cycle markers, p21waf1 and p53, in addition to the p16INK4a cell cycle inhibitor, this 
would reflect the active proliferative rates at PD50 of CB-MSCs during expansion period in culture 
(Spencer et al. 2013).  
Investigation of CB-MSCs at PD100 during continued culture expansion suggested an important 
senescent change. The main difference here was the significant decrease in mean telomere lengths. 
It is well-documented that shortening of telomeres is associated with cell ageing and senescence 
(Hiyama and Hiyama 2007; Salpea and Humphries 2010). CB-MSCs, however, exhibited no decline 
in the proliferation nor in the colony forming ability; and they again showed a decline in cell surface 
area. This may lead to expect a presence of a high proliferative subpopulation within the 
heterogenous populations of CB-MSCs. Upregulation of p53 expression was seen here, which refers 
to ageing effects specifically in the high glucose group. Whereas expression of p16INK4a may be 
linked to the process of shortening of the telomere, although some studies reported no link between 
the two processes (Rayess et al. 2012). Furthermore, other studies find the expression of p16INK4a is 
due to the accumulation of reactive oxygen species in bad culture environment (Ramirez et al. 2001).  
                                                           
63 
 
 At PD200, CB-MSCs continued growing and actively expanding in culture. Intriguingly, the pivotal 
changes here, were significant reduction in colony forming ability in high glucose and some of MSC 
markers disappeared. Reduced CFE capacity in glucose group would be as a result of the long-term 
effects of hyperglycemia on regenerative capacity on CB-MSCs (Albiero et al. 2011). While loss 
expression of CD105, TERT and TR was reported due to long-term expansive culture (Russell et al. 
2011). Herein, telomere lengths recorded significant increases, which could come from a growing 
immature high proliferative population within the heterogenous population. Expression of a high 
level of p53 and a low level of p21waf1 suggest a low level of DNA damage and thus, means a healthy 
cell cycle although with a trace expression of p16INK4a (Rayess et al. 2012). Investigation of 
population changes, however, require further confirmation by a more sophisticated approach to track 
the cells to provide evidence to elucidate how these changes in subpopulations happen. 
Worthy of remark within this study, high glucose has shown significant effects on CB-MSCs, in 
terms of regenerative capacity of this heterogenous population. Telomere length reduction was 
reported to be associated with an increased level of oxidative stress and advanced glycation end 
products (AGEs), come from high glucose, which in turn induce oxidative telomeric DNA damage 
and eventually shortened telomeres. Ultimately this leads to premature cell senescence (Salpea et al. 
2010; Salpea and Humphries 2010). Interestingly, the CFE data demonstrated significant increases 
at PD50 and PD100. These findings are in disagreement with that of Li et al. (2007) and Stolzing et 
al. (2011), however, they both were using cell-lines and Li was using telomerase immortalized cells, 
which may differ from the CB-MSCs. Subsequently, the probable cumulative effects of high glucose 
demonstrated a significant decline in CFE at PD200. This may reflect the long-term detrimental 
effects of glucose on the regenerative capacity of MSCs, when ultimately leads to delay the healing 
ability (Li et al. 2007; Albiero et al. 2011; Stolzing et al. 2012). Another ageing and detrimental 
effect, which may be attributed to high glucose is significant increase in p53 expression when CB-
MSCs underwent long-term culture at PD100 and PD200 (Stolzing et al. 2011), whereas a low 
expression of p21waf1 indicates continued growth in culture (Spencer et al. 2013). It is also observed 
that increased p16INK4a expression may be linked to DNA damage (Giacinti and Giordano 2006). On 
the other hand, MSCs became smaller in surface area, which was reported with increased cell 
proliferative capacity and telomere length according to Samsonraj et al. (2015). Taken together, 
these findings reveal pronounced harmful effects of high glucose on the heterogenous population of 
CB-MSCs during an expansive culture period, which may reflect that one of the subpopulations 
could be affected more than the other, for example, immature and committed mature populations. 
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Understanding this valuable part of high glucose effects would open the door for deeper knowledge, 
which is still vague and requires further investigations. 
 One limitation of this study related to the measurement of telomere lengths, which needs to be 
considered. In this study, telomere length was measured by terminal restriction fragment assay 
(TRF). Although TRF has been a widely-used method, there are certain limitations, such as 
measuring the mean telomere length of all subpopulations. Thus, this technique is less sensitive in 
the heterogeneous population, when there are different cell phenotypes (Aubert et al. 2013). 
However, such a technique was only available to be used in our laboratory and would uncover a 
general insight about the change in telomere length in CB-MSCs populations and the effects of high 
glucose. Alternatively, the recommended technique to be considered for future work is the single 
telomere length analysis (STELA), using picogram range of DNA to individually evaluate cells 
(Baird et al. 2003).    
 Overall, results from this Chapter suggested that the isolated CB-MSCs have heterogeneous 
populations with different proliferative capacities and susceptibility to prolonged culture expansion 
and high glucose exposure. There was a change in this heterogeneity at PD50 confirmed by an 
increase in CFE, smaller cell surface area and longer telomere length that infers to the presence of 
more immature cells. Long-term cell expansion in culture demonstrated no effects on various MSC 
surface markers. High glucose exhibited a reduction in MSCs regenerative capacity as the CFE 
decreased; and a marked shortening of the telomere length. However, both normal and glucose 
groups have successfully continued expansion in culture. Further investigations to prove the ability 
of CB-MSCs to bi-potent capacity; differentiate into osteogenic and adipogenic lineages will be 
shown with the forthcoming experiments. 
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Chapter 3: Effects of High Glucose on the Bi-differentiation of CB-MSCs Osteogenic and    
Adipogenic Lineages 
 
    3.1: Introduction 
 
MSCs have been demonstrated to possess the ability to differentiate into various cell phenotypes, 
such as osteoblasts, chondrocytes, adipocytes and neural cells (Sharma et al. 2014). MSCs derived 
from bone are the main source of proliferative osteoprogenitor cells, which can be induced to 
differentiate into pre-osteoblasts and then into osteoblasts (Walsh et al. 2001; Porter et al. 2003).This 
process can be achieved through series of complex steps; proliferation, differentiation, matrix 
deposition and mineralisation; and eventually obtaining a mature osteocyte. This process has been 
found to be affected by the tissue microenvironment, such as during hyperglycemia (Juncheng et al. 
2013). Consequently, this could impair bone repair and regeneration processes. However, the exact 
mechanisms involved in hyperglycemic-induced bone loss remain unclear. 
 
Although glucose is a central source of energy for all cells, it has been noted that a hyperglycemic 
microenvironment in rat MSCs, affects self-renewal, proliferation, and differentiation, in addition 
to enhancing early premature cell senescence and apoptosis (Albiero et al. 2011 Kim et al. 2013; 
Salabei et al. 2016). Impairment of MSC proliferation and differentiation has been attributed to a 
chronic exposure to advanced glycation end products (AGEs) and reactive oxygen species (ROS), 
which are found increased in the circulation during hyperglycemia (Denu and Hematti 2016). 
Although detrimental effects are associated with these products, a normal physiological level of 
them have been reported to be required to maintain cell proliferation and osteogenic differentiation 
(Autréaux and Toledano 2007; Byon et al. 2008; Atashi et al. 2015). Increased levels of oxidative 
stress are proposed to activated various cell signalling pathways, such as PI3K/Akt and 
cAMP/protein kinase A (PKA)/extracellular signal‐regulated kinase (ERK) pathways, that not only 
inhibits osteogenic differentiation, but stimulates adipogenic differentiation, leading to osteoporosis, 
abnormal bone healing and repair (Botolin et al. 2005; Botolin and Mccabe 2007; Wang et al. 
2010a). 
 
A number of studies have investigated the effects of high glucose on MSCs. As far as it is being 
aware, however, most of these studies do not specify whether the detrimental effects of high glucose 
are on mature MSCs, immature cells, transit amplifying TA or on osteoprogenitor cells. Obtaining 
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this piece of knowledge would assist in more understanding the healing ability in case of the 
hyperglycemic microenvironment.   
 
Different concentrations of high glucose have been studied to investigate its effects on heterogenous 
populations of MSC proliferation, differentiation and function. These investigations have shown 
contradictory results. García-Hernández et al. (2012) and Liu et al. (2015) have respectively shown 
that 15.5mM and 24 mM glucose concentrations increased cell proliferation and biomineralisation 
process by activating the PI3K/Akt pathway, while elevated glucose concentrations from 25mM to 
35mM had a negative impact on cell proliferation and osteogenic ability, which appeared to 
gradually decline. On the contrary, Li et al. (2007)  demonstrated MSCs are more resistant to high 
(25mM) toxicity during short (several days) and long-term exposure (4 weeks), depending on the 
stemness of the MSCs, as effects of high glucose on the transit amplifying compartment of MSCs 
may differ from the mature cells, although this is still yet to be proven. However, they reported that 
40mM glucose affected both cell proliferation and osteodifferentiation. These discrepant findings 
may be due to varying experimental protocols and different sources of cell lines, so further studies 
are needed to uncover the molecular mechanism of high glucose resistance in various MSC 
phenotypes. 
 
One of the important extracellular proteins, playing a pivotal role in bone healing, remodelling and 
bone repair is osteopontin (OPN). OPN is one of the earlier secreted proteins by pre-osteoblasts and 
it accumulates against resorbed bone surfaces forming what is called OPN-rich cement line (Pedraza 
et al. 2008; McKee et al. 2011). Here, it is reported to act as an adhesion and cell signaling protein 
for recruiting mature osteoblasts to the bone surface, regulating early stages of mineralisation and 
assisting in the bonding of old bone to new bone evident as an OPN cement line. However, OPN 
binding to mineral crystals inhibits their growth aiding in bone remodelling; and therefore increased 
expression would inhibit bone formation (Pedraza et al. 2008; McKee et al. 2011). OPN has been 
reported to act as a substrate for the covalent cross-linking activity of transglutaminase 2 (Kaartinen 
et al. 2002), proposed to contain several integrin-binding motifs (Lund et al. 2009) and acts as a 
potent regulator of mineralisation (Boskey 1995; Pampena et al. 2004). 
 
Interestingly, within MTG, Colombo et al. (2011) have found an increase in expression of OPN in 
the extracellular matrix of rat diabetic healing bone, compared to normal bone healing. This would 
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have detrimental effects and might be linked to the inhibition of bone formation. Therefore, this 
study also focussed on this protein in high glucose microenvironment in order to investigate its 
action on osteogenic differentiation process.  
 
This Chapter aimed to investigate the ability of various CB-MSC population doublings during on-
going expansion in culture, to differentiate into osteogenic and adipogenic lineages. In the previous 
Chapter of this thesis, experiments identified that culture expansion of CB-MSC populations led to 
a change in the heterogeneous profile of the MSCs. At early population doublings (PDs), a cell 
population containing a high proportion of committed osteoblasts along with immature cells was 
identified. At PD50, the committed osteoblasts were no longer the dominant cell population. Using 
this knowledge, the current Chapter investigated the influence of high glucose concentrations on 
differentiation potential of the different heterogeneous cell populations. Pertinently, this work was 
designed to continue to understand the in vitro influence of high glucose on OPN expression of these 
cells, which is hypothesized to be increased in high glucose healing bone in vivo and proposed to 
impede osteogenesis. 
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    3.2: Materials and Methods 
 
The population doubling of CB-MSCs at PD15, PD50, PD100 and PD200 were investigated in 
normal (5.5mM) and high (25mM) glucose conditions.  
 
   3.2.1: Investigation of MSCs Differentiation Capacity into Osteogenic and Adipogenic   
Lineages 
CB-MSCs bi-potential differentiation capacity was assessed by inducing differentiation into 
osteogenic and adipogenic lineages until day 28 and day 21, respectively. During this period, various 
specific differentiation markers and transcription factors of MSCs were investigated, both at a gene 
and protein levels. 
 
    3.2.1.1: Osteogenic Induction 
Cells were seeded at 4x103/cm2 in a 6-well plate, with culture medium (CM) [ (αMEM) with 
ribonucleosides and deoxyribonuclosides (Gibco, ThermoFisher Scientific), supplemented with 
10% Fetal Bovine Serum (FBS) (ThermoFisher Scientific, UK), 1% antibiotics-antimycotics 
(Sigma-Aldrich, UK)] for 24h and then replaced with osteogenic medium comprised of CM, 10nM 
dexamethasone and 10 mM β-glycerolphosphate (both from Sigma-Aldrich), incubated at 37oC and 
5% CO2 for 28 days. Media were changed every two days, cells were collected on day 2, 7, 14, 21 
and 28 for a total RNA extraction, reverse transcription for cDNA and then qPCR analysis. 
Osteogenic marker expressions investigated mRNA levels of osterix (OSX), osteopontin (OPN) and 
osteocalcin (OCN), (Table 3.1). To conduct a negative control, cells were cultured in CM only. 
Osteogenic differentiation analyses were performed in triplicate on three separate occasions. 
 
    3.2.1.2: Alizarin Red S Staining and Mineral Quantification  
2% Alizarin Red S solution (w/v in distilled water) was prepared and pH was adjusted to between 
4.1-4.3 with ammonium hydroxide, prior to being filtered through a 0.22μm syringe filter (Millipore, 
USA) and then the stain was stored in darkness. At day 28, media were removed from cells, washed 
3 times with phosphate buffer saline (PBS), followed by 30min fixation with 4% paraformaldehyde 
solution (PFA) (Santa Cruz, USA) at room temperature. The PFA was then removed and the fixed 
cells were washed 3 times with PBS. 200 µL of Alizarin Red S solution was added to each well and 
gently agitated for 20min. The excess staining solution was removed and washed with distilled 
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water. Wells were left to dry at room temperature. Images were taken by digital cameras (Canon 
PC1234 UK Ltd., UK), while viewing under light microscopy (Nikon Eclipse TS100).  
The mineral formation of PDs was quantified according to Gregory et al. (2004). 800µL of 10% 
(v/v) acetic acid was added to each well and incubated at room temperature for 30min with shaking. 
The cell monolayer was removed using a cell scraper and transferred to a 1.5mL Eppendorf tube 
using a stripette to obtain all the insoluble materials. Eppendorf tubes were vortexed for 30s, 
wrapped with parafilm to prevent evaporation when heated to 85oC for 10min in a heat block and 
then immediately transferred onto the ice for 5min to cool down. The samples were centrifuged at 
20,000xg for 15min at 4oC. 500µL of the supernatant was transferred to a new 1.5 mL Eppendorf 
tube. 150µL aliquots of the supernatant were read in triplicate at 405nm in a 96-well plate, using a 
SPECTROstar Omega Plate Reader (BMG Labtech, Germany). 
    3.2.1.3: Adipogenic Induction 
Cells were seeded at 1x104/cm2 and cultured with CM until 90% confluent. CM was then replaced 
with adipogenic induction medium consisting of 10% FBS, 1% antibiotic-antimycotic, 1μM 
dexamethasone (Sigma-Aldrich) which dissolved in ethanol (ThermoFisher Scientific, UK). 100µM 
3-isobutyl-1-methylxanthine (IBMX) dissolved in dimethyl sulfoxide (DMSO), 10μg/mL insulin 
(all from Sigma-Aldrich) dissolved in 1M hydrochloric acid (HCl) (ThermoFisher Scientific); and 
100μM indomethacin (Sigma-Aldrich) dissolved in methanol (ThermoFisher Scientific), at 37oC, 
5% CO2 for 6 days, with media changed every 3 days. At day 7 media were removed and replaced 
with adipogenic maintenance medium consisted of 10% FBS, 1% antibiotic-antimycotic, in αMEM 
and supplemented with 10μg/mL insulin for 2 days. Adipogenic differentiation was conducted for a 
total of 21 days. Media were changed during this period as follows: induction at day 1 and 4, 
maintenance at day 7, induction at day 9 and 12, maintenance at day 15 and induction at day 17. The 
pre-prepared as stock solutions were vortexed to give a precipitate-free solution, and filtered with 
0.22μm filter and stored at -20oC until use. Media were prepared for each change by thawing 
adipogenic components, mixing and adding 10% FBS and vortexing for thorough dissolution. 
Negative control samples were cultured with CM for 21 days (non-adipogenic). Total RNA was 
extracted on day 0 and day 21. cDNA was obtained for each sample to visualize adipogenic 
expression markers (adiponectin and PPARγ) using qPCR (Table 3.1). 
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Table 3.1: Primer sequences and product sizes of selected osteogenic and adipogenic markers for 
qPCR analysis. 
Source Annealing 
Temperature 
(oC) 
Product 
length 
(bp) 
Primer sequence Forward (F) and 
Reverse(R) 
Gene 
(Xing et 
al. 2009) 
55 74 F: GCA AGA GAG AGG CCC TCA G 
R: TGT GAG GGA GAT GCT CAG TG 
GAPDH 
(Georgiou 
et al. 
2012) 
55 136 F: GCT TTT CTG TGG CAA GAG GTT C 
R: CTG ATG TTT GCT CAA GTG GTC G  
OSX 
Dr. Wayne     
Ayre 
(Cardiff 
University) 
55 132 F: AAG CAA GAA ACT CTT CCA AGC 
AA 
R: GTG AGA TTC GTC AGA TTC ATC 
CG 
OPN 
(Korkalainen 
et al. 2009) 
55 75 F: AAG CCC AGC GAC TCT GAG TCT 
R: CCG GAG TCT ATT CAC CAC CTT 
ACT 
OCN 
(Ding et 
al. 2013) 
55 224 F: GAATCATTATGACGGCAGCAC        
R: CTTGGAGCCAGACTTGGTCTC 
 
  Adiponectin 
 
(Ji et al. 
2009) 
55 174 F: GGAAGCCCTTTGGTGACTTTATGG  
R: GCAGCAGGTTGTCTTGGATGTC 
PPARɣ 
Sigma-
Aldrich, 
Centre. 
 
55 108 F: TGAAGATCAAGATCATTGCTCCTCC 
R:CTAGAAGCATTTGCGGTGGACGATG 
β-actin 
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    3.2.1.4: Neutral Lipid Detection (Lipid ToxTM Green) 
Cells were cultured in adipogenic and control conditions to perform neutral lipid analysis in BD 
Falcon™ glass chamber slides (BD Biosciences, UK). As described above, at day 21, cells were 
fixed and stained using HCS Lipid TOXTM Green neutral lipid stain according to manufacturer's 
protocol (Invitrogen, UK). Briefly, cells were washed twice with PBS, fixed with 4% PFA for 10min 
at room temperature, washed twice with PBS, and stained with Lipid TOXTM diluted 1:200 in PBS, 
for 30min. The slide chambers were removed, cells on the slides were stained with DAPI 
Vectashield Hard-Set Mounting Medium (Vector Labs, UK) and covered with cover slips 
(ThermoFisher Scientific). Nuclear DAPI and green-lipid fluorescence were observed using 
Olympus Provis AX70 microscope with Nikon ACT-1 v.2.63 software. 
 
   3.2.1.5: Quantitative Real-Time Polymerase Chain Reaction (qPCR) to Examine Osteogenic 
and Adipogenic-Specific Markers 
qPCR was used to assess the osteogenic and adipogenic gene markers, as described in Chapter 2, 
section (2.2.8). Reverse and forward primers used and annealing temperatures are given in (Table 
3.1). 
  
 3.2.2: Protein Extraction and Quantification 
In this study, protein investigation focused on CB-MSC populations of PD15 and PD50. Protein was 
investigated in two ways. Firstly, by examining the total protein in cells and extracellular matrix by 
analyzing the cell lysate extracts. Secondly, by detecting the protein released into the cell culture 
medium. Cells were seeded at 4,000 cells/cm2 in T75 tissue culture flasks, cultured in 10mL 
osteogenic induction medium and incubated at 37°C in 5% CO2. The medium was changed every 2 
days on a regular basis. At day 7, 14 and 21, culture media were collected and the cell monolayer 
was washed twice with ice-cold PBS, and treated with 1mL of extraction RIPA buffer 
[(ThermoFisher Scientific) supplemented with Complete™ Protease Inhibitor Cocktail with a ratio 
of one tablet in 50mL of RIPA buffer (Roche, UK)] to each T75 flask for 5min, while incubated 
onto ice at 4oC. The cell lysate and matrix were removed using a cell scraper, collected into a 
universal tube and kept at 4oC (on ice), then sonicated by cell sonicator for 20s (on ice) and 
centrifuged for 15min at 1500 rpm at 4oC to sediment particulate material. The culture media 
supernatants were exhaustively dialyzed using 25mm width cellulose dialysis tubing membrane, 
12,000Da molecular weight cut-off (MWCO) (Sigma-Aldrich). Dialysis was performed for 5 days 
against deionized distilled water containing protease inhibitor solutions (0.5mM iodoacetic acid, 
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0.5mM benzamidine, and 0.1mM N-ethylmaleimide, all from Sigma-Aldrich) at 4°C with a 
magnetic stirrer in a continuous agitation. Dialysis solution was changed every day. Protein was 
recovered by lyophilization (Edwards Freeze-dryer Modulyo, UK) and kept at -20oC.  
 
    3.2.2.1: Bicinchoninic Acid Protein Assay (BCA)  
Lyophilized protein was re-suspended in 1mL of tris-buffered saline (TBS; 50mM Tris, pH 7.4 and 
0.15 M NaCl), until completely dissolved. Protein concentration was analyzed using BCA Protein 
Assay Kit, according to the manufacturer’s protocol instructions (Pierce® Thermo Scientific). 
Briefly, 25μL of each standard and protein sample was added to 96 well-plate in triplicate. 200μL 
working reagent [reagent A: bicinchoninic acid in 0.1M sodium hydroxide and reagent B: 4% (w/v) 
cupric sulfate, (50:1, reagent A: B)] was added to each well in triplicate and mixed thoroughly on a 
plate shaker for 30s. The plate was incubated at 37oC for 30min. Colorimetric absorbance was read 
at 562 nm using a SPECTROstar Omega Plate Reader (BMG Labtech). Absorbance readings were 
corrected and averaged using empty wells. Protein concentrations were calculated using the standard 
curve and polynomial equation with Microsoft® Excel® 2016 package. 
    3.2.2.2:  Western Blot (WB) for Protein Electroblotting 
20μg of protein samples (determined above) were diluted 1:1 with 1X Laemmli buffer (Bio-Rad, 
USA). Samples were heated to 95oC for 5min and 18µL loaded on 4-15% Mini- Protean® TGX™ 
Precast Gels (Bio-Rad) along with 8μL Kaleidoscope™ Prestained Standard Markers (Bio-Rad). 
Gels were placed into Mini-PROTEAN® Tetra Vertical Electrophoresis Cell (BioRad Laboratories, 
UK) in 1x sodium dodecyl sulphate-polyacrylamide gel-electrophoresis (SDS-PAGE) running 
buffer [1.92M glycine (ThermoFisher Scientific), 250mM tris-base (Sigma-Aldrich), 1% SDS, pH 
8.3). Protein samples were separated by gel-electrophoresis at 200V, for 40min in Mini-PROTEAN® 
Tetra Vertical Electrophoresis Cell, (BioRad). Gels were removed from the cast and soaked in a 
transfer buffer (192mM glycine, 25mM tris-base, 20% (v/v) methanol, pH8.3) for 10min. 
Meanwhile, the electroblot ‘sandwich’ components were prepared by soaking 2 electroblot sponges, 
2 sheets of thick blot filter paper (BioRad) and cut to size piece of nitrocellulose membrane (GE 
Healthcare, UK) in a transfer buffer for 5min. One of the electroblot sponge was laid onto a plate of 
the blotting device, followed by a sheet of filter paper, the gel containing the proteins separated by 
electrophoresis, nitrocellulose membrane, then another sheet of the filter paper and lastly the second 
electroblot sponge. The electroblot sandwich was placed into the Mini-PROTEAN® Tetra Vertical 
Electrophoresis Cell at 75volt and the electrical current passed across the membrane for 1h. Protein 
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transfer was confirmed by staining the nitrocellulose membrane with Ponceau Red stain for 5min 
and de-staining by washing with TBS. 
 
    3.2.2.3: Protein Detection by Immunoblotting 
Membranes were blocked overnight at 4oC with 5% (w/v) non-fat milk (Tesco, UK) in TBS-T [(TBS 
supplemented with 0.05% Tween-20 (Sigma-Aldrich)] with a gentle agitation. Membranes were 
transferred to blocking buffer solution supplemented with primary antibody of goat polyclonal IgG 
osteopontin (Insight Biotechnology, UK) (dilution 1:500) for 1h at a room temperature.  Membranes 
were washed 3 times for 5min each in TBS-T, transferred to a blocking buffer supplemented with 
rabbit anti-goat horseradish peroxidase (HRP)-conjugated secondary antibody at 1:30,000 dilution 
(Insight Biotechnology) and incubated for 1h at room temperature. Membranes were washed 3 times 
for 5min each in TBS-T, with two additional washes for 5min in TBS only, to reduce a high 
background. Negative controls were performed to confirm the specificity of OPN antibody. OPN 
primary antibody was incubated with a 10X excess of the respective OPN blocking peptide (Santa 
Cruz) for 1h at room temperature. The nitrocellulose membrane was incubated in ECL™ Prime 
Detection Reagent (GE Healthcare) for 2min. Chemiluminescence was detected by exposing the 
membrane to Hyperfilm™ (GE Healthcare) and developed using an Auto-developer machine (Curix 
60, AGFA, Belgium). 
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    3.2.2.4: Immunoprecipitation (IP) of Osteopontin from Cell Medium 
Total protein was obtained from medium supernatant of cells, as previously described in Section 
3.2.2. Immunoprecipitation (IP) of OPN was conducted using a Pierce® Crosslink IP Kit (Thermo 
Fisher Scientific), according to the manufacturer’s protocol. Experimental steps were performed at 
4oC, unless otherwise stated. The centrifugation was conducted at 1,000g for 1min. Each protein 
sample was performed in a separate Pierce spin column. 20μL of Pierce protein A/G plus agarose 
was applied into a spin column, then centrifuged and the flow-through discarded. The resin was 
washed twice with 100μL of couple buffer. The column base was tapped onto a paper towel and 
then sealed with a bottom plug. 10µg of OPN antibody goat polyclonal IgG osteopontin (Insight 
Biotechnology) was added to 5µL of 20x couple buffer and the total volume was adjusted to 100µL 
with ultrapure water (18.2MΩ H2O). OPN antibody solution was added to the resin-containing spin 
columns, sealed and incubated for 1h at room temperature. The spin columns were centrifuged, 
washed once with 100µL of couple buffer and twice with 300µL of couple buffer and the flow-
through discarded in each time. To cross link OPN antibody to the resin, 2.5µL of 20x couple buffer, 
9μL of 2.5mM Disuccinimidyl suberate (DSS) and 38.5μL of 18.2MΩ H2O were added to each 
column and incubated for 1h at room temperature with gentle agitation. The spin columns were 
centrifuged and washed by adding 50µL of elution buffer, followed by 2 washes with 100µL of 
elution buffer; and then 2 washes with 200µL of IP lysis/wash buffer. The spin columns were sealed 
and stored until further use at 4oC after pipetting 200µL of IP lysis/wash buffer into each column. 
For pre-clearing the samples, 80µL of the control agarose resin slurry (40µL of settled resin) was 
applied into the fresh spin columns and centrifuged and washed with 100µL couple buffer. 1mg of 
total protein was reconstituted in 1mL of TBS, while the final volume was adjusted to 1.2mL. Protein 
concentrations were determined according to Section 3.2.2.1. 600µL of protein solution was added 
to each spin column which already containing 40µL of settled resin. Spin columns were sealed with 
a top plug and incubated for 1h with gentle end-over-end mixing. The columns were centrifugated 
and the flow-through kept for the IP confirming procedures. The spin columns containing 
immobilised antibodies were washed twice with 100µL of TBS and sealed with a bottom plug. 
600μL of total protein solution was added to each column. The columns were then sealed and 
incubated overnight with gentle end-over-end mixing at 4oC. The spin columns were centrifuged 
and retained the flow-through. Columns then washed, by adding 200µL of IP lysis/wash buffer and 
centrifuged. The columns were then washed twice with 200µL of IP lysis/wash buffer and then once 
with 100µL of conditioning buffer. The spin columns were placed into a new 1.5mL collection tube 
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provided with 5µL of 1M tris-base at pH of 9.5. 10μL of Elution Buffer was pipetted into each 
column and centrifuged. 50μL of elution buffer was added to the resin in each spin column and 
incubated for 5min at room temperature. The spin columns were centrifuged and flow-through 
retained for confirmation IP procedures. The spin column was centrifuged and the samples were 
collected and loaded on a gel to perform SDS-PAGE to confirm the purified OPN at the right 
molecular weight. The amount of obtained protein was estimated by BCA protein assay. Volumes 
for OPN depleted flow-through and enriched elution pools utilised in forthcoming experiments were 
proportional, relative to the total volume of depleted elution.                                                                                                                                                                                                                                                                                                      
   3.2.2.5: Enzyme Linked-Immunosorbent Assay (ELISA) of Rat Osteopontin in Supernatant 
Culture Media 
CB-MSCs were cultured for 21 days in osteogenic conditioning media in normal and high glucose 
conditions. Samples were collected at day 7, 14 and 21. The secreted OPN from the supernatant was 
quantified using Osteopontin (Rodent) ELISA kit (Enzo Life Science, UK). The 96-well plate 
provided within the kit was pre-coated with a monoclonal antibody specific for OPN. According to 
the manufacturer’s instructions, 2 wells of this plate were left empty; in addition, 2 wells were loaded 
with 50µL of assay buffer. Protein standard was loaded into nominated wells in duplicate in a 
descending way (100 - 3.13 ng/mL). 50µL of each pre-diluted purified OPN sample in assay buffer 
were loaded to each well in duplicate and incubated for 1h with a constant agitation at room 
temperature. Supernatant was decanted from the well. Each well was washed four times with ELISA 
washing buffer. Wells were gently tapped on a tissue to make sure complete dryness of the wells. 
50 µL of biotinylated polyclonal antibody specific for OPN was added to each well except the blank 
ones and incubated for 1h on a mixer at room temperature. Wells were evacuated and washed as 
above, then adding 50µL of streptavidin conjugated to horseradish peroxidase antibody specific for 
OPN and incubated for 30min on a mixer at room temperature. Wells were washed as above and 
then 50µL of substrate solution was added to each well including the two blank wells and left on a 
mixer for 30min at room temperature. The enzyme activities were stopped by applying 50µL of stop 
solution, to each well including the blanks. Absorbance was measured using a spectrophotometry 
plate reader at 450nm. The amount of OPN was quantified by plotting the standard samples as a 
reference standard curve. The experiment was performed in triplicate and the results were expressed 
in ng/mL/1mg protein. 
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    3.2.3: Detection of Phosphorylated Osteopontin by Anti-Phosphoserine Antibody  
Fractions of purified OPN which are proportionally equal to 10µg from 1mg of total protein was 
electrophoretically separated by SDS-PAGE and protein components electroblotted onto 
nitrocellulose membranes, as described in Section 3.2.2.2 and 3.2.2.3. Fractions were probed with 
(1:250) diluted anti-phosphoserine primary antibody (Abcam, UK) in 5% bovine serum albumin 
(BSA) with 0.1% (w/v) gelatin (Sigma-Aldrich). Three washes were performed by TBS-T, then 
probing for 1h with goat anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody 
at a dilution of 1:30,000 (Insight Biotechnology), at room temperature. Three washes were repeated 
by TBS-T 5min each and the fourth with TBS only for reducing a high background. Membranes 
were probed by ECLTM Prime Detection Reagent and visualized by developer machine, as described 
previously in Section 3.2.2.3. 
    3.2.4: Statistical Analyses 
Statistical analyses were performed using One-Way ANOVA with a post-hoc Tukey test to 
determine the statistical differences between sample groups, using the software GraphPad InStat 3 
(v3.06). Statistical significance of differences was defined as significant (*, p<0.05), very significant 
(**, p<0.01) or highly significant (***, p<0.001). 
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    3.3: Results 
 
    3.3.1: CB-MSC Differentiation 
 
    3.3.1.1: Osteogenic Differentiation of Rat CB-MSCs 
MSC osteogenic differentiation capacity was analysed by culturing cell populations in osteogenic 
induction media in normal (5.5mM) and high glucose (25mM) conditions. All the selected 
population doublings (PD) successfully attained osteogenic differentiation. However, each PD 
exhibited different levels of this differentiation. PD15 demonstrated the highest ability to form 
mineral, whereas PD50 exhibited the lowest. PD100 and PD200 showed decreased ability to 
differentiate, as described by results of Alizarin Red, mineral quantification, and expressions of 
mRNA osteogenic-specific markers (Figure 3.1; 3.2; 3.3).  
 
    3.3.1.2: Alizarin Red Staining 
CB-MSCs cultured in osteogenic media were stained at day 28 with Alizarin Red and exhibited 
distinct red colour following MSC differentiation and mineral formation. Cells in control media 
demonstrated very minimally or no red staining. PD50 exhibited faint red colour in both normal and 
high glucose groups. Importantly, extending cell growth until day 35 exhibited deep red colour for 
PD50. PD100 and PD200 exhibited a darker staining compared to PD50, but they were still showing 
less red colour staining than PD15. Interestingly, there was a clear less red staining associated with 
high glucose groups at all PDs in comparison to the normal physiological glucose concentrations 
(Figure 3.1). 
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Figure 3.1 A: Alizarin Red staining of differentiation CB-MSCs at PD15,50, 100 and 200 at day 28 
in normal and glucose conditions, in addition to day 35 for PD50. The red colour represents mineral 
deposition by extracellular matrix secreted by newly formed osteoblasts. Clear differences in the red 
colour can be noticed between normal and glucose conditions in all PD groups, which demonstrated 
that cells in glucose conditions had less osteogenic differentiation capacity. X10 magnification. 
Scale bar =100µm.                       
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B. Extending PD50 until day 35 exhibited a deeper red colour, indicating osteoblast differentiation. 
X10 magnification. Scale bar =100µm. 
 
   3.3.1.3: Quantification of Mineral Formation after Alizarin Red Staining  
PD15 normal (N) showed the highest mineral deposition, whereas PD50 had the least. PD50 N was 
significantly (p<0.001) lower than PD15 N. PD100 N was lower minerals than PD15 N, but not 
significant (p>0.05). PD200 N demonstrated significantly reduced mineral deposition, compared to 
PD15 N. Regarding high glucose, PD15 glucose (G) was significantly (p<0.05) lower than PD15 N. 
PD50 G exhibited higher mineral deposition compared to PD50 N, but not significant (p>0.05). 
PD100 N and PD200 N were significantly (p<0.05) higher compared to their high glucose 
counterparts (Figure 3.2). 
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Figure 3.2: The quantification of the mineral formation after CB-MSC differentiation at different 
PDs. PD15 demonstrated the highest mineral formation, while PD50 was the lowest. Glucose 
conditions exhibited a significant impact on mineral deposition at all PD groups, except PD50. Error 
bars represent ± Standard error of the mean. n=3, * = p<0.05, ** = p<0.01, *** = p<0.001. 
 
    3.3.1.4: Quantitative and Analysis of mRNA Levels of Osteogenic mRNA Markers Using  
    qPCR 
The mRNA expression of osteogenic markers was investigated at different time points. OSX is 
considered as an early expression gene during osteogenic differentiation, thus it was examined at 
day 2 and day 7. PD15 exhibited a significant increase in expression (p<0.001) at day 2 compared 
to PD50, PD100 and PD200, which showed downregulation of OSX at day 2 and day 7. OPN was 
investigated on day 7, day 14 and day 21. PD15 demonstrated significantly higher mRNA expression 
of OPN (p<0.001) at day 21 glucose, compared to normal conditions. At PD50, OPN mRNA 
expression revealed significantly higher expression (p<0.001) normal compared to high glucose 
conditions, on day 7 and day 14. OPN was then downregulated at day 21. At PD15 mRNA 
expression for OCN was exhibited significant upregulated (p<0.001) in high glucose at day 21, 
whereas OCN mRNA expression in high glucose showed significantly downregulated (p<0.05) at 
day 28. PD100 revealed significant differences (p<0.05) between normal and high glucose groups 
at day 28. At PD200, day 28 OCN mRNA expression under normal conditions was higher than high 
glucose group but was not significantly different (p>0.05) (Figure 3.3).  
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Early Osteogenic Marker               Osterix 
 
 
 
 
 
 
 
Figure 3.3: The bar chart shows mRNA level of osteogenic marker expression, early OSX, Mid 
OPN, and late OCN, using qPCR. Cells were induced for osteogenesis in normal and high glucose 
osteogenic conditions for 28 days. The values were normalized as a percentage expression of the 
endogenous gene (GAPDH). n=3. Error bars represent ± Standard error of the mean, * = p<0.05 and 
*** = p<0.001. 
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Mid Osteogenic Marker            Osteopontin  
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Late Osteogenic Marker              Osteocalcin 
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    3.3.1.5: Adipogenic Differentiation and Lipid TOXTM Green Neutral Lipid Stain    
CB-MSCs adipogenic differentiation capacity was investigated and showed cells were successfully 
transformed into adipocytes with large lipid droplets noted. Lipid TOXTM Green neutral lipid stain 
was examined at day 21 to confirm adipogenic differentiation and lipid vacuoles stained by a green 
colour appeared like clusters mostly at PD15 and PD50, whereseas there were fewer lipid vacuoles 
at PD100 and PD200 (Figure 3.4). 
 
 
 
Figure 3.4: Lipid TOXTM staining of CB-MSCs at day 21 of adipogenic induction. Lipid vacuoles 
appeared green with cluster forming shapes at PD15 and PD50. As cells were further grown in 
culture (PD100, PD200), CB-MSCs exhibited a reduced capacity to differentiate into adipocytes. 
20X magnification. Scale bar =100µm. 
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    3.3.1.6: Quantitative Analysis of mRNA Levels of Adipogenic Markers Using qPCR 
PPARγ and adiponectin mRNA expression were chosen, as late adipogenic-differentiation markers 
to investigate CB-MSCs adipogenesis differentiation capacity. Day zero was considered as a 
baseline and day 21 considered the day of adipocytes formation. Both markers showed significant 
upregulation (p<0.001) at day 21 at PD15 and PD50. However, almost no mRNA expression of 
PPARγ and adiponectin were observed in either PD100 and PD200. In high glucose media at day 
21, PPARγ and adiponectin were significantly down-regulated (p<0.001), in comparison to the cells 
in normal adipogenic induction media (Figure 3.5).  
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Figure 3.5: The bar chart shows mRNA levels of adipogenic markers PPARγ and adiponectin of 
CB-MSCs grown in adipogenic induction media at day 0 and day 21. Cells were induced for 
adipogenesis at normal and glucose conditions. Values were normalized as a percentage expression 
of the endogenous gene (β-actin). Error bars represent ± Standard error of the mean. n=3. * = p<0.05 
and *** = p<0.001. 
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    3.3.2: Investigation of Osteopontin Protein Content 
  
    3.3.2.1: Western Blot Analyses of Osteopontin in Cell Lysate  
OPN was detected in cell lysates in both normal and high glucose supplemented osteogenic 
induction media at day 7, 14 and 21. OPN immuno-detected bands appeared at 55kDa at both PD15 
and PD50. At PD15, the general protein profile started at day 7 with increasing protein levels at 
day14 and day 21. At PD50, OPN bands demonstrated increasing levels at day 14, then declined at 
day 21. Interestingly, the high glucose groups in both PD15 and PD50 exhibited more intense bands 
compared to normal control (Figure 3.6).  
          
                 
Figure 3.6: Western blot analysis of OPN immuno-detected bands in cell lysate of CB-MSCs grown 
in osteogenic induction media at PD15 and PD50, under normal and high glucose conditions. OPN 
bands were identified at 55kDa. The high glucose groups exhibited more intense bands. Western 
blots were repeated twice.  
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    3.3.2.2: Western Blot Analyses of OPN in Culture Media 
OPN was investigated in osteogenic culture media at day 7, 14 and 21. OPN was immuno-detected 
at three molecular weights. The main immuno-detected bands were at 55kDa, whereas there were 2 
other bands at 120kDa and 25kDa. These features demonstrated potential post-translational 
modifications of the protein in the extracellular region. At PD15 normal samples, OPN bands were 
the highest level and more intense at day 7 compared to day 14 and then gradually decrease at day 
21. PD50 demonstrated a different protein profile when there were small bands at day 7 and day 14, 
while showing intense bands at day 21. The high glucose bands, interestingly, were more intense 
than normal samples (figure 3.7).  
  
 
           
 
Figure 3.7: Western blot analysis of OPN immuno-detection in normal and high glucose osteogenic 
induction media. PD15 and PD50 were investigated in normal and glucose conditions. Three levels 
of immuno-detected bands were identified for OPN at 55kDa, 120kDa and 25kDa. The high glucose 
samples exhibited more intense bands. Western blots were repeated twice. 
 
    3.3.2.3: Enzyme Linked-Immunosorbent Assay (ELISA) Analyses of OPN in Culture Media 
Quantification of OPN levels revealed that OPN was significantly (p<0.001) highest at PD15 
compared to all other groups. OPN levels gradually declined at day 14 and day 21 at PD15. PD50 
demonstrated less than half fold level, compared to PD15 at day 7. This level was low at both day 
14 and day 21. In respect to the high glucose groups, OPN was expressed at higher levels at all 
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groups except PD15 day 7 and PD50 day 14 compared to normal samples, but were not significant 
(* = P>0.05) (Figure 3.8). 
 
 
 
         
            
 
Figure 3.8: Quantification of OPN levels in osteogenic culture media using ELISA. OPN was 
measured on day 7, day 14 and day 21 for both PD15 and PD50 in normal and high glucose 
conditions. Error bars represent ± Standard error of the mean. n=3. *** = p<0.001. 
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    3.3.3: Detection of Phosphorylated OPN  
Western blot was performed to detect the phosphorylation status of OPN released in osteogenic 
culture media. The protein profile revealed that all samples had phosphorylated OPN at two 
molecular weights of the immuno-detected protein 55kDa and 120kDa (Figure 3.9). 
 
 
 
 
 
Figure 3.9: Western blot analysis by targeting anti-phosphoserine side of phosphorylated OPN from 
osteogenic induction culture media of CB-MSCs. PD15 and PD50 were analysed in normal and 
glucose conditions. Two immune-detected bands were identified for phosphorylated OPN at 55 kDa 
and 120 kDa. Western blots were repeated twice. 
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    3.4: Discussion 
 
This Chapter focused on the assessment of the bi-potential capacity of different populations of CB-
MSCs to differentiate into osteoblasts and adipocytes under culture in normal and high glucose 
conditions. CB-MSCs successfully attained osteogenic differentiation at committed population 
PD15. This differentiation capacity was found to decrease in later populations. Regarding 
adipogenic differentiation, both committed and immature populations exhibited a better capacity to 
adipogenic differentiation, compared to the later populations. The high glucose microenvironment 
significantly affected osteogenesis in all populations except with the immature PD50. High glucose 
conditions reduced adipogenesis at committed and immature CB-MSCs populations. OPN was 
demonstrated to increase levels in cell lysates in high glucose conditions, regardless whether they 
were committed or immature populations. 
 
Within this study, various investigated heterogeneous populations showed a different capacity to 
osteogenic differentiation. PD15 was the population selected to investigate after CB-MSCs passed 
the lag phase in culture, as previously described in Chapter 2; and proposed to consist of 
predominantly committed osteoprogenitor cells. This PD demonstrated the highest ability to 
differentiate into osteoblasts and deposition of minerals among all the population doublings. This 
high capacity of PD15 would be referred to as the committed osteoprogenitor and pre-osteoblastic 
stromal cells, which have been described to be present within the bone marrow stroma, namely the 
endosteal and perivascular niche (To et al. 2011). PD15 in high glucose microenvironment, however, 
exhibited a significant decrease in this mineral deposition capacity, which may be attributed to the 
detrimental effects of exposure to high glucose during the differentiation period. These results come 
in line with those of (Sugimoto et al. 2005; Liu et al. 2015; Zhang et al. 2016). However, Weil et al. 
(2009) have shown no effects of high glucose on cell proliferation and differentiation capacity. Thus, 
different cell mechanisms have been described to explain the effects of high glucose on bone 
formation, although, the exact cause is still inconclusive. Osteogenic-specific gene markers 
represented the osteogenic differentiation process. Herein, OSX is an essential osteogenic marker 
for the commitment of pre-osteoblasts to differentiate into mature osteoblasts (Iohara et al. 2009;  
Chi 2012). At PD15, OSX demonstrated significantly highest expression, supporting the 
characteristic findings in Chapter 2, describing the PD15 population as containing a 
mature/committed MSC phenotype. This outcome aligns with previous findings (Nakashima et al. 
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2002; Liu et al. 2015). OPN is known to inhibit hydroxyapatite crystal formation and regulate the 
size of newly formed crystals (Hunter et al. 1996). It was considered as a mid-osteogenic specific 
marker so that within this study, it was investigated at day 7, day 14 and day 21 during the osteogenic 
induction period. The interesting finding here was the significant increase in OPN expression at day 
21 at PD15 under high glucose conditions. This important finding came in accordance with that of  
Colombo et al. (2011), who reported an increased OPN level in diabetic healing rat bone. Thus, this 
outcome sheds light on OPN having a possible role in delaying healing in diabetic bone. Regarding 
OCN, this is a late expressed osteogenic marker and always considered to be associated with mature 
osteoblasts, as it is tightly bound to the hydroxyapatite of the mineralised bone matrix (Hoang et al. 
2003). PD15 normal at day 28, demonstrated a significantly higher expression of OCN compared to 
high glucose groups. These results are in agreement previous studies (Wang et al. 2010a, Kanazawa 
2015; Liu et al. 2015). The commitment of PD15 to osteogenic lineage, however, does not expect 
to negate that committed cells were able to adipogenic differentiation. PPARγ can induce 
transdifferentiation of osteoblast MC3T3-E1 cells into mature adipocytes, as described by Kim et 
al. (2005). With this in mind, this heterogeneous population is proposed to have a subpopulation of 
immature cells which are already able to become adipogenic, when induced by PPARγ. Thus, PD15 
successfully differentiated into adipocytes confirmed by Lipid TOX fluorescent staining, when cells 
showed a cluster of lipid droplets. Adipogenic-specific gene markers, PPARγ and adiponectin, were 
also upregulated indicating a presence of an adipose lineage.  
 
On the other hand, PD50 has shown a change in the heterogenous population and has been described 
to have predominantly immature cells (as shown at Chapter 2). Herein, there was a delay in 
osteogenic differentiation, compared to other populations. Nevertheless, when CB-MSCs were 
maintained for a further 7 days in osteogenic induction media, they exhibited good differentiation 
into osteoblasts. This finding confirmed the outcomes of the previous characterization procedures 
and led to the proposal that this population contained immature MSCs. Alizarin Red staining 
supported this suggestion with a less intense red stain. Furthermore, this population revealed the 
lowest mineral deposition among all investigated populations, confirmed by Alizarin Stain and 
mineral quantification. Interestingly, in terms of mineral formation, high glucose exhibited no 
significant effects on immature cells. As far as possible, this is the first study to identify this novel 
result, which may need further research to assist in elucidation the real causative factors after the 
delay bone healing in a diabetic patient. Osteogenic specific markers confirmed these findings, OSX 
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and OCN at mRNA levels demonstrated very low expression, confirming the idea of immature 
MSCs phenotypes, which have been observed to spend a longer time to differentiate into pre-
osteoblasts and then osteoblasts. OPN at the molecular level, exhibited upregulation in normal group 
and downregulation in high glucose samples, whereas OPN at protein level increased in the 
extracellular compartment in high glucose which is considered the place for OPN function 
(Nomiyama et al. 2007; Berezin and Kremzer 2013). Although this delay in osteogenesis process 
occurred, adipogenic induction of CB-MSCs within this population showed a higher capacity. 
Adipogenic-specific markers PPARγ and adiponectin were upregulated promoting adipogenesis. 
This tendency to adipogenesis may be due to the absence of committed osteoprogenitor cells so that 
the immature cells were easily driven to differentiate into adipocytes, unlike PD15, which contained 
committed osteoprogenitor cells. Herein, high glucose conditions exhibited significant effects on 
the adipogenic differentiation process as adipogenic-specific markers (PPARγ and adiponectin) 
demonstrated by significant downregulations them at day 21. However, these results did not concur 
with other studies (Chuang et al. 2007, Wang et al. 2010a), whereas Shilpa et al. (2013) have shown 
a significant decrease in adipogenesis due to long-term exposure to a very high glucose (105mM). 
These differences may be attributed to the different cell niche origin of the MSCs, which might 
express contradictory results. 
  
PD100 revealed a better osteogenic differentiation ability than PD50. This population was reported 
to have the shortest telomere lengths in the previous Chapter (Chapter 2). This would infer that there 
is a mature subpopulation present within this heterogeneous population, which would be able to 
achieve osteogenic differentiation. These findings were confirmed by Alizarin Red staining and the 
amount of mineral deposition detected. Additionally, upregulation of osteogenic-specific marker 
expression, OCN, supported this notion. CB-MSCs, nonetheless, in this population failed to attain 
adipogenic differentiation. This outcome was also reported in other studies, when cells are no longer 
able to differentiate into adipocytes in vitro culture with increasing passage number (Ntambi and 
Kim 2000; Sethe et al. 2006; Ali et al. 2013).  
  
 In case of continuing cell growing in culture to PD200, the cells exhibited a decreased capacity to 
differentiation not only of osteogenesis and mineral deposition but also adipogenesis, which could 
be attributed to MSCs ‘losing’ their stemness characters as cells continue to grow in culture (Ntambi 
and Kim 2000). Nevertheless, the decreased ability for bone formation associated with age was 
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suggested to be owing to lower cell numbers rather than decreased cell proliferative capacity or loss 
of function (Stenderup et al. 2003). Regarding osteogenic-specific markers, OSX, OPN and OCN, 
there were all downregulated in this population, in addition to adipogenic-specific markers, PPARγ 
and adiponectin. These findings infer that this population would not be useful in bone repair process 
or assist in cell therapy research.  
 
High glucose effects on bone regeneration have been studied by many researchers. However, a high 
number of contradictory results have found. Botolin and Mccabe (2006), Li et al. (2007) and García-
hernández et al. (2012), have demonstrated an increase in cell proliferation and biomineralisation 
under hyperglycemic conditions. On the contrary, other studies have shown deleterious effects of 
high glucose on MSCs differentiation into osteoblasts and consequently affected their functions 
(Zayzafoon et al. 2000; Gopalakrishnan et al. 2006; Kim et al. 2006; Wang et al. 2010b). These 
contradictory results from different groups, investigating high glucose effects on bone 
biominerelisation might be due to several causes. Firstly, the heterogeneous nature of the cells, 
which is a common feature of the MSCs. This was well noted at PD15 and PD50 in this study. 
Secondly, the source of the cells from different species and cell-lines may give different responses. 
Thirdly, the different glucose concentrations were applied to various studies. Furthermore, the 
relative difference in the setting of the experiment and cell seeding density depending on different 
labratory protocols. All these inconsistent results would propose a mandatory investigation of cell 
response to any new condition, such as high glucose and its effects on the newly isolated CB-MSCs.  
 
Chronic hyperglycemia, however, undeniably induces detrimental effects on MSCs. These cells 
would normally differentiate into osteoblasts, adipocytes and chondrocytes, which if associated with 
high glucose could alter the cellular differentiation of the bone marrow.  Bone remodelling and 
repair depend on a balance between two activities; bone resorption and bone formation. In case of 
any change to this equilibrium, it may lead to bone loss (Botolin et al. 2005; Botolin and Mccabe 
2007). High glucose has been reported to inhibit osteoblast differentiation in favour of adipocytes. 
This process is proposed to be governed by PPARγ, which does not only drive MSCs to differentiate 
into adipocytes, but guides committed osteoprogenitor cells to transdifferentiate into adipocytes 
(Kim et al. 2005). This pathological impact of high glucose may be behind osteoporosis and delay 
bone healing associated with diabetes (Keats et al. 2014). Within this study, it has been observed 
that high glucose reduces adipogenic-specific markers, however, for long-term cultures in diabetic 
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microenvironment could also accumulate more oxidative stress, which has been reported to induce 
adipogenesis a the expense of osteogenesis (Botolin et al. 2005; Botolin and McCabe 2007; Wang 
et al. 2010a). 
 
Within this study, OPN was detectable at 55kDa and 120kDa with additional bands at 25kDa. This 
may be due to the functional post-translational modifications. OPN monomeric protein always 
appeared at 50-60kDa, whereas it has been reported to be cross-linked to transglutaminase 2 (TG2) 
at 120kDa. Both protein profiles were described to play important roles in mineral regulation 
(Kaartinen et al. 1999; Nishimichi et al. 2009). Interestingly, OPN was upregulated at day 21 at 
PD15 glucose. This dramatic increase in OPN expression suggests that there might be a relation 
between upregulated OPN and high glucose, which demonstrated a reduction in mineral deposition. 
OPN has also been deeply investigated at a protein level. Interestingly, this significant upregulation 
of OPN level revealed at the committed cells (PD15) in high glucose, whereas immature cells 
(PD50) showed lower levels. This information would assist in understanding the pathological bone 
loss in diabetes. Colombo et al. (2011) reported OPN upregulation in diabetic bone. Subsequently, 
herein, we can claim that this upregulated OPN came from committed osteoprogenitor cells. Taken 
together, these findings open the door to further investigating OPN role in diabetic bone. 
  
This Chapter has shown that CB-MSCs at different PDs have different capacity for osteogenic and 
adipogenic differentiation. PD15 committed progenitor cells have demonstrated the highest capacity 
for osteogenic differentiation and mineral deposition. However, the change in cell heterogeneity at 
PD50 (immature cells) has clearly shown a reduction in this osteogenic ability. On the other hand, 
committed and immature cells demonstrated good ability to adipogenic differentiation. Intriguingly, 
high glucose has been observed to exhibit a significant decrease in osteogenic differentiation process 
in committed cells (PD15), but not immature (PD50), such a novel finding is yet to be mentioned as 
far as we are aware. OPN was reported to be increased at committed osteoprogenitor cells in high 
glucose samples. Obtaining this information about increased OPN levels supports the future 
investigation of the effects of Porphyromonas gingivalis-lipopolysaccharide, which has been 
described as a causative factor for periodontal disease and impaired bone osteogenesis.  
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Chapter 4: Effects of Porphyromonas Gingivalis Lipopolysaccharide on CB-MSC Osteogenesis 
under Normal and High Glucose Conditions 
 
   4.1: Introduction 
Periodontal disease is an inflammatory pathologic state of the supporting structures of the 
periodontium, including the gingiva, alveolar bone, periodontal ligament and cementum. The 
etiology of the disease is of complex bacterial origin. Between the 1930s-1970s, researchers were 
unable to identify specific etiological agents of periodontal disease and hypothesized that it was due 
to a consortium of micro-organisms as the “non-specific theory” (Theilade 1986). Nevertheless, 
after the 1970s, more specific microorganisms were isolated and proposed to be the etiological 
factors of periodontitis (Tanner et al. 1979; Slots et al. 1986; Moore and Moore 1994). Intensive 
studies have now confirmed that the prime periodontopathic bacterial species among these 
etiological factors is Porphyromonas gingivalis (Pg), (Marcotte and Lavoie 1998; Maiden et al. 
2003; Paster et al. 2006; Hajishengallis et al. 2012). Pg was found in 86% of subgingival plaque 
samples from patients affected by chronic periodontitis (Datta et al. 2008). This periodontopathic 
species is known to produce a plethora of virulence factors, including fimbriae, capsules and 
lipopolysaccharide (LPS) (Holt et al. 1999; Hajishengallis and Lamont 2014). LPS has been 
investigated in many studies and found to be involved in specific deleterious effects on bone 
formation and immunoglobulin proteases (Roberts et al. 2008; How et al. 2016). 
 
Pg-LPS is a complex glycolipid forming an important part of the outer membrane of this Gram-
negative bacterium. It plays critical roles in maintaining the cellular and structural integrity and 
controlling the entry of hydrophobic molecules and toxic chemicals (Silhavy et al. 2010). In terms 
of virulence, it is found to be the most significant pathogenic factor among other periodontopathic 
bacteria. Pg-LPS consists of a relatively large size molecule of at least 10kDa (Hamada et al. 1994) 
and a polysaccharide (O-antigen), the core oligosaccharide and the hydrophobic domain known as 
lipid A, which attaches the LPS to the bacterial cell membrane (Ogawa and Yagi 2010). Lipid A is 
the biologically active region of LPS, that could trigger both Toll-Like Receptors 2 and 4 
(TLR2,TLR4), causing deregulation of the innate immune system in mammals (Darveau et al. 2004). 
Al-Qutub et al. (2006) have reported that lipid A has heterogeneous acylation patterns, which would 
be changed, depending on the microenvironmental conditions, to facilitate bacterial survival inside 
the host. Furthermore, Díaz et al. (2015) have observed that P. gingivalis isolated from periodontally 
involved subjects produced modified lipid-A molecules, unlike that from healthy subjects. It is worth 
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noting that the virulence and roles of the other components of pg-LPS are still poorly understood 
(How et al. 2016).  
A number of studies have described the ability of LPS to activate the host inflammatory responses 
through TLR2 and TLR4, which in turn induce the production of proinflammatory cytokines, 
interleukin-1β (IL-1β), IL-6, IL-8 and tumor necrosis factors-α (TNF-α), disrupting bone 
remodelling and repair processes (Jiang et al. 2002; Graves et al. 2011; Herath et al. 2011; Kato et 
al. 2014). Understanding these mechanisms may be a prime step for the treatment of periodontal 
disease. Li et al. (2014) have demonstrated that blockage of TLR4-mediated NF-kB signaling 
pathway, prevented alveolar bone destruction by E. coli-LPS. Little is known, however, about the 
mechanisms of bone loss induced by pg-LPS. Despite the various research, investigating different 
concentration effects of pg-LPS on the osteogenic capacity of bone, overall findings have been 
contradictory. A growing number of studies have shown that 0.1, 0.2, 1 and 10µg/mL concentrations 
of pg-LPS could affect osteogenic differentiation (Roberts et al. 2008; Kato et al. 2014; Xing et al. 
2015). On the contrary, Albiero et al. (2017) demonstrated that 0.1, 1 and 10µg/mL  concentrations 
of pg-LPS have no effects on cell proliferative capacity and the osteogenic differentiation of 
periodontal ligament stem cells (PDLSCs). Tang et al. (2015), nevertheless, reported that 
concentration of 0.1µg/mL of pg-LPS induced bone formation, but they showed 10µg/mL would 
inhibit bone regeneration in bone marrow mesenchymal stem cells (BM-MSCs). These 
contradictory results may be due to the different cell origins assessed, which would produce various 
responses, in addition to the experimental settings in different studies. Roberts et al. (2008) reported 
that pg-LPS reduced osteogenic differentiation in rat alveolar bone osteoblasts through alteration of 
the extracellular matrix proteoglycans, decorin, and biglycan, which have been ascribed roles in 
bone formation. However, a limited number of studies have further investigated the effects of pg-
LPS on the synthesis of extracellular matrix protein OPN. Kadono et al. (1999) demonstrated that 
pg-LPS inhibited OPN and OCN production in rat calvaria cells. OPN has a pivotal role in bone 
formation and remodelling when it binds to mineral crystals, inhibiting their growth to assist in the 
bone remodelling process (McKee et al. 2011). OPN levels have been found to be increased at the 
extracellular matrix of the bone in diabetic rats, which could have detrimental effects on bone 
regeneration (Colombo et al. 2011). Therefore, this study has focused on assessing OPN in high 
glucose conditions, aggravated by different concentrations of pg-LPS, to investigate the combined 
effects of these two factors on the osteogenic process and how they may affect the bone repair. 
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   With a view to addressing the contradictory studies, this Chapter aims to investigate the effect of 
pg-LPS on the osteogenic differentiation of both committed and immature compact bone 
mesenchymal stem cell populations, under normal and high glucose conditions. In addition, 
investigation of the effects of pg-LPS on OPN levels, which are described to be increased in high 
glucose conditions and how this may affect or delay bone remodelling and repair. This study would 
assist in further understanding and elucidate the bone destruction during periodontitis associated 
with T2DM. 
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    4.2: Materials and Methods 
All the subsequent analyses were performed on CB-MSCs at the PD15 and PD50 populations, under 
normal and high glucose conditions, focusing on these well-defined populations while neglected 
PD100 and PD200.  
 
    4.2.1: Characterisation of Porphyromonas Gingivalis Lipopolysaccharide (pg-LPS)       
  Pg-LPS was purchased from InvivoGen, USA. It came as a lyophilized protein within a vial 
containing 1mg and provided with 1mL of distilled water for dilution. Pg-LPS were prepared 
according to the manufacturer’s instructions to give a concentration of 1000µg/mL. A concentration 
of 10µg/10µL of pg-LPS was loaded on a pre-casted gel (Bio-Rad, Laboratories Ltd.), to conduct 
SDS-PAGE. An equal amount of E. coli-LPS (Sigma-Aldrich, UK) was also analyzed for 
comparison. 
 
    4.2.1.1: Coomassie Blue Staining 
   SDS-PAGE was conducted according to Chapter 3 (see Section 3.2.2.2). The gel was then 
submerged in a working solution of Coomassie Blue stain for 1h, with gentle agitation at room 
temperature [50mL Coomassie stock solution, 88mL methanol (Thermo Fisher Scientific, UK), 
24mL glacial acetic acid (Thermo Fisher Scientific) and 88mL ddH2O], [Coomassie Blue stock 
consisted of 250mL Methanol, 250mL ddH2O and 1.25g of Coomassie Blue (Sigma-Aldrich)]. The 
gel was destained overnight at 4oC with constant agitation, using destaining solution (5% methanol, 
7.5 % glacial acetic acid, and 87.5% ddH2O). The gel was finally rinsed with ddH2O to remove 
excess Coomassie Blue stain and imaged by GelDoc™ Scanner using DocTM EZ Imaging System 
with Image LabTM version5 (Bio-Rad, Laboratories Ltd.). 
 
   4.2.1.2: Silver Staining 
  Silver staining was conducted using Silver Stain PlusTM Kit (Bio-Rad, Laboratories Ltd.). SDS-
PAGE was conducted as above. The gel was submerged in a dish filled with fixative enhancer 
solution (50% reagent-grade methanol, 10% reagent-grade acetic acid, 10% fixative enhancer 
concentrate; and 30% ddH2O) for 20min at room temperature, with gentle agitation. The gel was 
rinsed twice with ddH2O for 10min each time, meanwhile the staining solution was prepared with 
thorough mixing (35% ddH2O, 5% silver complex solution, 5% reduction moderator solution; and 
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  5% image development reagent and immediately before use, adding 50% of accelerating solution at 
room temperature). The gel then placed in a dish filled with freshly prepared staining solution for 
20min, or at least until the O-antigen polysaccharide bands became visible with gentle agitation. To 
stop the reaction, 5% acetic acid was added for 15min, followed by washing with ultrapure water 
(18.2MΩ H2O) and imaged by GelDoc™ Scanner using DocTM as previously described. 
 
    4.2.1.3: Gel Electrophoresis for Nucleic Acid Detection 
     Gel electrophoresis was conducted according to Chapter 2 (Section 2.2.5.1.3). 10µg/mL of pg-LPS 
was loaded into the gel to investigate the purity, with E. coli-LPS for comparison. 
 
    4.2.2: Cell Proliferation and Viability Assay 
Cells were seeded in 96-well plate at 4000/cm2 in osteogenic induction culture media (see Chapter 
3, Section 3.2.1.1), supplemented with pg-LPS at concentrations of 10µg/mL, 1µg/mL, 0.1µg/mL 
and 0µg/mL (negative control); and investigated at day 1, 3,5 and day 7. Briefly, media were gently 
removed and replaced with fresh culture media included 20µL of thiazolyl blue tetrazolium blue 
(MTT) assay reagent [5mg/mL MTT (Sigma-Aldrich) in phosphate buffered saline (PBS)]. The 
plates were incubated at 37oC, 5% CO2 for 5h. Culture media were removed and replaced with 
100µL of dimethyl sulfoxide DMSO (ThermoFisher Scientific) and incubated at 37oC, 5% CO2 for 
30min. The colorimetric absorbance was read at 570nm, using a FluoSTAR Omega Plate Reader 
(BMG Labtech, UK). Blank reading wells (empty wells) were incubated with MTT and the culture 
media only but without cells. The assay was conducted on three separate occasions. 
 
     4.2.3: Apoptosis Activity Assay 
 
     4.2.3.1: Positive Control for Apoptotic Assay 
 Four concentrations (0, 100, 200 and 500µM) of hydrogen peroxide (H2O2) (Sigma Aldrich) were 
analyzed to choose a positive control for Caspase-Glo® 3/7 Assay (Promega, UK). We found that 
200µM concentration was the most suitable for all the PDs of the experiment (Figure 4.1). 
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Figure 4.1 CB-MSCs were investigated with 0, 100, 200, and 500µM H2O2, to select a positive 
control for the Caspase Activity Assay. 200µM concentration appeared to be the most suitable for 
all PDs. Error bars represent ± SEM of the mean (n=3). ***=p<0.001. 
 
    4.2.3.2: Caspase Activity Assay 
The Caspase-Glo® 3/7 Assay (Promega) was used to quantify the apoptotic activity of CB-MSCs 
cultured with different concentrations of pg-LPS in osteogenic induction media, under normal and 
glucose conditions. Caspase-Glo® 3/7 reagent was prepared by thawing the Caspase-Glo® 3/7 Buffer 
and mixing the entire contents with Caspase-Glo® 3/7 substrate, with gentle agitation to ensure a 
complete mixture of the reagents. Prepared Caspase-Glo® 3/7 reagent was stored for up to 1 week 
at 4°C. Before use, it was warmed to room temperature. MSCs were seeded in white-walled optically 
clear 96-well plates (GBO, UK), at 4,000/cm2 in 10% FBS culture media supplemented with pg-
LPS at three concentrations; 0.1µg/mL, 1µg/mL, 10µg/mL and 0µg/mL (negative control). Caspase 
activity was investigated at three-time points 6, 24 and 48h at 37oC, 5% CO2. The plate was removed 
from the incubator and acclimatised to the room temperature. 50µL of Caspase-Glo® 3/7 reagent 
was added to each well. The plates were then shaken on a plate shaker at 300rpm for 30s, followed 
by 1h incubation at room temperature, wrapped with aluminum foil to protect from light. Optical 
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emission was measured by using a FluoSTAR Optima plate reader, which was set to the maximum 
optical gain settings and arbitrary relative luminescence units (RLUs). Blank readings were obtained 
from wells that were incubated with Caspase-Glo® 3/7 reagent and osteogenic induction media 
containing no cells. The experiment was conducted on three separate occasions. 
 
   4.2.4: Investigation of CB-MSCs Osteogenic Differentiation Capacity Under Various pg-LPS                    
concentrations 
 
    4.2.4.1: Osteogenic Conditioned with pg-LPS 
CB-MSCs were plated at 4000/cm2 in 6-well plates in osteogenic differentiation media for 28 days, 
in normal, high glucose and pg-LPS conditions. Pg-LPS was added to the media along the 28 days 
of osteodifferentiation at two concentrations; 0.1µg/mL and 1µg/mL. 10µg/mL pg-LPS was 
neglected as it was cytotoxic to CB-MSCs.  For osteogenic medium compositions, refer to Chapter 
3, (Section 3.2.1.1). 
 
    4.2.4.2: Alizarin Red Staining and Mineral Quantification  
Cells were stained with Alizarin Red staining at day 28 and images taken. Quantification of mineral 
formation was also performed at day 28.  All the procedures were discussed in detail, refer to Chapter 
3, (Section 3.2.1.2). 
 
    4.2.4.3: Quantification of Osteogenic mRNA Markers Using qPCR 
Cells were investigated at day 2, 7,14, 21 and day 28. Osteogenic mRNA markers Runx2, OSX, 
OPN and OCN expression were quantified using qPCR. Refer to Chapter 2 (Section 2.2.8). 
   
    4.2.5: Osteopontin Extraction and Analysis  
CB-MSCs were plated in osteogenic media, in normal, high glucose and pg-LPS conditions; and 
grown for 21 days. Total protein was extracted at days 7, 14 and day 21; and dialyzed for 5 days 
(Chapter 3, Section 3.2.2). Protein contents were then quantified (Chapter 3, Section 3.2.2.1). Total 
protein was purified (Chapter 3, Section 3.2.2.4). Immuno- and electro-blotting detection was 
performed to assess OPN (Chapter 3, Section 3.2.2.2 and Section 3.2.2.3). OPN levels were 
quantified by ELISA (Chapter 3, Section 3.2.2.5).    
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    4.2.6: Detection of Phosphorylated OPN through Targeting Anti-Phosphoserine Antibody  
OPN phosphorylation status was immunodetected using anti-phosphoserine antibody (Chapter 3, 
Section 3.2.3).  
 
   4.2.7: Statistical Analyses  
Statistical analyses were performed using One-Way ANOVA with a post-hoc Tukey test to 
determine the statistical differences between sample groups, using the software GraphPad InStat 3 
(v3.06). Statistical significance of differences was defined as significant (*, p<0.05), very significant 
(**, p<0.01) or highly significant (***, p<0.001). 
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    4.3: Results 
 
    4.3.1: Characterisation of pg-LPS 
 
    4.3.1.1: Coomassie and Silver Staining for Bacterial Protein detection, and Gel Electrophoresis 
for Nucleic Acid Detection 
Pg-LPS showed no staining when investigated with Coomassie Blue stain, while with Silver 
staining, pg-LPS demonstrated a classical heterogeneous pattern which may be attributed to O-chain 
moiety, similar to that obtained from E. coli-LPS, which was used for comparison, but with lower 
molecular weight material that appeared with pg-LPS, which may be owing to structural differences 
between the two species (Figure 4.2 A, B). Pg-LPS assessed by agarose gel electrophoresis revealed 
very low levels of nucleic acid, compared to E. coli-LPS, which demonstrated a trace amount nucleic 
acid (Figure 4.2 C). These results proved that the pg-LPS were free from bacterial protein 
components, whereas the E. coli-LPS exhibited multiple bands indicated of a significant amount of 
different bacterial proteins.   
                                         
Figure 4.2: SDS-PAGE to characterise pg-LPS, by staining with A. Coomassie Blue stain showed 
no protein stain for pg-LPS and E. Coli-LPS for comparison.                                      
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 B. Silver stain demonstrated clear bands of O-chain moiety of pg-LPS, whereas E. coli-LPS 
exhibited multiple bands indicated of bacterial proteins. C. Gel electrophoresis to investigate the 
nucleic acid purity of the pg-LPS which revealed very low amounts.  E. coli-LPS exhibited trace 
amount of nucleic acid impurities.                                                                         
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    4.3.1.2: Effects of pg-LPS on Cellular Proliferation and Viability 
Over 7 days in culture, 0.1µg/mL and 1µg/mL pg-LPS increased cell proliferation, but were not 
significant (p>0.05) compared to controls (concentration 0 µg/mL).  pg-LPS at a concentration of 
10µL/mL evoked a reduction of CB-MSC proliferation and viability mainly at day 7. At PD15 N, 
cell expansion developed gradually with no significant difference among various pg-LPS 
concentrations versus the control, until day 7. There were significant differences (p<0.01) between 
concentration 0.1µg/mL and 1µg/mL, compared to concentrations at 10µg/mL. In high glucose, 
PD15 exhibited similar growth trend as PD15 N. At day 7 in high glucose, there were significant 
differences (p<0.001) between 10µg/mL pg-LPS, compared to 0.1µg/mL, 1µg/mL and the controls. 
PD50 N day 7 exhibited a significant reduction (p<0.01) in cell proliferation compared to 1µg/mL 
pg-LPS and (p<0.001) compared to 0.1µg/mL pg-LPS concentrations. PD50 G demonstrated 
significant reduction at 10µg/mL compared to control (p<0.01), and significant reduction (p<0.001) 
compared to both concentrations 0.1 µg/mL and 1 µg/mL pg-LPS. Ultimately, 10µg/mL pg-LPS 
was neglected, considering it was cytotoxic to CB-MSCs (Figure 4.3). 
 
   4.3.1.3: Apoptotic Activity of CB-MSCs Treated with pg-LPS 
There was low caspase activity in all samples except PD50 G, which demonstrated significant 
increase (p<0.001). PD15 N exhibited significant increased (p<0.001) at the concentration 1µg/mL 
pg-LPS at 48h compared with 0.1 and 10µg/mL concentrations and 0 µg/mL (negative control). At 
0.1µg/mL pg-LPS of PD15 N, 48h showed significant increase in caspase activity (p<0.001) 
compared to 6h and 24h. At PD15 G, there were no significant differences between all 
concentrations in comparison to 0 µg/mL negative control. PD50 N demonstrated no significant 
differences among all concentrations, in comparison with the 0µg/mL control. However, there was 
significant increased at concentration of 1µg/mL at 48h, compared to 0.1 and 10µg/mL pg-LPS. At 
PD50 G, the caspase activity showed no significant differences at all concentrations, in comparison 
with the 0 µg/mL control, but demonstrated higher levels of Luminescence Units at 48h in 
comparison to 6h and 24h (Figure 4.4). 
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Figure 4.3: Monitoring cell proliferation and viability with various concentration of pg-LPS (0, 0.1, 
1 and 10 µL/mL of pg-LPS) using the MTT assay. A marked reduction in CB-MSC expansion was 
noticed at day 7 with 10 µL/mL pg-LPS in comparison to 0.1 and 1 µL/mL concentrations. There 
were no significant differences between 0.1µL/mL and 1µL/mL of pg-LPS concentrations with the 
controls over 7 days (p>0.05). Error bars represent ± SEM of the mean (n=3). *=p<0.05, **=p<0.01, 
***=p<0.001. 
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Figure 4.4: Caspase Activity Assay investigating the apoptotic activity of CB-MSCs cultured with 
various concentrations of pg-LPS (0, 0.1, 1 and 10 µg/mL). 200µM H2O2 were used as a positive 
control. Error bars represent ± SEM of the mean (n=3). ***=p<0.001. 
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    4.3.2: Osteogenic Differentiation and Mineral Tissue Formation by CB-MSCs Treated with    
Normal and High Glucose and pg-LPS  
CB-MSCs were cultured with osteogenic induction media and treated with 0, 0.1, and 1 µg/mL 
concentrations of pg-LPS. Alizarin Red staining and qPCR results for mRNA expression of 
osteogenic markers (Runx2, OSX, OPN and OCN), revealed that PD15 committed cells 
demonstrated a better capacity of osteogenic differentiation into osteoblasts than PD50 immature 
cells. High glucose demonstrated a reduction in osteogenic differentiation mainly at PD15, but not 
PD50.  Pg-LPS revealed a reduction in osteogenic differentiation at both PD15 and PD50. However, 
more pronounced effects were observed on PD50 when combined with high glucose (Figure 4.5). 
 
    4.3.2.1: Alizarin Red Staining and Mineral Quantification 
Alizarin red staining was conducted on day 28, when the CB-MSCs underwent differentiation. For 
PD15, there was a marked deep red colour with the 0 µg/mL (control) N. Alizarin staining became 
gradually less staining at 0.1 and 1 µg/mL concentrations of pg-LPS. The high glucose control 
appeared less stained than the N control. Adding pg-LPS revealed no further change. PD50 showed 
less staining at 0 µg/mL concentration in N and G controls, compared to PD15. Adding pg-LPS 
demonstrated less staining red colour in G groups (Figure 4.5). Regarding mineral quantification 
PD15 N, 0µg/mL concentration of pg-LPS (control) demonstrated the highest mineral formation 
and significantly different (p<0.001), compared to all other PD15 pg-LPS concentrations. High 
glucose exhibited a reduction in the mineral deposition in the control group. Interestingly, adding 
pg-LPS exerted further reductions in mineral formation in N groups. PD50 showed a different 
response, there were no significant differences (p>0.05) in mineral formation between N and G (0 
µg/mL) controls. At 0.1 and 1 µg/mL pg-LPS, there was a significant decline in mineral formation 
in G groups, compared to controls (0 µg/mL). Pg-LPS appeared to only affect mineral formation at 
0.1 µg/mL concentrations at N group (Figure 4.6). 
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Figure 4.5: Alizarin Red staining for differentiated CB-MSCs, treated with various concentrations 
of pg-LPS (0, 0.1 and 1 µg/mL) in both N and G media at day 28.  The red colour represents the 
mineral deposition by extracellular matrix secreted by newly formed osteoblasts. Differences in the 
red colour can be noticed between N and G and various concentration of pg-LPS in both population 
PD15 and PD50. Scale bar =100µm. 
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Figure 4.6: Bar chart represents the quantification of the mineral formation after osteogenic 
differentiation process of CB-MSCs. These cells were treated with various concentrations of pg-
LPS (0, 0.1 and 1 µg/mL) in both N and G media. PD15 mineralisation appeared highly affected by 
G, whereas PD50 affected by combined effects of pg-LPS and glucose. Error bars represent ± SEM 
of the mean (n=3). **=p<0.01, ***=p<0.001 
 
 
   4.3.2.2: Quantitative Analysis of Osteogenic mRNA Marker Expressions 
Runx2 is an early mRNA expression transcription factor for osteogenic differentiation. mRNA 
expression of Runx2 was upregulated at an early stage (day 2) in all groups and then downregulated 
at day 7. In PD15 glucose conditions, mRNA expression of Runx2 revealed a significant decrease 
in expression (p<0.05). Adding concentrations 0.1 and 1 µg/mL pg-LPS, downregulated Runx2 
expression but was not significant (p>0.05). Combined high glucose with pg-LPS concentrations 
demonstrated non-significant differences (P>0.05). For PD50, the expression profile of mRNA 
expression of Runx2 was lower than PD15N. PD50 G was significant downregulated mRNA 
expression of Runx2 in 0 µg/mL and 0.1 µg/mL concentration (*=p<0.05) (Figure 4.7 A).                                                    
Osterix (OSX) proposed to be downstream to Runx2. mRNA expression of OSX exhibited the same 
profile of Runx2, upregulation at an early stage of day 2 and then downregulated at day 7. Its 
expression in PD15 was higher than PD50. In high glucose condition, there was significant 
(p<0.001), (p<0.05) downregulation of mRNA of OSX expression in both PD15 and PD50 
respectively. Adding of 0.1 and 1 µg/mL of pg-LPS exerted no further downregulation (Figure 4.7 
A).  
OPN is considered as a mid-marker of osteogenic differentiation. mRNA expression of OPN showed 
upregulation at day 7 and continued downregulation through day 14 and 21 in PD15 and PD50. 
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Under high glucose condition, interestingly, there was upregulation of OPN at PD15 at day 21. In 
PD50 glucose conditions, however, there was downregulation of all mRNA expressions of OPN 
(Figure 4.7 B). Adding of 0.1 and 1 µg/mL of pg-LPS revealed no further significant effects. OCN 
is a late marker of osteogenic differentiation. mRNA expression of OCN was upregulated at day 28 
for both PD15 and PD50, however, the expression in PD50 was very low. In high glucose conditions, 
mRNA expression of OCN was upregulated earlier at day 21, while significantly (p<0.05) 
downregulated at day 28. Adding pg-LPS revealed no significant effects (Figure 4.7 C).  
 
 
A) Early Osteogenic Markers 
                                                              Runx2 
   
 
                                                           
Figure 4.7: Investigation of osteogenic mRNA markers (Runx2, OSX, OPN, and OCN) in normal, 
high glucose and pg-LPS conditions using qPCR. A) Early osteogenic markers, Runx2 and OSX 
were considered as early expressed osteogenic markers and analyzed at day 2 and day 7. Error bars 
represent ± SEM of the mean (n=3). *=p<0.05, **=p<0.01, ***=p<0.001. 
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                                                         Osterix 
 
B) Mid Osteogenic Marker 
 
                                                        Osteopontin 
 
B) Mid osteogenic marker, OPN was considered as a mid-expressed osteogenic marker and 
investigated at day 7, 14 and day 21. Error bars represent ± SEM of the mean (n=3). *=p<0.05, 
**=p<0.01, ***=p<0.001. 
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C) Late Osteogenic Marker 
 
                                                                  Osteocalcin 
   
 
                   
C) Late osteogenic marker, OCN considered late expression during osteogenesis and investigated 
at day 21 and day 28. Error bars represent ± SEM of the mean (n=3). *=p<0.05, **=p<0.01, 
***=p<0.001. 
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    4.3.3: Investigation of the Effects of pg-LPS on Osteopontin 
 
  4.3.3.1: Western Blot Analyses of Osteopontin in Cell Lysates and Extracellular Matrix (ECM) 
As cultures continued, OPN synthesis and its incorporation into the extracellular matrix was detected 
at days 7,14 and 21(Figure 4.8). The main immunodetected bands were found at 55kDa molecular 
weight at all time-points, considered as monomeric OPN. Polymeric OPN appeared as faint bands 
at 120kDa on day 14 and day 21. At day 7, PD15 N and PD50 N showed denser bands, compared 
to G groups. At day 14, PD15 N pg-LPS concentrations (0, 0.1 and 1 µg/mL) demonstrated denser 
bands, compared to PD50 N. PD15 G control (0 µg/mL) exhibited dense bands and then became 
gradually less dense at 0,1 and 1 µg/mL. PD50 N and G demonstrated the same trend with less dense 
bands. At day 21, PD15 and PD50 G exhibited denser bands at all groups compared to normal 
(Figure 4.8).  
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Figure 4.8: Western blot analysis of OPN levels in cell lysates and extracellular matrix of CB-MSCs 
grown in osteogenic media under normal and high glucose conditions. Cells were treated with 0, 0.1 
and 1 µg/mL pg-LPS concentrations. Samples were investigated on day 7, 14 and 21. OPN bands 
were identified at 55kDa with some bands at 120 kDa. Western blots were repeated twice. 
 
    4.3.3.2: Western Blot Analyses of Osteopontin in Culture Media 
OPN was also detected in culture media and identified of a post-translational modification at 120kDa 
and 55kDa in all samples. Cleaved OPN at 25kDa appeared mostly at day 7. At day 7, PD15 OPN 
exhibited a dense 55kDa bands in control groups, whereas adding 0.1 and 1 µg/mL pg-LPS reduced 
OPN levels. At PD50, however, a dense band occur with 0.1 µg/mL pg-LPS. In high glucose, it 
seems that combined effects of glucose and pg-LPS caused a gradual increase in OPN levels 
according to pg-LPS concentrations at PD15, while no further effects were evidenced at PD50 
(Figure 4.9).  
At day 14, control groups for both PD15 and PD50 showed dense OPN bands, which gradually 
became smaller in the presence of pg-LPS. In high glucose and in the presence of pg-LPS, there 
were smaller bands due to combined effects of both glucose and pg-LPS (Figure 4.9). 
Day 21 revealed different OPN profiles, in PD15 and PD50 under normal conditions. OPN bands 
became denser with gradual increase of pg-LPS concentrations. In the presence of high glucose, 
denser OPN bands appeared. However, adding pg-LPS exerted inhibitory effects on OPN levels 
(Figure 4.9). 
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Figure 4.9: Western blot analysis of OPN levels in culture media of CB-MSCs grown in osteogenic 
media under normal and high glucose. Cells were treated with 0, 0.1 and 1 µg/mL pg-LPS. Samples 
were analysed on day 7, 14 and 21. OPN bands were identified at 55kDa, 120kDa and 25kDa. 
Western blots were repeated twice. 
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    4.3.3.3: ELISA Quantification and Analyses of OPN in Culture Media 
 
Quantification of OPN revealed that OPN levels in PD15 were about one-fold higher than PD50 at 
day 7. PD15 N, 0µg/mL pg-LPS, demonstrated significantly highest OPN levels (p<0.001). Addition 
of high glucose, OPN level was significantly reduced (p<0.001). In the presence of 0.1 and 1µg/mL 
pg-LPS, OPN levels was significantly reduced (p<0.001). PD50 N day 7, however, there was no 
significant differences under normal and high glucose conditions. Addition of 0.1 and 1µg/mL pg-
LPS exerted no significant differences. In the presence of high glucose, however, 0.1 µg/mL and 1 
µg/mL pg-LPS exhibited significant differences (*=p<0.05) compared to normal control. At day 14 
and day 21, OPN levels decreased gradually in both PD15 and PD50 N and G groups without any 
significant differences (*=p>0.05) (Figure 4.10). 
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Figure 4.10: Quantification of OPN levels osteogenic induction media conditioned with high 
glucose and 0, 0.1, 1 µg/mL of pg-LPS concentrations using ELISA. OPN levels were measured on 
day 7, day 14 and day 21 for both PD15 and PD50. Error bars represent ± Standard error of the mean 
(SEM). * = p<0.05 and *** = p<0.001. ELISA repeated 3 times. 
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    4.3.4: Phosphorylated Osteopontin Detection 
Western blot was conducted to detect the phosphorylation status of OPN released to the osteogenic 
culture media. It revealed that all samples had phosphorylated OPN associated with the polymeric 
and monomeric forms at 120kDa and 55kDa. In high glucose conditions, extra bands appeared at 
0.1 and 1µg/mL pg-LPS in PD15 at around 70-80 molecular levels. In addition, high glucose 
samples revealed denser bands specially at PD50 (Figure 4.11). 
 
 
Figure 4.11: Western blot analysis by targeting anti-phosphoserine side of phosphorylated OPN in 
osteogenic induction media of CB-MSCs. The media were conditioned with 0.1, 1 µg/mL pg-LPS 
concentrations under normal and high glucose conditions. Two bands were identified for 
phosphorylated OPN at 55kDa, 120kDa. Western blots were repeated twice. 
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    4.4: Discussion 
 
This Chapter focused on the respective impacts of high glucose and pg-LPS on the osteogenic 
potential of CB-MSCs in two different populations, PD15 containing a high proportion of committed 
osteoprogenitor cells and PD50, which were previously characterised as immature MSCs. In pg-
LPS condition, The PD15 population revealed a dose-dependent reduction in osteogenic 
differentiation under normal condition. However, in the presence of pg-LPS and high glucose, there 
were no further osteogenic reductions. For the PD50 population, adding pg-LPS reduced osteogenic 
differentiation at 0.1µg/mL pg-LPS concentrations only, whereas the combined effects of pg-LPS 
and high glucose caused further reductions at 1µg/mL pg-LPS. OPN revealed a peak level at day 7 
and declined gradually through the culture period. Its levels were significantly higher for PD15 than 
PD50. In high glucose conditions, OPN demonstrated increased levels in cell lysates and matrix in 
both populations, while the addition of pg-LPS showed further inhibitory effects.  
 
Within this study, characterisation of the commercial pg-LPS was conducted to evaluate its purity 
from bacterial proteins and nucleic acids, using electrophoresis techniques. The presence of the O-
antigen polysaccharide was found attached to the lipid A-core; an important virulent component of 
pg-LPS, assisting in its detection by oxidation and reaction with silver nitrate staining (Tsai and 
Frasch 1982). The observed picture following silver staining (Figure 4.2 B) could be attributed to 
the variable of the O-antigen polysaccharide side chain (Tsai and Frasch 1982). Interestingly, similar 
patterns have been reported in other studies, where their own purified pg-LPS, rather than 
commercial sources (Kadono et al. 1999; Roberts et al. 2008). The commercial E. coli-LPS was also 
characterised and utilised as a comparative control. Characterisation showed that E. coli-LPS 
contained significant amounts of bacterial proteins and trace amounts of nucleic acids. These 
contaminates would be expected to affect the cellular activities of MSCs. On the contrary, we found 
that the commercial pg-LPS is pure, providing a more clinically relevant scenario to examine the 
direct effect of pg-LPS on the CB-MSCs in vitro. 
 
 MSCs of different origins have shown increases in proliferative capacity, but decreases in 
osteogenic differentiation by treating MSCs with certain concentrations of pg-LPS, namely 0.1, 1 
and 10µg/mL (Roberts et al. 2008; Kato et al. 2014; Xing et al. 2015). It is well-documented that 
the severity of periodontal disease is positively related to the concentration of pg-LPS in the local 
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microenvironment (Socransky and Haffajee 2005). Thus, for a better understanding of this different 
concentrations of pg-LPS were used to observe the biological response of CB-MSCs involved in 
bone repair, in order to choose the sub-lethal dose. Within this study, pg-LPS at concentrations 0.1 
and 1µg/mL demonstrated no inhibitory effects, whereas 10 µg/mL of pg-LPS concentration 
exhibited a reduction in the viability of CB-MSCs. This result is in agreement with Albiero et al. 
(2017) although they showed 10µg/mL concentrations causing an increase in proliferative capacity. 
Based on the results of both MTT and caspase activity, 10µg/mL concentrations have been excluded 
from the study and focussed on 0.1 and 1 µg/mL pg-LPS concentrations. 
  
         The osteogenic capacity and mineral formation of PD15 committed CB-MSCs has been observed 
to be significantly reduced by pg-LPS at both 0.1 and 1µg/mL concentrations, in a dose-dependent 
manner. Accordingly, Alizarin staining and mineral quantification confirmed these results by 
revealing different staining and mineral deposition among the treated groups. These results are in 
line with other studies, which also reported reductions in bone formation (Roberts et al. 2008; Kato 
et al. 2014; Xing et al. 2015). Albiero et al. (2017), however, reported that similar concentrations of 
pg-LPS had no effects on the osteogenesis of periodontal ligament stem cell (PDLSCs). These 
contradictory results may reflect contrasting biological responses to pg-LPS stimuli, depending on 
the source or the MSC status in the heterogeneous cell populations. Additionally, the relative 
difference in the setting of the experimental conditions and the source of the pg-LPS would also 
have an impact whether being commercially sourced or isolated and purified locally. More 
importantly, the heterogeneous nature of pg-LPS has been reported to be structurally different in a 
healthy individual, which is resistant to polymyxin B and exhibited low aggregation ability and is 
associated with low molecular weight O-antigen moieties (Díaz et al. 2015). Pg-LPS from a 
periodontally involved patient, however, produces modified lipid-A molecules, which are the most 
virulent factor  (How et al. 2016). In the presence of high glucose, there was a reduction in mineral 
formation. However, no further reduction was seen by adding either pg-LPS concentrations. These 
findings point out that high glucose even modulates pg-LPS mineral reducing effects specifically at 
1µg/mL concentration. These results were also confirmed by Alizarin Red staining. Intriguingly, 
this is the first study to investigate the combined effects of high glucose and pg-LPS on osteogenic 
mineralisation. However, García-Hernández et al. (2012) investigated the effects of high glucose 
and pg-E.Coli on the mineralisation of MSCs separately, but not in combination.  
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Osteogenic markers in PD15 showed greater reductions in the presence of high glucose more than 
the addition of pg-LPS. Runx2, which is a transcription factor for osteogenic differentiation, was 
negatively affected by high glucose. This result, however, was in partial agreement with Tang et al. 
(2015), who reported that Runx2 was upregulated at 0.1µg/mL concentrations, but downregulated 
at 1µg/mL of pg-LPS. OSX, which is downstream to Runx2, demonstrated a similar pattern as high 
glucose induced downregulation of this marker, whereas pg-LPS did not significantly affect OSX. 
Regarding OPN, at day 21, it was upregulated by high glucose which is similar to those findings of 
Colombo et al. (2011). Pg-LPS has an inhibitory effect on OPN. This very important finding would 
need further research to be explained. OCN was reported to be tightly bound to the hydroxyapatite 
within the mineralised bone matrix and found within mature osteoblasts (Hoang et al. 2003). Within 
this study, OCN was upregulated by high glucose at day 21. García-Hernández et al. (2012) and Liu 
et al. (2015) reported similar findings. This could be explained that high glucose proposed to assist 
in the formation of reactive oxygen species (ROS) (Evans et al. 2003), which in turn can activate 
phospholipase C, causing a release of calcium reserves inside the cells. This calcium may activate 
pathways, such as calmodulin kinase II, which allowed some osteogenic transcriptive molecules, for 
example Runx2 and OSX, to translocate into the nucleus and could assist in the transcription of 
biomineralisation molecules, namely OCN and OPN (Liu et al. 2015). This mineral formation, 
however, was found to be different than normal and with a low quality compared to control (García-
Hernández et al. 2012). The cumulative increase in ROS levels for long-term, nonetheless, reported 
contributing to the inhibition of osteogenic differentiation through PI3K/Akt pathway (Zhang and 
Yang 2013). At day 28 and in the presence of pg-LPS, however, OCN expression was 
downregulated at 0.1 and 1µg/mL pg-LPS concentrations. These results were in agreement with 
previous findings (Kadono et al. 1999; Kato et al. 2014).  In the case of combined high glucose and 
pg-LPS, the situation was exacerbated and OCN was downregulated.      
 
The PD50 immature population, however, revealed a completely different response to osteogenic 
induction with high glucose and pg-LPS. This population exhibited a delay in osteogenic 
differentiation. Nevertheless, when the cells were cultured for a week further in osteogenic induction 
culture (until day 35), they successfully transformed into osteoblasts. Interestingly, high glucose 
demonstrated no effects in terms of mineral formation on the immature population, unlike the 
committed cells at PD15. Upon adding pg-LPS to the cells, only 0.1µg/mL pg-LPS showed a 
significant inhibition to mineral formation. The combined effects of high glucose and pg-LPS, 
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however, reduced the mineral formation at both 0.1µg/mL and 1µg/mL concentrations. Alizarin Red 
staining confirmed this result and mineral quantification demonstrated low mineral deposition of 
this population, compared to the committed cell population. Osteogenic specific markers, Runx2, 
OSX and OCN, exhibited downregulation, supporting the notion of a lower osteogenic capacity of 
immature cells. OPN showed significant downregulation in high glucose, while pg-LPS revealed no 
effects on OPN level. This gave a suggestion that there are no pronounced inhibitory effects of pg-
LPS on OPN level within the PD50 population.  
 
High glucose has been reported to have deleterious effects on osteogenesis to form bone  (Juncheng 
et al. 2013; Liu et al. 2015). Within this study, we observed that high glucose exhibited significantly 
inhibitory effects on committed cell population (PD15), whereas it did not show any significant 
effect on immature cell population (PD50) as described previously. This profile has been observed 
to show different effects when adding pg-LPS. It has been noticed that committed cells (PD15) 
response to pg-LPS exposure can be described as dose-dependent effects on osteogenesis process, 
where 1µg/mL pg-LPS exerted more effect than 0.1µg/mL. However, in the presence of high 
glucose, the effect seemed no further amplified. On the contrary, this profile appeared differently in 
the immature population (PD50). High glucose revealed no effects on the immature cells, but the 
addition of pg-LPS to high glucose groups caused combined effects on osteogenesis at both 
concentrations, while 1µg/mL pg-LPS exerted no significant effects on the normal group. This may 
be a modulatory effect of high glucose on pg-LPS in the committed cells. On the other hand, pg-
LPS affected immature MSCs when combined with high glucose, which may reflect a more 
complicated response of the heterogeneous population to different stimuli. In addition, it would 
explain the contradictory outcome of various studies in this field. Furthermore, these results 
represent the novelty finding of this study, which as far as we are aware, did not mention by previous 
studies. 
  
The influence of pg-LPS on the synthesis of OPN protein was investigated. OPN is one of the earlier 
secreted proteins by (pre)-osteoblasts and it has been reported to be accumulated against resorbed 
bone surfaces forming a “OPN rich cement line”. OPN is proposed to act as an adhesion and cell 
signalling protein, to recruit the mature osteoblasts to the bone surface, regulating early stages of 
bone mineralisation and assisting in the bonding of old bone to new one forming an OPN cement 
line. However, OPN binds to mineral crystals to inhibit their growth assisting in bone remodelling 
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and therefore, increased expression might inhibit bone formation (McKee et al. 2011). OPN has 
been reported to act as a substrate for the covalent cross-linking activity of transglutaminase 2 
(Kaartinen et al. 2002), proposed to contain several integrin-binding motifs (Lund et al. 2009); and 
acts as a potent regulator of mineralisation (Boskey 1995; Pampena et al. 2004). Colombo et al. 
(2011) reported an upregulation of OPN in diabetic healing bone. Within this study, OPN levels 
within the committed population were initially high and then fell in the presence of pg-LPS. This 
profile, however, was different in the immature population, when OPN appeared not to be affected 
by the presence of pg-LPS. In other words, the combination of those two factors; high glucose and 
pg-LPS did not seem to aggravate OPN levels. This trend is not in accordance with our hypothesis 
stated that OPN level supposed to be increased because of high glucose and in the presence of pg-
LPS, proposing to impede bone regeneration and exacerbate the bone loss in the periodontally 
involved diabetic patient.  
 
This Chapter has demonstrated that pg-LPS exerts different inhibitory effects on the osteogenesis of 
CB-MSC populations. PD15 committed cell population demonstrated the highest response to high 
glucose levels, rather than pg-LPS. On the contrary, the PD50 immature population was profoundly 
affected by pg-LPS, when combined with high glucose. Such novel findings have not been reported 
by previous studies, but it is important to elucidate the role of pg-LPS in the inhibition of bone 
repair. Pg-LPS was reported to have inhibitory effects on OPN levels in the committed population. 
On the other hand, pg-LPS demonstrated no effects on OPN levels in the immature population. 
Taken together, these findings were not consistent with the hypothesis that OPN would be 
upregulated in high glucose conditions, which leads us to consider macrophages as an alternative 
source of increased OPN during diabetic bone repair. Thus, the next Chapter will investigate 
macrophages derived from rat femur hematopoietic cells and their roles in secreting OPN under high 
glucose and pg-LPS conditions, which may perpetuate high levels of OPN, as a causative factor for 
impairment of bone regeneration under diabetic conditions. 
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Chapter 5: Investigating the Effects of High Glucose Microenvironment and Porphyromonas 
Gingivalis-Lipopolysaccharides (Pg-LPS) on Macrophage Phenotype and Osteopontin Synthesis 
 
    5.1: Introduction 
Macrophages have a central role in response to pathogens as part of innate and adaptive immunity, 
acting as critical mediators of inflammatory processes, controlling tissue homeostasis, in addition to 
regulating various stages of wound and bone healing. Recently, two main populations of 
macrophages have been described; resident macrophages and circulating monocytes. The resident 
macrophages are proposed to be derived during early hematopoiesis from the embryonic yolk sac, 
which populate the tissues and have the capacity of self-renewal (Schulz et al. 2012; Sieweke and 
Allen 2013). These are present in all tissues of adult mammals, taking various nomenclatures 
according to their tissue location and may differentiate into osteoclasts in bone, Kupffer cells in liver 
and microglia in the brain. These specific populations have been proposed to have such highly 
different transcriptional profiles, they considered as unique classes of macrophages (Gautier et al. 
2012). Circulating macrophages are described to originate from hematopoietic stem cells (HSCs) in 
bone marrow and consequently differentiate into macrophages (Akashi et al. 2000; Fogg et al. 2005; 
Liu et al. 2009; Hettinger et al. 2013). It has been described that both resident and circulating 
monocytes have the ability to differentiate into macrophages, M1 macrophages by means of 
granulocyte-macrophage colony stimulating factors (GM-CSF) and M2 macrophages by 
macrophage colony stimulating factor (M-CSF) (Burgess and Metcalf 1980; Gasson 1991). M1 cells 
are involved in the inflammatory state and phagocytosis in response to pathogenic stimuli. 
Consequently, inflammation is associated with deleterious effects and needs to be repressed by other 
type of cells, such as M2. M2 cells are reported to play a major role in the resolution of inflammation 
by producing anti-inflammatory cytokines and chemokines; and eliminating tissue debris (Tushinski 
et al. 1982; Bartocci et al. 1987; Hamilton 2008). The most acceptable theory of the function of 
macrophage phenotypes is the same in all tissue. However, although circulating macrophages, which 
mostly stay for 1-2 days in the circulation, assist in supporting the function of resident macrophage 
phenotypes. If they have not been recruited to fight a pathogenic infection, they undergo apoptosis 
and are removed (Italiani and Boraschi 2014).  
Adipose tissue accumulation represents one of the important causes of the insulin resistance in type 
2 diabetes mellitus (T2DM), (Olefsky and Glass 2010). Bone marrow-derived macrophages have 
been reported to be recruited in adipose tissue and initiate a low-grade chronic inflammation, which 
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has been described to comprise 40% of the total adipose tissue cells in obese rodents (Xu et al. 2003; 
Heilbronn and Campbell 2008). On the other hand, macrophages have been observed to consist of 
10% of adipose tissue in counterpart lean mice (Weisberg et al. 2006). Free fatty acid (FFA) can be 
recognized by the Toll-Like Receptors 2 and 4 (TLR-2, TLR-4) of macrophages, which can switch 
macrophage polarity from M2 to more M1 regulated by peroxisomal proliferator-activated receptor 
gamma (PPARγ) transcription factor. In this case, the inflammatory response can be amplified, 
promoting the development of insulin resistance and consequently exacerbating T2DM (Shi et al. 
2006; Davis et al. 2008). Interestingly, Espinoza-Jim´enez et al. (2012), have reported that using 
helminth parasites to induce M2, has been found to be effective in reducing hyperglycemia, obesity 
and decreased the incidence of T2DM. 
Porphyromonas gingivalis- lipopolysaccharide (pg-LPS) is known to be the prime virulence factor 
of periodontal disease. It plays a pivotal role in triggering the immune response, through inducing 
macrophage TLR2 and TLR4 and aggravating the inflammatory process. This induction has been 
described to release inflammatory mediators, such as tumour necrosis factor (TNF-α), interleukin 
(IL)-1, IL-6, which are reported to perpetuate inflammation (Rittling 2011). These immune 
mediators, namely TNF-α and IL-1β, result in attracting more macrophages to the infected area and 
enhance activated macrophages to be pro-inflammatory (M1 phenotype), to be ready for killing and 
phagocytosis activities. This situation is strongly apparent, when the symptoms of periodontal 
disease have clinically appeared (Yang et al. 2017). The balance between M1/M2, however, has 
been associated with inflammation at the gingivitis stage, yet to progress into periodontitis (Yu et 
al. 2016; Yang et al. 2017). With this in mind, hyperglycemia has also been described to exhibit 
high levels of TNF-α in the circulation of affected individuals, which result in insulin resistance. 
Pg-LPS and hyperglycemia may thus act synergistically in individuals with periodontal disease and 
diabetes, resulting in rapid attachment loss and alveolar bone resorption (Lo 2005). 
A prime functional protein in the recruitment and regulation of the macrophage function is 
osteopontin (OPN). Strong evidence has suggested that OPN may act as an opsonin to facilitate 
macrophage adhesion and engulf the newly formed mineral crystals, which may hinder bone 
biomineralisation at the healing site (Pedraza et al. 2008; McKee et al. 2011). In the case of 
inflammation, macrophages secrete pro-inflammatory cytokines, TNF-α, IL-1, IL-6, and interferon-
γ (INF-γ), which in turn increase OPN levels (Rittling 2011). Colombo et al. (2011) demonstrated 
an increase in OPN levels as well as an increase in macrophages in diabetic healing bone. 
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Furthermore, in the case of LPS, Gao et al. (2005) reported that LPS induced S-nitrosylation of 
heterogeneous nuclear ribonucleoprotein A/B (hnRNP-A/B), which was described as RNA-binding 
proteins with chromatin-associated and can bind with RNA polymerase II, forming a complex. This, 
in turn, can inhibit OPN transcription through repressing its DNA binding activity. However, recent 
research suggested that secreted OPN is not regulated by LPS in RAW264.7 and mouse peritoneal 
macrophages (Zhao et al. 2010). Moreover, Nares et al. (2009) observed that OPN expression was 
not increased in macrophages in the presence of LPS as confirmed by Microarray analysis. Taken 
all together, more experiments are required to elucidate the real effects of LPS in regulating OPN in 
macrophages from different species. This knowledge would assist in understanding the role of this 
protein in bone loss, complicated by hyperglycemia.  
Against this background, it is valuable to investigate the effects of high glucose in the presence of 
pg-LPS on circulating macrophages, which have a pivotal role in defending the body against this 
prime virulence factor of periodontal pathogens. This Chapter aims to investigate the role of M1 and 
M2 macrophages in OPN production under high glucose, pg-LPS or both conditions. These two 
factors are proposed to increase OPN levels, which in turn act as detrimental factors, resulting in 
delayed bone healing and remodelling in diabetic individuals with periodontal disease. 
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    5.2: Materials and Methods 
 
    5.2.1: Isolation and Characterization of Rat Bone Marrow-Derived Macrophages  
Rats were handled and sacrificed, according to the Code of Practice for the Human Killing of 
Animals Under Schedule 1 of the Animals Scientific Procedures Act (1986). Four-week old male 
Wistar rats were bought from Charles River UK Ltd., (Margate, UK). Femurs and tibias were taken 
from sacrificed rats, the ends were cut off and bone marrow flushed with ice-cold phosphate buffer 
saline (PBS) into containers, using a syringe with a 21-gauge needle. The PBS containing cells was 
centrifuged at 1800rpm for 5min. Supernatants were discarded and the cell pellets were suspended 
in 2mL of collagenase dispase (4µg/mL) (Sigma-Aldrich, Poole, UK) and incubated at 37oC, 5% 
CO2 incubator
 for 45min with gentle agitation every 15min. Cells were passed through a 70μm cell 
strainer (Sigma-Aldrich, UK) and collected into universal tubes. The collected cells were then 
centrifuged at 1800rpm for 5min, discarding the supernatants and the cell pellets were re-suspended 
with 2mL of Lysing Buffer (BD Biosciences, UK) with gentle agitation for 2min at room 
temperature. The universal tube containing cells were then filled with an isolation medium [RPMI 
1640 (Invitrogen, UK) 1% antibiotics-antimycotics (Sigma-Aldrich, UK)], centrifuged and the 
supernatants discarded. The cell pellets were washed once again, re-suspended in 1mL of the 
isolated medium, counted and seeded at a density of 1x106 cells/cm2 in T-25 flasks (Sarstedt Ltd., 
UK). The cells were cultured in a standard culture medium [isolation medium containing 10% fetal 
bovine serum (FBS)], supplemented with either granulocyte-macrophage colony-stimulating factor 
(GM-CSF, 10ng/mL) to drive the monocyte cells to differentiate into M1 macrophages, or a 
combination of macrophage colony-stimulating factor (M-CSF, 10ng/mL) and interleukin-4 (IL-4, 
10ng/ml) to allow the differentiation of monocytes into M2 macrophages. All the stimulating factors 
were bought from (PeproTech, USA). The monocytes were incubated in the culture medium for 7 
days. The medium was changed every two days. Some cells were incubated in BD Falcon™ glass 
chamber slides (BD Biosciences, UK) for detection F4/80 a specific macrophage marker. 
 
The culture media were collected at day 1 and day 7 to perform Enzyme Linked-Immunosorbent 
Assay (ELISA), to confirm the successful cell differentiation into macrophages by investigating 
specific cytokines; TNF-α, IL-6, TGF-β1 and IL-12p40, in addition, to analysing OPN at protein 
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levels. Cells were recovered at day 1 and day 7 to quantify mRNA expression of OPN, using 
quantification polymerase chain reaction (qPCR).  
 
    5.2.1.1: Detection F4/80 Specific Macrophage Marker Using Immunocytochemistry 
Cells were investigated on day 1 and day 7, using BD Falcon™ glass chamber slides (BD 
Biosciences, Oxford, UK). Culture media were removed, cells were washed twice with PBS, fixed 
in ethanol for 30min and cell non-specific binding was blocked with 1% Bovine Serum Albumin 
(BSA) diluted in Tris Base Saline (TBS). F4/80 primary rabbit polyclonal IgG antibody (Insight 
Biotechnology, UK) was added at 1:50 dilution in 1% BSA/TBS and incubated overnight at 4oC. 
Normal rabbit IgG (Insight Biotechnology, Wembley, UK) was used as isotype control at 1:50 
dilution in BSA/TBS in place of F4/80 antibody. Another control was antibody exclusion with 1% 
BSA/TBS only. Cells were rinsed twice with TBS for 5min and then incubated in secondary 
antibody goat anti-rabbit IgG-FITC (Insight Biotechnology, UK) with 1:200 dilution in 1% 
BSA/TBS for 1h at room temperature. Cells were rinsed twice with TBS for 5min. The chambers 
were removed, slides were stained with DAPI Vectashield Hard-Set Mounting Medium (Vector 
Laboratories Ltd, Peterborough, UK) and covered with cover slips (Thermo Scientific, UK). Nuclear 
DAPI and green-lipid fluorescence were observed using an Olympus Provis AX70 Microscope, with 
Nikon ACT-1 v.2.63 software. 
 
 
    5.2.1.2: Detection of M1 and M2 Specific Markers from Supernatant Using ELISA 
 
5.2.1.2.1: Detection of Rat TNF-α  
Cell culture medium samples were collected on day 1 and day 7. Secreted TNF-α in the supernatant 
was quantified using Rat TNF-α Quantikine® ELISA Kit (R&D Systems®, UK). The assay was 
conducted according to the manufacturer’s instructions. Briefly, samples were centrifuged to 
remove particulates, diluted 3-fold with calibrator diluent, prior to loading 50µL into the wells of 
the plate which were pre-coated with TNF-α monoclonal antibodies. 50µL of the TNF-α standards 
were loaded in duplicate to separate wells in descending order of concentration, samples were 
incubated for 2h at room temperature, with gentle shaking. Each well content was removed and 
wells were washed five times with washing buffer. 100µL of rat TNF-α conjugate was added to each 
well, incubated for 2h and washed, as described previously. 100μL of the substrate solution was 
added to each well, incubated for 30min at room temperature and protected from light. The enzyme 
activity was terminated by addition of 100µL of stop solution and the plate was measured by 
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spectrophotometer at 450nm. The amount of TNF-α in the samples was calculated from reference 
standards of known concentrations of TNF-α. Experiments were performed in triplicate of two 
independent experiments and results were expressed as pg/mL. 
 
5.2.1.2.2: Detection of Rat IL-6 
This assay was conducted using Quantikine® ELISA Kit (R&D Systems®, UK) with the same steps 
as TNF-α and the plate was measured by spectrophotometer at 450nm. The amount of IL-6 in the 
samples was calculated from reference standards of known concentrations of IL-6. Experiments 
were performed in triplicate of two independent experiments and results were expressed as pg/mL. 
 
5.2.1.2.3: Detection of Rat TGF-β1 
Cell culture medium samples were collected on day 1 and day 7. The secreted TGF-β1 in the 
supernatants was quantified using Rat TGF-β1 Quantikine® ELISA Kit (R&D Systems®, UK). The 
assay was conducted according to the manufacturer’s instructions. Samples were centrifuged to 
remove particulates. 20µL of 1N HCl was added to 100µL of samples, which were then mixed well, 
incubated for 10min at room temperature, for activation then neutralized with 1.2 N sodium 
hydroxide (NaOH)/0.5M HEPES. 50µL of assay diluent (provided by the Kit) was added to each 
well prior to loading 50µL volume of duplicate standards in ascending order concentrations, control 
and activated samples (wells were already coated with TGF-β1 monoclonal antibodies); and 
incubation for 2h at room temperature with gentle shaking. Well contents were removed and washed 
five times with washing buffer (provided with the Kit). 100µL of rat TGF-β1 conjugate was added 
to each well, incubated for 2h and washed, as above. 100μL of substrate solution was added to each 
well, incubated for 30min at room temperature and protected from light. The enzyme activity was 
terminated by adding 100µL of stop solution. The plate was measured by spectrophotometer at 
450nm. The amount of TGF-β1 in the samples was calculated from reference standards of known 
concentrations of TGF-β1. Experiments were performed in triplicate of two independent experiments 
and results were expressed as pg/mL. 
 
5.2.1.2.4: Detection of Rat IL-12p40 
Cell culture medium samples were collected on day 1 and day 7. The secreted IL-12p40 in the 
supernatant was quantified using Rat IL-12p40 ELISA Kit (Origene, USA). The assay was 
conducted according to the manufacturer’s instructions. Briefly, 100µL of the samples, control, and 
standards were loaded into each well. A 50µL working solution of Biotin-Conjugate was added and 
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incubated for 2h at room temperature with a gentle agitation. Each well content was removed and 
the wells were washed 5 times with washing buffer (provided with the Kit). 100µL of rat IL-12p40 
Conjugate was added to each well, incubated for 2h and washed, as above. 100μL of working 
solution of Streptavidin-HRP was added to each well, incubated for 30min at room temperature and 
protected from light. The washing steps were repeated, as before. 100µL of substrate solution was 
added to each well and incubated for 20min at room temperature with light protection. The enzyme 
activity was terminated by adding 100µL of stop solution. The plate was measured by 
spectrophotometer at 450nm. The amount of IL-12p40 in the samples was calculated from reference 
standards of known concentrations of IL-12p40. Experiments were performed in triplicate of two 
independent experiments and results were expressed as pg/mL. 
 
    5.2.2: Quantification of Osteopontin Expression in M1 and M2 Macrophages by qPCR 
 
    5.2.2.1: RNA Extraction and qPCR 
RNA was extracted from the adherent cells at day 1 and day 7 and utilised for qPCR analysis. Total 
RNA was extracted using the RNeasy® Mini Kit (Qiagen, UK). cDNA Reverse transcription was 
obtained from RNA by reverse transcription, as described in Chapter 2 (Section 2.2.5.1.1). OPN 
expression was quantified using qPCR, described in Chapter 2 (Section 2.2.8). OPN forward and 
reverse primers were as stated in Chapter 3 (Table 3.1).  
 
    5.2.3: Quantification of Osteopontin Protein Levels in the Culture Media of M1 and M2 
Macrophages by ELISA 
Media were collected from cells at day 1 and day 7. ELISA was conducted according to methods 
described in Chapter 3 (Section 3.2.2.5) using Osteopontin (Rodent) ELISA Kit (Enzo Life Science, 
UK). Experiments were performed in triplicate of two independent experiments and results were 
expressed as ng/mL. 
    5.2.4: Statistical Analyses  
Statistical analyses were performed using One-Way ANOVA with a post-hoc Tukey test to 
determine the statistical differences between sample groups, using the software GraphPad InStat 3 
(v3.06). Statistical significance of differences was defined as significant (*, p<0.05), very significant 
(**, p<0.01) or highly significant (***, p<0.001). 
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    5.3: Results 
 
    5.3.1: Morphological Observation of Macrophages During 7 Days in Culture 
Monocytes treated with either GM-CSF or M-CSF/IL-4 are proposed to form M1 and M2 
macrophages, respectively. After 24h in culture, all cells exhibited a homogenous small round 
morphology. At day 3, all cells appeared almost the same size with short processes. At day 5, the 
monocytes demonstrated considerable changes in their morphology and increase in cell size. Cells 
treated with GM-CSF exhibited rounded morphology with some spindle-like shape and possessed 
long cytoplasmic processes. On the other hand, cells stimulated with M-CSF and IL-4 revealed 
larger round and more spindle-shaped cells, with shorter processes. At day 7, monocytes showed 
further differentiation with their morphological populations, indicating different shapes depending 
on the stimulated cytokines treatment. M1 cells were round, oval with longer processes with very 
little spindle-like and heterogenous cell shape. M2 demonstrated mostly spindle-like and oval 
morphology (Figure 5.1).  
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 Figure 5.1: Images of monocyte cells stimulated by either GM-SCF or M-CSF and IL-4 for 7 days 
to differentiate into M1 and M2 macrophages respectively. Images were taken at days 1, 3, 5 and 7. 
Magnification of 20X, scale bar 100µm. 
 
    5.3.2: Characterisation of Identified Macrophages 
 
    5.3.2.1: Immunocytochemistry for F4/80 Identification 
F4/80 specific marker for macrophages were clearly seen at day 7, as indicated by green FITC 
staining in both M1 and M2 populations. This indicated that monocytes stimulated by either GM-
SCF or M-CSF and IL-4 were successfully differentiated into macrophages (Figure 5.2). 
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Figure 5.2: Immunocytochemistry identification of activated macrophages at day1 and day 7. F4/80 
was confirmed by green-FITC colour at day 7. The control isotype (IgG) antibody and exclusion 
antibody were both negative. DAPI nuclei stain blue. Magnification of 40X, scale bar 100µm. 
 
 
    5.3.2.2: Quantification of M1 and M2 Macrophage Cytokines by ELISA 
TNF-α exhibited higher levels in M1 compared to M2 macrophages, in normal glucose (N) 
conditions. In high glucose (G) conditions, TNF-α exhibited significantly increased levels in M1 
compared to N condition (p<0.01). Addition of 0.1µg/mL concentration of pg-LPS to the media, 
caused TNF-α levels significantly decreases in M1 macrophages N condition (p<0.01). Increase in 
pg-LPS concentrations from 0.1µg/mL to 1µg/mL exhibited different response profiles. TNF-α 
levels increased significantly again in N condition (p<0.001) for M1 macrophages. Interestingly, in 
G conditions adding 0.1µg/mL of pg-LPS decreased TNF-α levels in M1 macrophages, whereas 
1µg/mL caused increased TNF-α levels by 2-fold but still significantly less when comparing to G 
condition alone in M1 macrophages (Figure 5.3A). 
 
IL-6 levels in M1 demonstrated higher by about 2-fold compared to M2 macrophages, in N 
condition. G conditions caused no significant differences. Addition of 0.1µg/mL concentration of 
pg-LPS revealed significant increase in IL-6 levels in M1 macrophages (p<0.01) in N conditions. 
Whereas 1µg/mL pg-LPS led to significant decrease in IL-6 levels in both M1 and M2 macrophages 
in N condition (p<0.001). In G conditions, 0.1µg/mL pg-LPS demonstrated a significant increase in 
136 
 
IL-6, however, adding 1µg/mL pg-LPS, leading to significant decrease in IL-6 levels in both M1 
and M2 macrophages (Figure 5.3 B). 
 
TGF-β1 levels showed a different profile, it was higher by about 1.5-fold in M2 compared to M1 
macrophages. G conditions caused slight increase in TGF-β1 levels in M2 macrophages but was not 
significant. Addition of 0.1µg/mL concentration of pg-LPS resulted in significant increase in TGF-
β1 levels at both M1 and M2 macrophages accordingly (p<0.05), (p<0.01) compared to N conditions. 
While 1µg/mL concentration pg-LPS exhibited a significant increase in TGF-β1 levels at both M1 
and M2 macrophages (p<0.05) compared to N conditions. In G conditions, adding 0.1µg/mL 
concentration showed significant increase in TGF-β1 levels (p<0.05), (p<0.001) in M1 and M2 
macrophages. 1µg/mL concentration caused significant increase of TGF-β1 levels (p<0.001) 
compared to G conditions alone (Figure 5.3 C). 
 
IL-12p40 expressed 1.5-fold higher levels in M2 compared to M1 macrophages in N conditions. 
Addition of G caused significantly increased levels in M2 macrophages (p<0.01) compared to N 
conditions. 0.1µg/mL concentration of pg-LPS exhibited significant increase IL-12p40 levels 
(p<0.001), (p<0.01) at both M1 and M2 macrophages respectively compared to N conditions. 
Addition of 1µg/mL pg-LPS exerted significant increase at M1 only (p<0.01) compared to N 
conditions. In G conditions, interestingly, 0.1µg/mL concentration demonstrated significantly 
elevation of IL-12p40 levels (p<0.001) in M1 macrophages, whereas it was inhibited in M2 
macrophages (p<0.01). 1µg/mL concentration revealed significant increase in IL-12p40 levels 
(p<0.001) in M1 and a significant decrease in M2 macrophages (p<0.001) (Figure 5.3 D). 
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A) TNF-α 
 
        
 
        
 
 Figure 5.3: Bar charts represent quantifications of A) TNF-α, B) IL-6, C) TGF-β1 and D) IL-12p40 
levels using ELISA. TNF-α and IL-6 levels were higher in M1, whereas TGF-β1 and IL-12p40 were 
higher in M2 control groups. Addition of 0,1 and 1 µg/mL concentrations of pg-LPS caused variable 
effects, increasing or decreasing the level of these cytokines. Error bar represents standard error of 
mean ±. n=3. (* = p<0.05) (** = p<0.01) (*** = p<0.001). 
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B) IL-6 
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C) TGF-β1 
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D) IL-12p40  
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    5.3.3: Detection of Osteopontin in M1 and M2 Macrophages 
 
    5.3.3.1: Quantification of Osteopontin Expression by qPCR 
OPN expression indicated no significant differences between day 1 and day 7 in N conditions for 
both M1 and M2 macrophages. In the case of G, there was also no significant differences between 
day 1 and day 7 in M1 and M2 macrophages. Adding 0.1µg/mL concentration of pg-LPS to the 
normoglucose condition resulted in an increase in OPN expression in M2 macrophages, but this was 
not significant. At the 1µg/mL concentration in N conditions, there was a significant increase in 
OPN expression in M2 macrophages (p<0.01). Adding 0.1µg/mL concentration to G conditions, 
caused a significant increase in OPN expression for M2 macrophages (p<0.001), whereas addition 
of 1µg/mL concentration resulted in a significant increase in OPN expression (p<0.01), but lower 
expression than 0.1µg/mL concentration (Figure 5.4). 
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Figure 5.4: Bar charts represent mRNA OPN expression of M1 and M2 macrophages treated with 
glucose and 0,1 and 1 µg/mL concentrations of pg-LPS by qPCR. Error bar represents standard error 
of mean ±. n=3. (* = p<0.05), (** = p<0.01) and (*** = p<0.001). 
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   5.3.3.2: Quantification of Osteopontin Levels in Culture Media for M1 and M2 Macrophages 
by ELISA 
OPN levels in normoglucose groups were very low at day 1 and day 7, in both M1 and M2 
macrophages. Addition of high glucose caused no significant differences in OPN levels for both M1 
and M2. Addition of 0.1 and 1µg/mL of pg-LPS to the normoglucose conditions, resulted in 
significant increase in OPN levels in M2 macrophages (p<0.001). In the case of combining the 
effects of glucose and pg-LPS, it was found that 0.1 and 1µg/mL concentrations significantly 
increased OPN levels in both M1 and M2 (p<0.001, Figure 5.5). 
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Figure 5.5: Bar charts represent OPN levels in the culture media of activated M1 and M2 
macrophages treated with glucose and 0,1 and 1 µg/mL concentrations of pg-LPS by ELISA. Error 
bar represents standard error of mean ±. (n=3), (* = p<0.05), (** = p<0.01) and (*** = p<0.001). 
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    5.4: Discussion 
 
This Chapter has investigated OPN secreted by bone-marrow derived macrophages under normal, 
high glucose and pg-LPS conditions. In addition, studies analysed OPN levels after the combined 
application of high glucose and pg-LPS. These two factors may potentiate bone loss in periodontal 
disease, however, the mechanisms have remained unclear to date. This study has hypothesized that 
increased OPN level could be the causative factor of this delayed bone healing. The study findings 
revealed that the isolated monocytes successfully differentiated into M1 and M2 macrophages 
according to their stimuli, GM-CSF and M-CSF with IL-4 respectively and expression of related 
cytokines, TNF-α, IL-6, TGF-β1 and IL12p40. OPN levels in M1 and M2 either in normal or in high 
glucose conditions alone did not increase. Pg-LPS increased OPN levels in M2 macrophages only. 
The combined conditions, however, in both high glucose and pg-LPS, demonstrated a significant 
elevation of OPN levels in M1 and M2 macrophages. 
The first aim of this study was to confirm monocyte differentiation in normal culture media. The 
isolated monocytes demonstrated round-shaped cells mostly homogenous with no distinct 
morphological appearances at day one. The cell-shape exhibited morphological changes at day 5, 
when there were distinct morphological differences between GM-CSF and M-CSF and IL-4 
stimulated cells. M1 cells revealed round and oval cells with long process cells. M2 demonstrated 
mostly spindle-like shaped and little number of round cells with shorter processes. These findings 
are partly in line with Gordon and Taylor (2005) who described the cells as heterogeneous, variable 
size, granular and nuclear morphology. In addition, Rey-Giraud et al. (2012) reported that the 
majority of cells are elongated and fibroblast-like. The heterogeneity was described to be highly 
dependent on various factors, for example, cell origin, the level of differentiation and the variation 
of the stimulated microenvironmental cytokines (Chakraborty et al. 2005).  
The isolated monocytes were characterised throughout the induction period to differentiate into M1 
and M2 macrophages. F4/80 is considered as a specific surface marker of macrophages. Within this 
study, the fully differentiated macrophages expressed this marker at day 7. This result is in line with 
the studies of (Nguyen et al. 2007; Zhang et al. 2008), who showed F4/80 in differentiated 
macrophages. Although F4/80 revealed some expression in bone-derived cell phenotypes, Schulz et 
al. (2012) have reported that resident macrophages derived from yolk sac, such as microglia cells in 
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the brain, Langerhans cells in the skin and Kupffer cells in the liver, exhibited brighter F4/80 
macrophages than the bone-derived macrophages, which are hematopoietic in origin and would 
demonstrate lower F4/80 expression.  
Macrophages which were driven to differentiate into inflammatory M1 cells were characterised and 
found to secrete more pro-inflammatory cytokines. These pro-inflammatory mediators play a prime 
role in phagocytosis of pathogens. TNF-α represents the most important cytokine in this process. 
Within this study, the secreted TNF-α and IL-6 were estimated in the culture medium. M1 revealed 
significant levels of TNF-α and IL-6, which confirms the inflammatory nature of M1 phenotypes, 
stimulated by GM-CSF. These results are in accordance with other studies (Lund et al. 2009; Rittling 
2011; Wang et al. 2013; Italiani and Boraschi 2014). On the other hand, M2 stimulated by M-CSF 
and IL-4 exhibited significant levels of TGF-β1 and IL-12p40. TGF-β1 was described as a very 
important anti-inflammatory factor and with pivotal roles in starting the healing process 
(Mohammad et al. 2006; Lund et al. 2009; Rittling 2011). It is worth stating that Dr. Norhayati 
Yusop from our laboratory group, had precisely completely characterised these cells by investigating 
TNF-α, IL-6, iNOS related to M1 and TGF-β1, IL12p40, CD163, Arginase1 (Arg1), MRC1 and 
VEGF related to M2 ; both cells have been isolated by the same protocol (unpublished data). 
This study then continued to consider the effects of high glucose on the developing M1 and M2 
phenotypes. There was a significant increase in the secretion of TNF-α by M1 macrophages in high 
glucose, compared to M1 cultured in normal conditions. TNF-α has been described to be related to 
insulin resistance and aggravates diabetes (Hotamisligil et al. 1993;   Engebretson et al. 2006). This 
result may confirm the Colombo et al. (2011) findings, who reported a prolonged high level in TNF-
α in diabetic rat alveolar bone at week 3-6. Prolonged expression of TNF-α was described to have 
an established role in inhibiting osteoblast differentiation (Gowen et al. 1988) and stimulating 
osteoclast bone resorption (Nanes 2003), which appears to significantly correlate with periodontal 
disease severity (Tunes et al. 2010). However, other studies have shown a decrease in TNF-α and 
other pro-inflammatory cytokines secreted by peritoneal-derived macrophages, when investigated 
under high glucose conditions at day 1 and day 5 (Doxey et al. 1998). Taken collectively, TNF-α 
demonstrated a prolonged expression from macrophages under hyperglycemic condition, leading to 
dysregulation of immune response, which may result in destruction of periodontal tissue in the 
presence of subgingival Gram-negative bacteria, such as Porphyromonus gingivalis (Graves et al. 
2007; Tunes et al. 2010). Interestingly, inhibition of TNF-α by using a recombinant TNF-α receptor 
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immunoglobulin G protein was found to improve insulin sensitivity (Hotamisligil et al. 1993). In 
the present study, however, IL-6 under high glucose condition did not reveal any differences 
compared with the normal conditions. 
 
Within this study, TGF-β1 the anti-inflammatory cytokines from M2, exhibited an increased level 
in the presence of high glucose. This result may explain the findings of Colombo et al. (2011), who 
reported a delayed expression, but a significant increase in TGF-β1 in diabetic healing bone. In 
addition, macrophages derived from adipose tissue of insulin-resistant individuals indicated that 
macrophages expressed anti-inflammatory M2 cell characterisation, but with a higher susceptibility 
to produce pro-inflammatory cytokines, that tend to develop more insulin resistance and higher rates 
of fibrosis (Zeyda et al. 2007; Spencer et al. 2010).  
 
In the presence of pg-LPS, TNF-α was more affected by pg-LPS in a dose-dependent manner. This 
may explain that the severity of periodontal disease depends on the dose of the virulent bacterial pg-
LPS, which was mentioned to be a predominantly high constituent of subgingival plaque of diabetic 
individuals (Preshaw et al. 2012; How et al. 2016). IL-6, which is reported to activate TNF-α by 
means of IL-1β, demonstrated to be increased by 0.1µg/mL pg-LPS. These findings came partially 
in line at a concentration of 1µg/mL with that of Belfield et al. (2017), who reported that TNF-α  
secretion, increased in M1 and decreased in M2 macrophages. However, they reported no effects of 
pg-LPS on IL-6 in both M1 and M2 macrophages.  
 
The combined effects of high glucose and pg-LPS indicated change in the profile of cytokines 
synthesized by M1 and M2 populations. Hung et al. (2013) studied this synergistic effect, however, 
they investigated macrophages from cell line (U937) without specifying the effects on M1 or M2 
macrophages. Within this study, low concentration of pg-LPS (0.1µg/mL) under high glucose 
decreased TNF-α levels in M1 by one-fold, compared to pg-LPS under normal conditions. In 
contrast, increased pg-LPS concentrations to 1µg/mL, resulted in an almost one-fold higher level of 
TNF-α. This may suggest that low concentration of pg-LPS may be able to modulate the 
inflammatory process, unlike 1µg/mL concentration, which increased TNF-α levels. These results 
again suggest the dose-dependent manner of pg-LPS, described to play a pivotal role in the 
inflammatory process within periodontium and can induce more tissue destruction. IL-6 levels in 
the combined effects of high glucose and pg-LPS, showed high secretion at 0.1µg/mL 
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concentrations of pg-LPS. These findings agree partially with Hung et al. (2013), who also 
demonstrated dose-dependent increases in TNF-α and  IL-6 levels, in high glucose and 0.1 and 
1µg/µL of pg-LPS. The synergistic effects from this data suggest that the doses of both high glucose 
and pg-LPS play an important factor in increasing the inflammatory process, however, the amount 
of periodontal tissue destruction depends on the host response.  
Herein, combined high glucose and pg-LPS increased TGF-β1 and IL-12p40 levels, as evidence 
proposed that IL-12p40 may upregulate TGF-β1 (Sindrilaru et al. 2011; Zhang et al. 2013). Thus, 
overexpression caused by combined high glucose and pg-LPS suggests an important role in 
periodontal disease progression. It is worth mentioning, that differences in cytokine responses to 
high glucose and LPS were reported in various research studies and might be attributed to the 
diversity in differentiation protocols of macrophages, concurrent with different sources and 
antigenic structures of pg-LPS used.  
OPN protein is proposed to regulate different aspects of macrophage function; migration to the site 
of infection, phagocytosis and bacterial cell killing. Pedraza et al. (2008) and McKee et al. (2011) 
proposed that OPN may act as an opsonin to facilitate macrophage adhesion and then engulf the 
newly formed bone mineral crystals, which may hamper the biomineralisation process at the healing 
site. Colombo et al. (2011) reported OPN upregulation in diabetic bone concomitantly with an 
increased number of macrophages. This result could lead to an inference that the source of 
accumulated OPN could be from the accumulated macrophages at sites of diabetic healing bone. 
However, this was still not conclusive. Within this study, it is suggested that this increase in OPN 
could be derived mainly from M2 macrophages, although M1 macrophages also showed increased 
OPN levels, but they were statistically not significant. The synergistic conditions of high glucose 
and pg-LPS were found to significantly elevate OPN levels. These findings support the hypothesis 
that OPN might be the causative factor, which targets newly formed bone crystals and inhibits their 
growth, which potentially occurs in T2DM patient with periodontal disease. This information has 
not been previously described. 
This Chapter has successfully demonstrated the differentiation of monocytes derived from bone 
marrow into GM-CSF activated (M1) and M-CSF and IL-4 activated (M2) macrophages. Cell 
characterisation was performed and inflammatory macrophages (M1) revealed to secrete TNF-α and 
IL-6 more than M2 macrophages. On the other hand, anti-inflammatory (M2) secreted higher levels 
of TGF-β1 and IL12p40. High glucose or pg-LPS have exhibited certain effects on the pro-
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inflammatory mediators, however, the combined effects of these aforementioned factors revealed 
significant effects on these cytokines, whether inducing or inhibiting their levels. Importantly, the 
novelty of this study is the identification that OPN is mainly secreted by M2, in addition to M1 
macrophages under synergistic effects of both high glucose and pg-LPS conditions. This result, as 
far as we are aware, has not been reported in previous studies. This valuable piece of information 
could be the key point to continue studies to track the role of OPN in the progression of bone loss 
in periodontal disease, especially when associated by T2DM. 
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    Chapter 6: General Discussion 
 
The aims of this Thesis were to elucidate the effects of high glucose levels on compact bone 
mesenchymal stem cells (CB-MSCs) during cell culture expansion and in terms of osteogenic and 
adipogenic differentiation. This would help elucidate some of the harmful effects of high glucose 
(HG) on the healing and repair processes. These detrimental effects may be worsened by the role of 
lipopolysaccharides (LPS) derived from Porphyromonas gingivalis (Pg), resulting in exacerbation of 
the situation in periodontal disease. This study attempted to develop an understanding of these effects, 
to elucidate more the proposed link between type 2 diabetes mellitus (T2DM) and periodontal disease, 
which may assist in offering a better management for periodontal individuals with T2DM.  
Initially there was a need to develop and characterise a cell culture model system, which enabled 
examination of cell populations, where differentiation status of the CB-MSCs differed. Within this 
Thesis, a primary rat cell-line from the endosteal region was used to develop such a model. Upon 
isolation, the cells showed a slow-growing lag phase at the beginning of culture until around PD10. 
This lag phase may be an attempt of the CB-MSCs to adapt to the new culture environment, as it is 
already different from their in vivo stem cell niche. Such a cell growth trend has also been observed 
with MSCs from dental pulp (Harrington et al. 2014; Lee et al. 2015). Therefore, cells were 
investigated at PD15, considering that they had started to proliferate and adapt to their new 
environment. CB-MSCs here demonstrated to be a heterogenous population and as expansion 
continued, two distinct populations were established. The first one was at PD15, where the cells 
demonstrated heterogenous phenotypes with predominant mature committed osteoprogenitor cells 
with large spindle cells and a proportion of stellate cells. As growth continued, there was a change in 
this heterogeneity, the committed cells appeared to be lost, leaving smaller stellate-shaped, high 
proliferative immature cells at PD50. Thorough characterisations were performed to identify these 
CB-MSC populations. It is worth mentioning that CB-MSCs expressed the classical stem cell markers 
endoglin (CD105), 5’-ectonucleotidase (CD73) and Thy-1 (CD90) concomitantly, but no expression 
of hematopoietic stem cell markers, CD45 or CD34 in all investigated populations, which confirmed 
almost pure MSC populations. Moreover, CB-MSCs expressed CD146, Snail, Slug, Tert and Terc 
(TR), whereas they were negative for the expression of Nanog and Oct4, indicating adult CB-MSC 
phenotypes, having multipotency rather than pluripotency, as associated with embryonic stem cells.  
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PD15 demonstrated various cell shapes, ranging from large spindle, stellate and flat-shaped cells. 
Those cells exhibited low ability to proliferate with low colony forming efficiency (CFE), which 
reflect that the cells may reach the lineage-committed stage or a number of them could have 
approached a terminal proliferative stage. Telomere restriction fragment (TRF) length analysis, 
revealed shorter average telomere length, compared to PD50. The protein expression of p16INK4a and 
cell cycle marker was seen to be elevated, in addition to an expression of p21waf1, which have both 
been detected by Zhang et al. (2010) in fully-differentiated osteoblasts derived from MC3T3 cells. 
This may support our notion that their presence may represent a subpopulation of committed and 
mature osteoblasts. The protein expression of p21waf1 , however, was downregulated, considering its 
increase, when cells enter the G0 quiescent phase (Spencer et al. 2013). Thus, it is suggested a 
presence of a subpopulation of highly proliferative capacity within this heterogenous population. 
Furthermore, β-galactosidase staining (SA β-gal) exhibited a relatively low number of senescent cells. 
This predominantly committed population exhibited the highest capacity for osteogenic 
differentiation and mineral formation among other assessed populations, confirmed by the expression 
of osteogenic markers, Runx2, Osterix (OSX) and osteocalcin (OCN); and mineral crystal formation. 
Furthermore, although this population was described to consist mainly of committed osteoprogenitor 
stem cells, it successfully achieved adipogenic differentiation. Kim et al. (2005), reported that the 
committed cells can be induced to transdifferentiate into adipocytes by peroxisomal proliferator-
activated receptor gamma (PPARγ). 
Conversely, PD50 showed a change in this heterogeneous profile, where most of the spindle cells 
vanished, leaving smaller cell surface areas and predominantly stellate-like cells. Herein, this would 
suggest that ‘the lost cell’ from the PD50 profile could be linked to the large committed cells. This 
conclusion was reasonably based on the characteristic outcomes exemplified by long average 
telomere lengths, increases in CFEs, high proliferative capacity and a significant decrease in the cell 
surface areas. Increase in the mean of telomere length may indicate the cells are actively proliferating, 
and took a longer period to achieve osteogenic differentiation, which underpins the notion of a 
predominantly young population emerging. Furthermore, cell cycle marker expression of p16INK4a 
demonstrated a decline, informing that the cells were not senescent, in addition to the low expression 
of p21waf1 (Spencer et al. 2013). Furthermore, SA β-gal staining showed a relatively very low number 
of senescent cells. The capacity of this population to undergo osteogenic differentiation was clearly 
less than PD15. However, by extending the time in culture a week longer, it showed a successful 
osteogenic differentiation into osteoblasts. This trend supported the suggestion of the immature 
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profile of this population. In terms of adipogenic differentiation, PD50 revealed a high capacity for 
adipocytes formation. Although both mature and immature cell populations were able to differentiate 
into adipocytes, Lipid TOX fluorescent staining showed more cluster of lipid droplets associated with 
immature cells, which would suggest that immature cell population was easily driven to differentiate 
into adipocytes. Importantly, after successful osteogenic and adipogenic differentiation of CB-MSCs, 
this confirmed their bi-potent capacity and was considered as a sound foundation to continue this 
work, assisting in investigating their role in bone repair.  
  
High glucose conditions appeared not to affect the classical and other assessed surface marker 
expression for CB-MSCs. However, the glucose did appear to cause a reduction in MSC regenerative 
capacity, as the CFE decreased and a marked shortening of the mean telomere lengths in PD50. The 
response of the CB-MSCs populations to osteogenic differentiation, however, was different. PD15, 
the predominantly mature cells, under high glucose conditions were observed to exhibit a significant 
decrease in osteogenic differentiation. Interestingly, PD50 the predominantly immature cells, 
demonstrated that osteogenic differentiation was not affected by high glucose conditions. Such a 
finding has not previously been reported in the literature, as far as we are aware. High glucose 
microenvironments also exhibited a significant decrease in adipogenesis in cells both PD15 and PD50 
through decline in the expression of PPARγ and adiponectin markers. Although some other studies 
identified an increases in adipogenesis under high glucose conditions (Chuang et al. 2007; Wang et 
al. 2010a), Shilpa et al. (2013) reported that long-term exposure to very high glucose conditions 
demonstrated also decreased adipogenesis. These controversial results may be a reflection of different 
MSC origins assessed (endosteal and bone marrow); and variation in the protocols for assessing cell 
differentiation. We extended cell expansion to more than 300 days and investigated PD100 and 
PD200, where osteogenesis, but not adipogenesis was achievable. This has also been mentioned in 
other studies, that after long-term cell expansion, cells were no longer able to undergo adipogenic 
differentiation in culture (Ntambi and Kim 2000; Sethe et al. 2006; Ali et al. 2013). 
 
 Pg-LPS is known to have inhibitory effects on bone formation, as it can activate the host cells, such 
as macrophages through TLR2 and TLR4 receptors. These, in turn, induce secretion of 
proinflammatory cytokines, interleukin (IL) IL-1β, IL-6, IL-8 and tumour necrosis factor (TNF) TNF-
α, resulting in disturbing bone remodelling and repair processes (Graves et al. 2011; Herath et al. 
2011; Kato et al. 2014). However, little is known about this mechanism. Within this study, two 
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concentrations of pg-LPS (0.1 and 1µg/mL) were assayed to evaluate their effects on osteogenesis 
process within the mature and immature CB-MSC populations. In terms of mineral formation, pg-
LPS was found to inhibit the osteogenic differentiation of committed cells in a dose-dependent 
manner, where 1µg/mL pg-LPS concentration showed more detrimental effects on mineral formation 
than 0.1µg/mL pg-LPS. The protein expression of osteocalcin (OCN) was downregulated at both 
concentrations of pg-LPS. These results were in line with other studies (Kadono et al. 1999; Kato et 
al. 2014). This profile, nonetheless, was different in immature cells, as this population appeared to be 
affected by 0.1µg/mL concentrations of pg-LPS, which exerted detrimental effects on the mineral 
formation. This again revealed the differences between the mature and immature MSC responses, 
which have consequential effects on the bone healing process. 
When studying the combined effects of high glucose and pg-LPS on CB-MSCs, by trying to mimic 
the diabetic individual with periodontal disease, this Thesis suggested that immature cells were more 
affected by pg-LPS in the presence of high glucose, in terms of the ability of the MSCs to form 
mineral containing bone matrix nodules. This important finding opens the door for a deeper 
understanding of the detrimental effects of combined pg-LPS and high glucose, especially on 
immature cells. In this case, the turnover of MSCs during their life cycle through maturation from 
transit amplifying (TA) stage, until becoming committed and mature osteoprogenitor cells, will be 
affected. This outcome is also supported by the finding of decreasing CFEs due to high glucose 
conditions. Thus, bone formation may decline due to this harmful effect on immature population, 
resulting in greater bone resorption versus bone formation. Therefore, this might explain the delay in 
healing and repair process in periodontal disease, leading to a net bone loss. This valuable outcome 
about the role of pg-LPS and high glucose on immature cells is of great importance and needs further 
research. 
Interestingly, OPN has been described to bind to the mineral crystals during bone mineralisation, 
which inhibit their growth, assisting in the remodelling process (Pedraza et al. 2008; McKee et al. 
2011). OPN was observed to be increased in the diabetic healing bone within an in vivo model 
(Colombo et al. 2011). In the present Thesis, it has been proposed that increased OPN in diabetic 
healing bone could be the causative factor, especially when associated with pg-LPS, resulting in an 
increased net bone loss in T2DM. Herein, OPN was found to be elevated under high glucose 
conditions in both PD15 and PD50, but reported decrease, where combined with pg-LPS conditions 
at both concentrations. Although this important finding required more studies to be interpreted 
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further, it meant that the source of OPN, which is proposed to inhibit the mineral formation, was not 
from the CB-MSCs. Thus, this finding led us to consider macrophages as an alternative source of 
OPN.  
Macrophages are known to play a pivotal role in defending the body against pathogens as part of 
innate, as well as adaptive, immunity. They act as critical mediators of inflammatory processes by 
controlling tissue homeostasis and by regulating different phases of wound and bone healing. In the 
present study, macrophages were derived from monocytes by stimulating them using granulocyte 
macrophage-colony stimulating factor (GM-CSF) and macrophage-colony stimulating factor and 
interleukin 4 (M-CSF/IL-4), to drive cells to differentiation into M1 (pro-inflammatory) and M2 (anti-
inflammatory) macrophages, respectively. The cells were previously fully characterised by Dr. 
Norhayati Yusop from our laboratory (Norhayati Yusop PhD Thesis 2015). Various cytokines were 
investigated: TNF-α, IL-6 and iNOS expression related to M1 macrophages; and TGF-β1, IL12p40, 
CD163, Arginase1 (Arg1), MRC1 and VEGF expression related to M2 macrophages. TNF-α, IL-6, 
TGF-β1 and IL12p40 were assessed, looking at the effects of high glucose or pg-LPS alone; and when 
combined together. M1 macrophages revealed higher secretion levels of TNF-α and IL-6, whereas 
M2 macrophages secreted higher levels of TGF-β1 and IL-12p40. High glucose exhibited a significant 
increase in TNF-α in M1 macrophages, which implies an increase in the pro-inflammatory process, 
but at the same time, TGF-β1 was also elevated in M2 macrophages, which is known to induce healing 
and repair (Hamilton 2008; Italiani and Boraschi 2014). The combined effects of these two factors, 
HG and pg-LPS, however, revealed significant effects on these cytokines. TNF-α was affected in a 
dose-dependent manner, which was described to play a central role in periodontal disease, by 
inducing more tissue destruction. IL-6 levels were significantly elevated at 0.1µg/mL. Combined high 
glucose and pg-LPS was also found to increase TGF-β1 and IL-12p40 levels, when recent evidence 
proposed that IL-12p40 may upregulate TGF-β1 (Sindrilaru et al. 2011; Zhang et al. 2013). Thus, the 
changes in cytokine profile expression owing to the combined effects of HG and pg-LPS, suggested 
an important role in periodontal disease progression. In normal healing conditions, there is a balance 
between M1/M2 macrophage activities. Nevertheless, when this balance is disrupted and becomes 
more in favour of proinflammatory M1 macrophages, this can result in more tissue destruction, than 
healing and repair. This has been reported by a significant increase in TNF-α owing to high glucose 
effects (Davis et al. 2008; Kraakman et al. 2014). Although Hung et al. (2013), reported this 
synergistic effect on cytokines, they investigated macrophages from a cell line (U937). Within this 
study, the effects of HG and pg-LPS on M1 or M2 macrophages have been identified. The synergistic 
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effects from this data suggested that pg-LPS concentrations play an important role in elevating 
inflammatory events in addition to, HG. However, the amount of periodontal tissue destruction 
evident would depend on individual variations in the host response. 
One of the important proteins secreted by macrophages is OPN. In normal or high glucose conditions, 
OPN revealed low expression levels at the molecular and protein levels. Intriguingly, the synergistic 
effects seen where adding pg-LPS at both concentrations, caused significant increases in OPN levels 
in both M1 and M2 macrophages. In addition, pg-LPS alone also elevated OPN levels in M2 
macrophages. Such a significant increase in OPN levels could be linked to severe bone resorption, 
which is typically observed in periodontal disease with T2DM, when the pro-inflammatory phase 
predominantly consists of M1 macrophage activities. On the other hand, OPN levels registered a 
higher secretion from M2 macrophages, due to combined effects of pg-LPS and high glucose; and 
even in the case of pg-LPS alone. This led to speculation that OPN could cause detrimental effects 
when host conditions become more anti-inflammatory. These findings as far as we are aware, are 
novel and unveil a new mechanism of bone resorption at the expense of bone formation, in the case 
of patients with periodontal disease concurrently with T2DM.  
It is worthy to mention one limitation in this study, that it was better to use freshly isolated MSCs 
from aged Goto-Kakizaki (GK) rats, which already had T2DM for 12 weeks. However, difficulties 
in isolation of these MSCs from old animals led to the performance of long-term CB-MSCs culture 
under high glucose conditions. 
 
    6.1: Future Work 
  
The outcomes of this Thesis have been successful in identifying that the macrophage secretion of 
OPN is higher under the combined effects of pg-LPS and high glucose conditions, especially from 
M2 macrophages. This finding would assist in solving the complicated profile of periodontal disease 
associated with T2DM. However, there is still a lack of knowledge about mechanisms by which these 
changes happen and how the signalling pathways increase OPN levels. Despite the interesting 
outcomes of this Thesis, it would be advantageous for future work to use three-dimension culture 
model, instead of two-dimensions in vitro. This may reflect the real profile of in vivo conditions, 
which is more complicated by other factors, such as a plethora of subgingival bacterial biofilm 
formation, rather than pg-LPS alone. In addition to various immune cells and signalling pathways, 
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 which all need to be considered when trying to make a precise conclusion about the underlying 
mechanisms of bone loss.  If this understanding could translate into a therapeutic intervention, one 
suggestion is to investigate OPN levels in an in vivo model, such as GK rat with experimental 
periodontitis through a ligature on central teeth. In this case, we would obtain a translatable model to 
the human. By blocking OPN according to (Walker et al. 2010; Saito et al. 2016; Foster et al. 2018) 
and then assessing the mineral formation to evaluate the differences between the presence and 
absence of OPN, this may assist in identifying the proposed role of OPN in enhancing detrimental 
effects on bone formation in such circumstances. Interestingly, knock out of OPN may give an 
increase in tissue density, dental pulp and periodontal ligaments as mentioned by Foster et al. (2018). 
However, OPN was assayed in healthy knock out OPN mice. With this proposed model, it would be 
possible to observe the progression of periodontal disease. In addition, identifying the phosphorylated 
status of OPN is quite important as it is proposed that phosphorylated OPN is needed for mineral 
function, whereas dephosphorylated OPN may play a pivotal role in signalling and chemotactic 
activities. This will assist in better understanding the role of OPN in periodontium, which may aid to 
identify some of the potential therapeutic options in promoting the repair process in periodontal 
disease individuals with T2DM. Another suggestion related to the finding is that the immature cell 
population (PD50) was seen to be more affected by synergistic effects of HG and pg-LPS. Therefore, 
it would be worthwhile to isolate clonal cells from this population, in order to perform 
characterisation; investigating proliferative ability, multi-potency and unipotency under 
aforementioned synergistic conditions to confirm present findings. With a view to addressing T2DM 
with periodontitis, however, it is worth to state that proper oral hygiene and good HbA1c of blood 
glucose control, still remain to be the best approach to solve this complicated problem as evidenced 
by “prevention is better than cure”. 
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